amodiaquine has been researched along with Malaria in 421 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "IPTsc with dihydroartemisinin-piperaquine or artesunate-amodiaquine is a safe and effective approach to reducing malaria parasitaemia, clinical malaria, and related morbidities, and is feasible to implement through programmes delivered by schoolteachers." | 9.69 | Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. ( Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023) |
| "Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations." | 9.51 | Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022) |
| "Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first line therapy of uncomplicated malaria in Burkina Faso." | 9.34 | Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. ( Barry, N; Compaoré, YD; Kaboré, N; Nikiéma, F; Ouédraogo, JB; Somé, FA; Zongo, I; Zongo, M, 2020) |
| "The purpose of this study was to update efficacy data of Artesunate-Amodiaquine (AS+AQ) and Artemether-Lumefantrine (AL) used as first-line malaria treatment in Côte d'Ivoire since 2005." | 9.34 | Efficacy and safety of artesuante-amodiaquine and artemether lumefantrine, the first line malaria treatment in six sentinel's sites of Côte d'Ivoire, West Africa. ( Abba, T; Angora, EK; Assi, SB; Bedia, VA; Daho, AK; Emmanuel, B; Kiki-Barro, PMC; Konate, AA; Menan, H; Tiacoh, LN; Toure, OA; Yavo, W, 2020) |
| " Pyronaridine-artesunate and dihydroartemisinin-piperaquine are potentially useful for diversification of ACTs in this region, but further safety and efficacy data are required on malaria retreatment." | 9.27 | Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. ( , 2018) |
| "Amodiaquine plus artesunate is the recommended antimalarial treatment in many countries where malaria is endemic." | 9.27 | Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. ( Adjei, GO; Ali, AM; Aweeka, F; Barnes, KI; Denti, P; Jullien, V; Kiechel, JR; Kristensen, K; McGready, R; Mwesigwa, J; Penny, MA; Rijken, MJ; Sasi, P; Smith, TA; Stepniewska, K; Tarning, J; Workman, L, 2018) |
| "Based on per protocol analysis, unadjusted cure rates in malaria infected patients treated with artemether-lumefantrine (ALU), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DHP) were 89%, 94% and 91% respectively." | 9.22 | Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. ( Baraka, V; Kamugisha, E; Kapesa, A; Kidenya, B; Konje, E; Marwa, K; Mukonzo, J; Swedberg, G, 2022) |
| "It is recommended that children aged 3 months to five years of age living in areas of seasonal transmission in the sub-Sahel should receive Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) during the malaria transmission season." | 9.22 | Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial. ( Ba, EH; Cairns, M; Cissé, B; Fall, FB; Faye, B; Gaye, O; Gomis, JF; Greenwood, BM; Kouevijdin, E; Milligan, PJ; Molez, JF; NDiaye, JL; Ndour, CT; Niane, FK; Rogier, C; Sokhna, C; Trape, JF, 2016) |
| "The WHO recommends that children living in areas of highly seasonal malaria transmission in the Sahel subregion should receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ)." | 9.20 | Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. ( Compaore, YD; Greenwood, B; Milligan, P; Nosten, F; Ouedraogo, JB; Rosenthal, PJ; Some, AF; Sutherland, C; Tarning, J; Zongo, I, 2015) |
| "To evaluate the comparative efficacy and safety of artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and artesunate-amodiaquine-chlorpheniramine (AQC) for the treatment of acute uncomplicated malaria among Southwest Nigerian children." | 9.19 | Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo™) for the treatment of acute uncomplicated malaria in Nigerian children. ( Ademowo, OG; Dada-Adegbola, HO; Falade, CO; Nash, O; Oguike, MC; Ogunkunle, OO, 2014) |
| "6 mg/kg of amodiaquine per day) for the treatment of children and adults with uncomplicated falciparum malaria." | 9.16 | The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. ( Chavchich, M; Dai, B; Edstein, MD; Phong, NC; Quang, HH; Shanks, GD; Thanh, NX; Trung, TN, 2012) |
| " A significantly higher proportion of children treated with artesunate-amodiaquine developed sinus bradycardia compared with artemether-lumefantrine treated subjects (7/47 vs 0/30; χ² p=0." | 9.16 | Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine. ( Adjei, GO; Alifrangis, M; Goka, BQ; Hoegberg, LC; Kurtzhals, JA; Oduro-Boatey, C; Rodrigues, OP, 2012) |
| "Pregnant women with non-severe, slide proven, falciparum malaria were randomised to one of 4 regimes: sulfadoxine-pyrimethamine [SP]; chlorproguanil-dapsone [CD]; SP+amodiaquine [SP+AQ] or amodiaquine+artesunate [AQ+AS]." | 9.14 | Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. ( Briceño, M; Drakeley, C; Greenwood, BM; Mutabingwa, TK; Muze, K; Ord, R; Whitty, CJ, 2009) |
| "Sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) is a highly efficacious regimen for intermittent preventive treatment to prevent malaria in children (IPTc), but the amodiaquine component is not always well tolerated." | 9.14 | Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children. ( Ba, EH; Cairns, M; Cames, C; Cisse, B; Gaye, O; Greenwood, BM; Milligan, PJ; Simondon, K; Sokhna, C; Trape, JF, 2010) |
| "Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa." | 9.13 | An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. ( Adjuik, M; Amenga-Etego, S; Asante, KP; Chandramohan, D; Dosoo, DK; Greenwood, B; Gyapong, J; Owusu, R; Owusu-Agyei, S, 2008) |
| "The in vivo therapeutic efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination was evaluated in the treatment of uncomplicated Plasmodium falciparum malaria and of chloroquine for P." | 9.13 | [Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006]. ( Cortés, LJ; Guerra, AP; Knudson, A; Nicholls, RS; Pérez, MA; Usta, C, 2008) |
| "The Home Management of Malaria (HMM) strategy was developed using chloroquine, a now obsolete drug, which has been replaced by artemisinin-based combination therapy (ACT) in health facility settings." | 9.13 | Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites. ( Agyei-Baffour, P; Ajayi, IO; Balyeku, A; Bateganya, F; Browne, EN; Cousens, S; Doamekpor, L; Garshong, B; Munguti, K; Pagnoni, F; Yusuf, B, 2008) |
| "Artesunate plus amodiaquine was highly efficacious for malaria treatment in HIV-infected children but was associated with a high risk of neutropenia, especially in the context of concurrent antiretroviral use." | 9.13 | High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. ( Achan, J; Charlebois, E; Dorsey, G; Gasasira, AF; Havlir, D; Kalyango, JN; Kamya, MR; Kekitiinwa, A; Mebrahtu, T; Rosenthal, PJ; Ruel, T; Staedke, SG, 2008) |
| "We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine-pyrimethamine (AS + SP) in 180 children of age 6-59 months with uncomplicated malaria in Democratic Republic of Congo." | 9.12 | Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. ( Kayembe, G; Montgomery, J; Pota, H; Roper, C; Swarthout, TD; van den Broek, IV, 2006) |
| " The high endemicity of malaria in Africa may impact on the efficacy of artemisinin-based combination therapy." | 9.11 | Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. ( Bakyaita, N; Banek, K; Dorsey, G; Kamya, MR; Kilian, A; Kironde, F; Nsobya, SL; Reingold, A; Rosenthal, PJ; Slater, M; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2005) |
| "To compare the efficacy and side-effects of two therapeutic regimens for chloroquine-resistant falciparum malaria, a randomized study was carried out in 69 patients in Maputo Central Hospital in 1986-1987." | 9.06 | [Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique]. ( Dinis, DV; Schapira, A, 1990) |
| " Fifty cases of falciparum malaria were treated with 1800 mg amodiaquine for 3 days: the cure rate was 65." | 9.06 | Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China. ( Cai, XZ; Fu, SG; Huang, JK; Huang, OL; Ouyang, WC; Pang, XJ; Wang, XF; Wu, Z; Zhang, KY; Zhou, JX, 1988) |
| "Amodiaquine was compared to chloroquine in two groups of Filipino patients with uncomplicated falciparum malaria." | 9.06 | Amodiaquine less effective than chloroquine in the treatment of falciparum malaria in the Philippines. ( Alban, P; Laughlin, LW; Long, GW; Padre, L; Ranoa, CP; Sangalang, R; Watt, G, 1987) |
| "Amodiaquine cured 38% (13/34) of patients with falciparum malaria in Southeast Thailand." | 9.04 | Amodiaquine resistant falciparum malaria in Thailand. ( Hall, AP; Kosakal, S; Pearlman, EJ; Phintuyothin, P; Segal, HE, 1975) |
| "The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester." | 8.95 | Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. ( Clark, RL, 2017) |
| "Several African countries have begun using amodiaquine-containing combinations as first-line antimalarial treatment, with the result that a substantial number of pregnant women are likely to be exposed to amodiaquine." | 8.82 | Can amodiaquine be used safely during pregnancy? ( D'Alessandro, U; Erhart, A; Thomas, F, 2004) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 8.81 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2001) |
| "A meta-analysis study evaluating the efficacy and safety of chloroquine and alternative antimalarial drugs used in six African countries including Ethiopia, Kenya, Uganda, Cote D'Ivoire, Gambia and Nigeria is presented." | 8.80 | Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ( Makonnen, E; Mengesha, T, 1999) |
| "Amodiaquine has been widely used to treat malaria." | 8.80 | Amodiaquine for treating malaria. ( Mussano, P; Olliaro, P, 2000) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 8.80 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2000) |
| "Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia." | 8.31 | Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. ( Bazie, T; Beshir, KB; Bojang, K; Cairns, M; Ceesay, S; Diallo, A; Dicko, A; Doumagoum, D; Eloike, T; Gamougam, K; Kessely, H; Kolie, F; Lamine, MM; Laminou, IM; Loua, K; Maiga, H; Mansukhani, R; Merle, CS; Milligan, P; Moroso, D; Muwanguzi, J; Nader, J; NDiaye, JL; Ogboi, SJ; Ouedraogo, JB; Razafindralambo, L; Sagara, I; Scott, S; Snell, P; Sutherland, CJ; Traore, A; Zongo, I, 2023) |
| "Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in Liberia." | 8.12 | Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers. ( Asinya, M; Jeuronlon, MK; Kamara, P; Koko, VS; Kollie, A; Ma, L; Menard, D; Nyansaiye, P; Parwon, S; Pratt, OJ; Ringwald, P; Taweh, F; Tehmeh, L; Vonhm, B; Warsame, M, 2022) |
| "Based on reports of parasite resistance and on World Health Organization recommendation, chloroquine was replaced with the artemisinin-based combination therapies (ACTs) as the first choice of drugs for the treatment of uncomplicated malaria." | 8.02 | Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. ( Duah-Quashie, NO; Quashie, NB, 2021) |
| "Co-administration of amodiaquine with MAMA decoction (MD), an herbal antimalarial drug comprising the leaves of Mangifera indica L." | 7.83 | Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model. ( Adepiti, AO; Bolaji, OO; Elujoba, AA, 2016) |
| " The lower-dose combination of the leaf extract and amodiaquine had better antimalarial activity in CQ-sensitive murine malaria." | 7.83 | Evaluation of the combination of Uvaria chamae (P. Beauv.) and amodiaquine in murine malaria. ( Adepiti, AO; Iwalewa, EO, 2016) |
| "Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria, Rwanda replaced CQ with amodiaquine (AQ)+sulfadoxine-pyrimethamine (SP) in 2001, and subsequently with artemether-lumefantrine (AL) in 2006, as first-line treatments for uncomplicated malaria." | 7.83 | Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. ( Grobusch, MP; Hakizimana, E; Kateera, F; Kumar, N; Mens, PF; Mutesa, L; Nsobya, SL; Tukwasibwe, S; van Vugt, M, 2016) |
| "A novel class of benzoheterocyclic analogues of amodiaquine designed to avoid toxic reactive metabolite formation was synthesized and evaluated for antiplasmodial activity against K1 (multidrug resistant) and NF54 (sensitive) strains of the malaria parasite Plasmodium falciparum." | 7.81 | Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies. ( Chibale, K; Egan, TJ; Jurva, U; Masimirembwa, CM; Njoroge, M; Ongarora, DS; Strydom, N; Wicht, K; Wiesner, L; Wittlin, S, 2015) |
| "In 2003, artesunate-amodiaquine (AS+AQ) was introduced as the new first-line treatment for uncomplicated malaria in Burundi." | 7.74 | Community coverage of an antimalarial combination of artesunate and amodiaquine in Makamba Province, Burundi, nine months after its introduction. ( Brasher, C; Checchi, F; Cohuet, S; Edoh, K; Gerstl, S; Guthmann, JP; Lesage, A, 2007) |
| "Between 1998 and 2001, Kenya, Uganda, Tanzania, Zanzibar, Rwanda and Burundi changed antimalarial drug policy, in the face of widespread chloroquine resistance." | 7.72 | The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. ( , 2003) |
| "Amodiaquine (AQ) (2) is a 4-aminoquinoline antimalarial that can cause adverse side effects including agranulocytosis and liver damage." | 7.72 | Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. ( Bickley, JF; Bray, PG; Hindley, S; Hughes, RH; Maggs, JL; Mukhtar, A; O'Neil, IA; O'Neill, PM; Park, BK; Randle, LE; Stocks, PA; Storr, RC; Ward, SA; Winstanley, PA, 2003) |
| "Amodiaquine (AQ) is an antimalarial which is effective against chloroquino-resistant strains of Plasmodium falciparum but whose clinical use is severely restricted because of associated hepatotoxicity and agranulocytosis." | 7.71 | "One-pot" synthesis and antimalarial activity of formamidine derivatives of 4-anilinoquinoline. ( Dali Ali, F; Delarue, S; Girault, S; Grellier, P; Maes, L; Sergheraert, C, 2001) |
| "The activities of Mannich base antimalarials, including pyronaridine, have been explored against drug-sensitive (Plasmodium berghei N) and chloroquine-resistant (Plasmodium yoelii NS) rodent malaria parasites in vivo." | 7.68 | The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials. ( Peters, W; Robinson, BL, 1992) |
| "The authors evaluate the comparative efficiency of chloroquine and amodiaquine (35 mg/kg during 3 days) for uncomplicated malaria treatment in an area with high chemoresistance level." | 7.68 | [Uncomplicated malaria attack in an area with high chloroquine resistance. 2. Evaluation of first-choice therapeutic scheme]. ( Arrive, A; Eberlé, F; Gazin, P; Hengy, C; Jambou, R; Kouka-Bemba, D, 1990) |
| " Oral amodiaquine (AQ) has been used to treat patients with symptomatic malaria in Zambia (n = 14) and Nigeria (n = 5)." | 7.68 | The disposition of amodiaquine in Zambians and Nigerians with malaria. ( Breckenridge, AM; Edwards, G; Kofi-Ekue, JM; Orme, ML; Salako, LA; Simooya, O; Walker, O; Winstanley, PA, 1990) |
| "In eastern Thailand, 14 adults with moderately severe falciparum malaria were treated with intravenous amodiaquine dihydrochloride, loading dose 10 mg base/kg infused over 4 h followed by three further intravenous infusions of 5 mg base/kg at 24, 48, and 72 h." | 7.67 | Intravenous amodiaquine and oral amodiaquine/erythromycin in the treatment of chloroquine-resistant falciparum malaria. ( Attanath, P; Benjasurat, Y; Karbwang, J; Looareesuwan, S; Phillips, RE; Warrell, DA; White, NJ, 1985) |
| "6 out of 7 patients with severe neutropenia associated with the use of amodiaquine for malaria prophylaxis amodiaquine (400 mg weekly) plus proguanil (200 mg daily); 1 of these patients had also taken cotrimoxazole and another had taken sulphaguanidine." | 7.67 | Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. ( Bunch, C; Edwards, G; Hatton, CS; Pasvol, G; Peto, TE; Russell, SJ; Singer, CR; Winstanley, P, 1986) |
| "This report describes two patients who developed agranulocytosis while receiving prophylactic amodiaquine treatment." | 7.67 | Amodiaquine-induced immune agranulocytosis. ( Abel, L; Aymard, JP; Chau, F; Coulombel, L; Rouveix, B, 1989) |
| "Seven cases of agranulocytosis and two of liver damage that were probably due to amodiaquine treatment were studied." | 7.67 | Amodiaquine induced agranulocytosis and liver damage. ( Fehr, J; Frick, PG; Neftel, KA; Schmid, M; Woodtly, W, 1986) |
| "A death from chloroquinoresistant falciparum malaria contracted by a traveller under chloroquine chemoprophylaxis during a stay in the Cameroon provides the authors with an opportunity to analyze the extension of chloroquinoresistance in Africa." | 7.67 | [A fatal case of chloroquine-resistant neuromalaria in a traveller to Cameroon]. ( Beylot, J; Combe, A; Le Bras, J; Le Bras, M; Raccurt, CP; Ripert, C, 1986) |
| "Two patients are presented who during malaria prophylaxis with amodiaquine developed a hepatitis associated with granulocytopenia of short duration." | 7.67 | [Amodiaquine-induced hepatitis with leukopenia]. ( Siegrist, P; Vonmoos, P; Woodtli, W; Zollikofer, H, 1986) |
| "We report a patient who developed agranulocytosis following exposure to three drugs: amodiaquine, pyrimethamine and dipyrone." | 7.67 | Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serum. ( Douer, D; Ramot, B; Schwartz, E; Shaked, N, 1985) |
| "A combination of the drugs amodiaquine and tetracycline was used in a clinical trial at Phrabuddhabat Hospital in Central Thailand for treating Plasmodium falciparum malaria." | 7.66 | Treatment of Plasmodium falciparum malaria with a combination of amodiaquine and tetracycline in Central Thailand. ( Benjapong, W; Duriyananda, D; Malikul, S; Noeypatimanond, S; Ungkasrithongkul, M, 1983) |
| "A patient is presented who developed agranulocytosis while taking amodiaquine for suppressive therapy of malaria." | 7.66 | [Amodiaquine-induced agranulocytosis in malaria prevention: demonstration of an amodiaquine-induced cytotoxic antibody against granulocytes]. ( Gmür, J; Neftel, K; Schulthess, HK; von Felten, A, 1983) |
| "Evidence of resistance ot chloroquine was found in 13 out of 14 children from the East New Britain Province of Papua New Guinea, with Plasmodium falciparum malaria." | 7.66 | Chloroquine resistant Plasmodium falciparum malaria in East New Britain, Papua New Guinea. ( Tulloch, A, 1980) |
| "Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia." | 7.11 | Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial. ( Bamadio, A; Chico, RM; Cohee, LM; Coumare, S; Dara, A; Diarra, M; Djimde, AA; Doumbo, OK; Kodio, A; Maiga, H; Opondo, C; Sagara, I; Sidibe, B; Tekete, M; Traore, OB; Traore, ZI, 2022) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 7.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| "Malaria is the leading cause of morbidity and mortality among infants and children under-five in sub-Saharan Africa." | 5.91 | Predictors of caregiver adherence to administration of amodiaquine during delivery of seasonal malaria chemoprevention in Nigeria, Burkina Faso, Chad, and Togo. ( Aidenagbon, A; Ibinaiye, T; Ogunmola, O; Oguoma, C; Oresanya, O; Rassi, C; Richardson, S, 2023) |
| "Malaria is the one of the deadliest infectious diseases worldwide." | 5.91 | Antimalarial Agents Derived from Metal-Amodiaquine Complexes with Activity in Multiple Stages of the Plasmodium Life Cycle. ( Araújo Nobrega, J; Azevedo Batista, A; Basilico, N; Colina-Vegas, L; D'Alessandro, S; da Cruz B Silva, M; de Souza Pereira, C; Isis Barros, A; Moreira, DRM; Navarro, M; Rottmann, M, 2023) |
| "Until recently, due to widespread prevalence of molecular markers associated with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) resistance in east and southern Africa, seasonal malaria chemoprevention (SMC) has not been used at scale in this region." | 5.69 | A non-randomized controlled trial to assess the protective effect of SMC in the context of high parasite resistance in Uganda. ( Abio, H; Achan, J; Baker, K; Beinomugisha, G; Bonnington, C; Bwanika, JB; Kajubi, R; Kyagulanyi, T; Magumba, G; Marasciulo-Rice, M; Nabakooza, J; Nakirunda, M; Nuwa, A; Odong, DS; Odongo, M; Opigo, J; Rassi, C; Richardson, S; Rubahika, D; Rutazaana, D; Tibenderana, J, 2023) |
| "IPTsc with dihydroartemisinin-piperaquine or artesunate-amodiaquine is a safe and effective approach to reducing malaria parasitaemia, clinical malaria, and related morbidities, and is feasible to implement through programmes delivered by schoolteachers." | 5.69 | Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. ( Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023) |
| " The present study hence evaluated the effect of MD on the disposition of AQ in mice with a view to investigating a possible pharmacokinetic interaction." | 5.56 | Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice. ( Adeagbo, BA; Adehin, A; Adepiti, AO; Bolaji, OO; Elujoba, AA, 2020) |
| " Here, we evaluated the population pharmacokinetic properties of amodiaquine and its active metabolite, desethylamodiaquine, in children receiving SMC under directly observed ideal conditions (n = 136), and the adherence of SMC at an implementation phase in children participating in a case-control study to evaluate SMC effectiveness (n = 869)." | 5.56 | Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children. ( Assao, B; Blessborn, D; Coldiron, ME; Ding, J; Grais, RF; Guindo, O; Koscalova, A; Langendorf, C; Tarning, J; Winterberg, M, 2020) |
| " Thus, the efficacy of ASAQ is maintained and appears to be increased after long-term use in contrast to what is observed for other ACTs used in Africa." | 5.56 | Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar. ( Abbas, FB; Ali, AS; Ali, AW; Barnes, R; Björkman, A; Frumento, P; Mårtensson, A; Morris, U; Msellem, M; Soe, A, 2020) |
| "Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations." | 5.51 | Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022) |
| "Antimalarial treatments with artesunate-pyronaridine and artemether-lumefantrine reduced the excretion of S." | 5.51 | Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study. ( Adegnika, AA; Akinosho, MA; Davi, SD; Dimessa-Mbadinga, LB; Handrich, C; Kreidenweiss, A; Kremsner, PG; Lell, B; Mombo-Ngoma, G; Ndzebe-Ndoumba, WF; Nordmann, T; Okwu, DG; Ramharter, M; Stelzl, D; Veletzky, L; Zoleko-Manego, R, 2022) |
| "Atovaquone-proguanil (ATV-PG) plus amodiaquine (AQ) has been considered as a potential replacement for sulfadoxine-pyrimethamine plus AQ for seasonal malaria chemoprevention in African children." | 5.51 | Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine. ( Abla, N; Chalon, S; Chughlay, MF; Haouala, A; Hutter, B; Lorch, U; Macintyre, F; Marie Tchouatieu, A, 2022) |
| "Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first line therapy of uncomplicated malaria in Burkina Faso." | 5.34 | Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. ( Barry, N; Compaoré, YD; Kaboré, N; Nikiéma, F; Ouédraogo, JB; Somé, FA; Zongo, I; Zongo, M, 2020) |
| "The purpose of this study was to update efficacy data of Artesunate-Amodiaquine (AS+AQ) and Artemether-Lumefantrine (AL) used as first-line malaria treatment in Côte d'Ivoire since 2005." | 5.34 | Efficacy and safety of artesuante-amodiaquine and artemether lumefantrine, the first line malaria treatment in six sentinel's sites of Côte d'Ivoire, West Africa. ( Abba, T; Angora, EK; Assi, SB; Bedia, VA; Daho, AK; Emmanuel, B; Kiki-Barro, PMC; Konate, AA; Menan, H; Tiacoh, LN; Toure, OA; Yavo, W, 2020) |
| " Pyronaridine-artesunate and dihydroartemisinin-piperaquine are potentially useful for diversification of ACTs in this region, but further safety and efficacy data are required on malaria retreatment." | 5.27 | Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. ( , 2018) |
| "Amodiaquine plus artesunate is the recommended antimalarial treatment in many countries where malaria is endemic." | 5.27 | Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. ( Adjei, GO; Ali, AM; Aweeka, F; Barnes, KI; Denti, P; Jullien, V; Kiechel, JR; Kristensen, K; McGready, R; Mwesigwa, J; Penny, MA; Rijken, MJ; Sasi, P; Smith, TA; Stepniewska, K; Tarning, J; Workman, L, 2018) |
| " A 25-mg base/kg dosage of amodiaquine produced parasite clearance in 34 of 38 (89%) children in a mean of 2." | 5.27 | Evaluation of amodiaquine treatment of chloroquine-resistant Plasmodium falciparum malaria on Zanzibar, 1982. ( Campbell, CC; Khatib, OJ; Payne, D; Schwartz, IK, 1983) |
| "Amodiaquine was not found in any sample, but the major metabolite monodesethylamodiaquine was detected and was assumed to be the sole derivative that contributed significantly to antimalarial activity in the blood." | 5.27 | Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. ( Blayo, MC; Faurisson, F; Le Bras, J; Pussard, E; Scherrmann, JM; Verdier, F, 1987) |
| " In an attempt to explain the discrepancy between its in vivo-in vitro activity, a pharmacokinetic study was conducted in healthy subjects with HPLC assays." | 5.27 | [Pharmacokinetics of amodiaquine and prevention of Plasmodium falciparum malaria]. ( Blayo, MC; Faurisson, F; Pussard, E; Verdier, F, 1985) |
| "Based on per protocol analysis, unadjusted cure rates in malaria infected patients treated with artemether-lumefantrine (ALU), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DHP) were 89%, 94% and 91% respectively." | 5.22 | Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. ( Baraka, V; Kamugisha, E; Kapesa, A; Kidenya, B; Konje, E; Marwa, K; Mukonzo, J; Swedberg, G, 2022) |
| " A total of 2400 children aged 3-59 months received either: (i) a short-acting ACT for case management of malaria (artemether-lumefantrine, AL) plus placebo SMC, or (ii) a long-acting ACT (dihydroartemisinin-piperaquine, DP) for case management plus placebo SMC or (iii) AL for case management plus active SMC with sulphadoxine-pyrimethamine and amodiaquine." | 5.22 | Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial. ( Acheampong, PR; Antwi, GD; Bart Plange, C; Cairns, M; Chandramohan, D; Tagbor, H, 2016) |
| "It is recommended that children aged 3 months to five years of age living in areas of seasonal transmission in the sub-Sahel should receive Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) during the malaria transmission season." | 5.22 | Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial. ( Ba, EH; Cairns, M; Cissé, B; Fall, FB; Faye, B; Gaye, O; Gomis, JF; Greenwood, BM; Kouevijdin, E; Milligan, PJ; Molez, JF; NDiaye, JL; Ndour, CT; Niane, FK; Rogier, C; Sokhna, C; Trape, JF, 2016) |
| "Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), given each month during the transmission season, is recommended for children living in areas of the Sahel where malaria transmission is highly seasonal." | 5.22 | Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. ( Ba, EH; Cairns, M; Cissé, B; Dial, Y; Fall, FB; Faye, B; Faye, E; Faye, O; Faye, OK; Faye, S; Flach, C; Gaye, O; Gomis, JF; Greenwood, B; Konate, L; Kouevijdin, E; Lo, A; Milligan, P; NDiaye, JL; NDiaye, M; Pitt, C; Sokhna, C; Sutherland, C; Sy, O; Thior, PM; Tine, R; Trape, JF, 2016) |
| " Pregnant women diagnosed with malaria are randomised to receive either amodiaquine-artesunate (AQ-AS), dihydroartemisinin-piperaquine (DHA-PQ), artemether-lumefantrine (AL), or mefloquine-artesunate (MQAS)." | 5.20 | Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial. ( Claeys, Y; D'Alessandro, U; De Crop, M; Halidou, T; Kalanda, G; Menten, J; Mulenga, M; Mutabingwa, T; Mwakazanga, D; Mwapasa, V; Nambozi, M; Phiri, LK; Ravinetto, R; Schurmans, C; Tagbor, H; Thriemer, K; Traore, M; Valea, I; Van Geertruyden, JP, 2015) |
| "Artemisinin-based combination therapies (ACTs) have been adopted by most African countries, including Nigeria, as first-line treatments for uncomplicated falciparum malaria." | 5.20 | Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in ( Adedeji, ON; Ademowo, OG; Bolaji, OO; Falade, CO; Osonuga, OA, 2015) |
| "The WHO recommends that children living in areas of highly seasonal malaria transmission in the Sahel subregion should receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ)." | 5.20 | Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. ( Compaore, YD; Greenwood, B; Milligan, P; Nosten, F; Ouedraogo, JB; Rosenthal, PJ; Some, AF; Sutherland, C; Tarning, J; Zongo, I, 2015) |
| "To evaluate the comparative efficacy and safety of artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and artesunate-amodiaquine-chlorpheniramine (AQC) for the treatment of acute uncomplicated malaria among Southwest Nigerian children." | 5.19 | Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo™) for the treatment of acute uncomplicated malaria in Nigerian children. ( Ademowo, OG; Dada-Adegbola, HO; Falade, CO; Nash, O; Oguike, MC; Ogunkunle, OO, 2014) |
| "Community health workers in Dangme-West district, Ghana, treated children aged 2-59 months with fever with either artesunate-amodiaquine (AAQ) or AAQ plus amoxicillin (AAQ + AMX) within a cluster-randomized controlled trial (registration no." | 5.17 | Impact of treating young children with antimalarials with or without antibiotics on morbidity: a cluster-randomized controlled trial in Ghana. ( Abbey, M; Adjuik, M; Chinbuah, MA; Cobelens, F; Gyapong, JO; Gyapong, M; Kager, PA; Koram, KA, 2013) |
| "6 mg/kg of amodiaquine per day) for the treatment of children and adults with uncomplicated falciparum malaria." | 5.16 | The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. ( Chavchich, M; Dai, B; Edstein, MD; Phong, NC; Quang, HH; Shanks, GD; Thanh, NX; Trung, TN, 2012) |
| " A significantly higher proportion of children treated with artesunate-amodiaquine developed sinus bradycardia compared with artemether-lumefantrine treated subjects (7/47 vs 0/30; χ² p=0." | 5.16 | Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine. ( Adjei, GO; Alifrangis, M; Goka, BQ; Hoegberg, LC; Kurtzhals, JA; Oduro-Boatey, C; Rodrigues, OP, 2012) |
| "During the 2008 malaria transmission season, 1,277 children under five years of age resident in villages within the rural Farafenni demographic surveillance system (DSS) in North Bank Region, The Gambia were randomized to receive monthly IPTc with a single dose of sulphadoxine/pyrimethamine (SP) plus three doses of amodiaquine (AQ) or SP and AQ placebos given by village health workers (VHWs) on three occasions during the months of September, October and November, in a double-blind trial." | 5.15 | A trial of intermittent preventive treatment and home-based management of malaria in a rural area of The Gambia. ( Bojang, KA; Greenwood, BM; Milligan, P; Sesay, S; Sowe, M; Touray, E; Webb, EL, 2011) |
| " Three rounds of treatment with sulphadoxine pyrimethamine plus amodiaquine or placebos were given at monthly intervals during the malaria transmission season." | 5.15 | Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. ( Chandramohan, D; Cousens, S; Diallo, DA; Diarra, A; Gansané, A; Greenwood, B; Kaboré, Y; Kangoyé, DT; Konaté, AT; Milligan, PJ; Ouédraogo, A; Ouédraogo, AZ; Ouédraogo, E; Ouédraogo, IN; Sirima, SB; Soulama, I; Tiono, AB; Yaro, JB, 2011) |
| "Sulphadoxine-pyrimethamine, in combination with artesunate or amodiaquine, is recommended for the treatment of uncomplicated malaria and is being evaluated for intermittent preventive treatment." | 5.15 | Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ( Barnes, KI; Beavogui, AH; Djimde, AA; Doumbo, OK; Evans, A; Fredericks, A; Maiga, H; Sangare, CP; Smith, P; Tekete, MM; Toure, S; Traore, ZI, 2011) |
| "A cohort of 129 children aged 1-10 years in Kampala, Uganda, were treated with amodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplicated malaria over a 29-month period as part of a longitudinal clinical trial." | 5.14 | Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. ( Clark, TD; Dorsey, G; Greenhouse, B; Hubbard, A; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Slater, M; Staedke, SG, 2009) |
| "Pregnant women with non-severe, slide proven, falciparum malaria were randomised to one of 4 regimes: sulfadoxine-pyrimethamine [SP]; chlorproguanil-dapsone [CD]; SP+amodiaquine [SP+AQ] or amodiaquine+artesunate [AQ+AS]." | 5.14 | Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. ( Briceño, M; Drakeley, C; Greenwood, BM; Mutabingwa, TK; Muze, K; Ord, R; Whitty, CJ, 2009) |
| "Pharmacokinetic (PK) data on amodiaquine (AQ) and artesunate (AS) are limited in children, an important risk group for malaria." | 5.14 | Population pharmacokinetics of artesunate and amodiaquine in African children. ( Gansané, A; Kiechel, JR; Morgan, CC; Ouedraogo, A; Ouedraogo, EB; Simpson, JA; Sirima, SB; Stepniewska, K; Taylor, W; White, NJ, 2009) |
| "Sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) is a highly efficacious regimen for intermittent preventive treatment to prevent malaria in children (IPTc), but the amodiaquine component is not always well tolerated." | 5.14 | Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children. ( Ba, EH; Cairns, M; Cames, C; Cisse, B; Gaye, O; Greenwood, BM; Milligan, PJ; Simondon, K; Sokhna, C; Trape, JF, 2010) |
| " Children were randomized upon their first episode, and then treated for all episodes of uncomplicated malaria with amodiaquine/sulfadoxine-pyrimethamine (AQ/SP), artesunate/amodiaquine (AS/AQ), or artemether/lumefantrine (AL)." | 5.14 | Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. ( Clark, TD; Dorsey, G; Greenhouse, B; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Staedke, SG, 2010) |
| "Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa." | 5.13 | An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. ( Adjuik, M; Amenga-Etego, S; Asante, KP; Chandramohan, D; Dosoo, DK; Greenwood, B; Gyapong, J; Owusu, R; Owusu-Agyei, S, 2008) |
| "The in vivo therapeutic efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination was evaluated in the treatment of uncomplicated Plasmodium falciparum malaria and of chloroquine for P." | 5.13 | [Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006]. ( Cortés, LJ; Guerra, AP; Knudson, A; Nicholls, RS; Pérez, MA; Usta, C, 2008) |
| "Monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% CI: 63%, 74%) and anaemia by 45% (95% CI: 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% CI: 14%,33%) and anaemia by 30% (95% CI: 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% CI: 6%, 27%) and anaemia by 32% (95% CI: 7%, 50%) compared to placebo." | 5.13 | Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. ( Adjuik, M; Binka, F; Chandramohan, D; Greenwood, B; Kweku, M; Liu, D; Seidu, M, 2008) |
| "The Home Management of Malaria (HMM) strategy was developed using chloroquine, a now obsolete drug, which has been replaced by artemisinin-based combination therapy (ACT) in health facility settings." | 5.13 | Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites. ( Agyei-Baffour, P; Ajayi, IO; Balyeku, A; Bateganya, F; Browne, EN; Cousens, S; Doamekpor, L; Garshong, B; Munguti, K; Pagnoni, F; Yusuf, B, 2008) |
| "Artesunate plus amodiaquine was highly efficacious for malaria treatment in HIV-infected children but was associated with a high risk of neutropenia, especially in the context of concurrent antiretroviral use." | 5.13 | High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. ( Achan, J; Charlebois, E; Dorsey, G; Gasasira, AF; Havlir, D; Kalyango, JN; Kamya, MR; Kekitiinwa, A; Mebrahtu, T; Rosenthal, PJ; Ruel, T; Staedke, SG, 2008) |
| "We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine-pyrimethamine (AS + SP) in 180 children of age 6-59 months with uncomplicated malaria in Democratic Republic of Congo." | 5.12 | Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. ( Kayembe, G; Montgomery, J; Pota, H; Roper, C; Swarthout, TD; van den Broek, IV, 2006) |
| " The high endemicity of malaria in Africa may impact on the efficacy of artemisinin-based combination therapy." | 5.11 | Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. ( Bakyaita, N; Banek, K; Dorsey, G; Kamya, MR; Kilian, A; Kironde, F; Nsobya, SL; Reingold, A; Rosenthal, PJ; Slater, M; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2005) |
| "To compare the efficacy and side-effects of two therapeutic regimens for chloroquine-resistant falciparum malaria, a randomized study was carried out in 69 patients in Maputo Central Hospital in 1986-1987." | 5.06 | [Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique]. ( Dinis, DV; Schapira, A, 1990) |
| " Fifty cases of falciparum malaria were treated with 1800 mg amodiaquine for 3 days: the cure rate was 65." | 5.06 | Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China. ( Cai, XZ; Fu, SG; Huang, JK; Huang, OL; Ouyang, WC; Pang, XJ; Wang, XF; Wu, Z; Zhang, KY; Zhou, JX, 1988) |
| "The effects of chloroquine, amodiaquine and pyrimethamine-sulfadoxine (SP) (Fansidar) on the infection rate and density of Plasmodium falciparum gametocytes were studied in 198 patients with falciparum malaria from an area in the Punjab where malaria is endemic but seasonally transmitted." | 5.06 | Effects of chloroquine, amodiaquine and pyrimethamine-sulfadoxine on Plasmodium falciparum gametocytemia. ( Fox, E; Khaliq, AA; Macdonald, M; Sarwar, M; Strickland, GT, 1986) |
| "Amodiaquine was compared to chloroquine in two groups of Filipino patients with uncomplicated falciparum malaria." | 5.06 | Amodiaquine less effective than chloroquine in the treatment of falciparum malaria in the Philippines. ( Alban, P; Laughlin, LW; Long, GW; Padre, L; Ranoa, CP; Sangalang, R; Watt, G, 1987) |
| "Amodiaquine cured 38% (13/34) of patients with falciparum malaria in Southeast Thailand." | 5.04 | Amodiaquine resistant falciparum malaria in Thailand. ( Hall, AP; Kosakal, S; Pearlman, EJ; Phintuyothin, P; Segal, HE, 1975) |
| "The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester." | 4.95 | Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. ( Clark, RL, 2017) |
| " Chemopreventive strategies have been increasingly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children aged between 3 months and 5 years across the sub-Sahel." | 4.90 | Malaria. ( Dondorp, AM; Faiz, MA; Hien, TT; Mokuolu, OA; Pukrittayakamee, S; White, NJ, 2014) |
| "To assess the relationship between the genetic and phenotypic factors linked to the cytochrome P-450 enzyme system and the response to the antimalarial drugs chloroquine, amodiaquine, mefloquine, and proguanil, as well as to determine how certain biological and social factors of the host influence the behavior of this enzymatic complex." | 4.83 | [Cytochrome P-450 and the response to antimalarial drugs]. ( Carmona-Fonseca, J; Guzmán, V, 2006) |
| "Several African countries have begun using amodiaquine-containing combinations as first-line antimalarial treatment, with the result that a substantial number of pregnant women are likely to be exposed to amodiaquine." | 4.82 | Can amodiaquine be used safely during pregnancy? ( D'Alessandro, U; Erhart, A; Thomas, F, 2004) |
| " These side effects include various mild heart rate changes (amodiaquine) to excessive prolongation of the QT interval (halofantrine) which may lead to lethal arrhythmias such as Torsade de Pointes (TdP)." | 4.82 | Antimalarial drugs: QT prolongation and cardiac arrhythmias. ( Dumotier, B; Traebert, M, 2005) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 4.81 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2001) |
| "A meta-analysis study evaluating the efficacy and safety of chloroquine and alternative antimalarial drugs used in six African countries including Ethiopia, Kenya, Uganda, Cote D'Ivoire, Gambia and Nigeria is presented." | 4.80 | Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ( Makonnen, E; Mengesha, T, 1999) |
| "Amodiaquine has been widely used to treat malaria." | 4.80 | Amodiaquine for treating malaria. ( Mussano, P; Olliaro, P, 2000) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 4.80 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2000) |
| "Amodiaquine is a 4-aminoquinoline used extensively for the treatment and prevention of malaria." | 4.31 | Cardiovascular concentration-effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies. ( Burton, RB; Capel, RA; Chan, XHS; Chotsiri, P; Cremer, MA; Hanafiah, M; Hanboonkunupakarn, B; Kiechel, JR; Lee, SJ; Ogutu, B; Pike, J; Tarning, J; Taylor, WRJ; White, NJ; Win, YN, 2023) |
| "Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia." | 4.31 | Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. ( Bazie, T; Beshir, KB; Bojang, K; Cairns, M; Ceesay, S; Diallo, A; Dicko, A; Doumagoum, D; Eloike, T; Gamougam, K; Kessely, H; Kolie, F; Lamine, MM; Laminou, IM; Loua, K; Maiga, H; Mansukhani, R; Merle, CS; Milligan, P; Moroso, D; Muwanguzi, J; Nader, J; NDiaye, JL; Ogboi, SJ; Ouedraogo, JB; Razafindralambo, L; Sagara, I; Scott, S; Snell, P; Sutherland, CJ; Traore, A; Zongo, I, 2023) |
| "Despite scale-up of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) in children 3-59 months of age in Burkina Faso, malaria incidence remains high, raising concerns regarding SMC effectiveness and selection of drug resistance." | 4.31 | Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. ( Aweeka, F; Conrad, MD; Haro, A; Huang, L; Legac, J; Ouédraogo, JB; Roh, ME; Rosenthal, PJ; Somé, AF; Wallender, E; Yerbanga, RS; Zongo, I, 2023) |
| "In a prospective longitudinal in vivo study, neutrophil rates were compared with malaria carriage after treatment with different ACTs: Artemether - lumefantrine (AL), Artesunate - amodiaquine (ASAQ), Dihydroartemisinin - piperaquine (DP) or Pyronaridine artesunate (PA)." | 4.31 | Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. ( Arama, C; Beavogui, AH; Dicko, A; Djimde, A; Djimde, M; Fofana, B; Kayentao, K; Mens, PF; Ouedraogo, JB; Sagara, I; Schallig, HD; Sirima, SB; Tshiongo, JK, 2023) |
| "Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in Liberia." | 4.12 | Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers. ( Asinya, M; Jeuronlon, MK; Kamara, P; Koko, VS; Kollie, A; Ma, L; Menard, D; Nyansaiye, P; Parwon, S; Pratt, OJ; Ringwald, P; Taweh, F; Tehmeh, L; Vonhm, B; Warsame, M, 2022) |
| "Artesunate-amodiaquine is a potential therapy for uncomplicated malaria in Cambodia." | 4.02 | Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia. ( Ariey, F; Chy, S; Dorina Bustos, M; Eam, R; Izac, B; Kauy, C; Ke, S; Khim, N; Kim, S; Kloeung, N; Leang, R; Mairet-Khedim, M; Marmai, C; Mey Bouth, D; Ringwald, P; Witkowski, B, 2021) |
| "Based on reports of parasite resistance and on World Health Organization recommendation, chloroquine was replaced with the artemisinin-based combination therapies (ACTs) as the first choice of drugs for the treatment of uncomplicated malaria." | 4.02 | Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. ( Duah-Quashie, NO; Quashie, NB, 2021) |
| " This study aimed to monitor the occurrence of adverse events (AEs) after the use of artemisinin-based combination therapies (ACTs), identify potential drivers of reporting suspected adverse drug reactions (ADRs) and monitor AEs among women who were inadvertently exposed to ACTs in the first trimester of pregnancy." | 3.96 | Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso. ( Bihoun, B; Derra, K; Kazienga, A; Nakanabo-Diallo, S; Pagnoni, F; Rouamba, E; Rouamba, T; Samadoulougou-Kirakoya, F; Sondo, P; Sorgho, H; Tarnagda, Z; Tinto, H; Valea, I, 2020) |
| "A tremendous level of success has been achieved since the introduction of chloroquine and the combination of amodiaquine and artemisinin for the treatment of both complicated and uncomplicated malaria infections in sub-Saharan Africa." | 3.96 | Clinical Probe of Cyp2C8*2 Mutants in a Malaria Hyperendemic Zone: Evidence from North-Central, Nigeria. ( Adeniyi, OM; Ajibaye, O; Aremu, OI; Asogwa, N; Babamale, OA; Fakayode, O; Fatoba, IM; Iyiola, OA; Omotesho, OB; Opeyemi, OA; Salawu, KM; Shittu, O, 2020) |
| " MRDT-positive children received artesunate-amodiaquine (ASAQ), while MRDT-negative children were treated based on the clinical diagnosis of non-malaria febrile illness." | 3.91 | Consequences of restricting antimalarial drugs to rapid diagnostic test-positive febrile children in south-west Nigeria. ( Ajayi, IO; Baba, E; Badejo, JA; Chandramohan, D; Dada-Adegbola, HO; Falade, CO; Funwei, RI; Hamade, P; Jegede, AS; Michael, OS; Ogunkunle, OO; Ojurongbe, OD; Orimadegun, AE; Ssekitooleko, J; Webster, J, 2019) |
| " Whether the addition of azithromycin to the monthly sulfadoxine-pyrimethamine plus amodiaquine used for seasonal malaria chemoprevention could reduce mortality and morbidity among African children was unclear." | 3.91 | Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. ( Barry, A; Cairns, M; Chandramohan, D; Coumare, S; Diarra, M; Dicko, A; Doumbo, O; Greenwood, B; Kuepfer, I; Milligan, P; Nikiema, F; Ouedraogo, JB; Sagara, I; Tapily, A; Thera, I; Tinto, H; Traore, A; Yerbanga, S; Zongo, I, 2019) |
| "We fit unadjusted and adjusted regression models to standardized patient-level data to estimate the risk ratio for death among patients with confirmed EVD who were prescribed artesunate-amodiaquine (artesunate-amodiaquine group), as compared with those who were prescribed artemether-lumefantrine (artemether-lumefantrine group) and those who were not prescribed any antimalarial drug (no-antimalarial group)." | 3.83 | Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. ( Azman, AS; Azuma, P; Bocquin, A; Cabrol, JC; Cannas, A; Ciglenecki, I; de Smet, M; Gignoux, E; Job, D; Kurth, A; Logue, C; Massaquoi, M; Petrucci, R; Potet, J; Pottage, T; Serafini, M; Sterk, E; Strecker, T; Suzuki, M; Tiffany, A; Yue, C, 2016) |
| "Co-administration of amodiaquine with MAMA decoction (MD), an herbal antimalarial drug comprising the leaves of Mangifera indica L." | 3.83 | Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model. ( Adepiti, AO; Bolaji, OO; Elujoba, AA, 2016) |
| " The lower-dose combination of the leaf extract and amodiaquine had better antimalarial activity in CQ-sensitive murine malaria." | 3.83 | Evaluation of the combination of Uvaria chamae (P. Beauv.) and amodiaquine in murine malaria. ( Adepiti, AO; Iwalewa, EO, 2016) |
| " A pre-tested interviewer administered questionnaire was used to collect information on availability and use of malaria Rapid Diagnostic Test (mRDT) and artemisinin combination therapy (ACT), for management of uncomplicated malaria." | 3.83 | Adherence to malaria diagnosis and treatment guidelines among healthcare workers in Ogun State, Nigeria. ( Ajayi, I; Ajumobi, O; Bamiselu, OF; Dairo, D; Fawole, O; Oladimeji, A; Steven, Y, 2016) |
| "Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria, Rwanda replaced CQ with amodiaquine (AQ)+sulfadoxine-pyrimethamine (SP) in 2001, and subsequently with artemether-lumefantrine (AL) in 2006, as first-line treatments for uncomplicated malaria." | 3.83 | Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. ( Grobusch, MP; Hakizimana, E; Kateera, F; Kumar, N; Mens, PF; Mutesa, L; Nsobya, SL; Tukwasibwe, S; van Vugt, M, 2016) |
| "A novel class of benzoheterocyclic analogues of amodiaquine designed to avoid toxic reactive metabolite formation was synthesized and evaluated for antiplasmodial activity against K1 (multidrug resistant) and NF54 (sensitive) strains of the malaria parasite Plasmodium falciparum." | 3.81 | Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies. ( Chibale, K; Egan, TJ; Jurva, U; Masimirembwa, CM; Njoroge, M; Ongarora, DS; Strydom, N; Wicht, K; Wiesner, L; Wittlin, S, 2015) |
| "42), showing antimalarial activity against drug-resistant and sensitive strains (EC50 values ∼ 3 μM), selectivity for malaria parasite and no cross-resistance with chloroquine, thus representing a potential new chemotype for further optimization towards novel and affordable antimalarial drugs." | 3.81 | Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype. ( Coelho, L; Lukens, AK; Mazitschek, R; Moreira, R; Nogueira, F; Paulo, A; Santos, SA; Wirth, DF, 2015) |
| " Thick smears stained with Giemsa were done for every febrile villager and malaria attacks were treated with combination of Artesunate plus Amodiaquine." | 3.81 | The implication of long-lasting insecticide-treated net use in the resurgence of malaria morbidity in a Senegal malaria endemic village in 2010-2011. ( Boyer, S; Diagne, N; Doucoure, S; Faye, N; Gaudart, J; Richard, V; Sokhna, C; Tall, A; Touré-Baldé, A; Trape, JF; Wotodjo, AN, 2015) |
| "Artesunate plus amodiaquine is used for malaria treatment in regions with overlapping HIV endemicity." | 3.80 | Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ( Adedeji, WA; Adewole, IF; Akinola, IT; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, FA; Lindegardh, N; Ma, Q; Morse, GD; Murphy, RL; Ojengbede, O; Parikh, S; Scarsi, KK; Taiwo, B; Tarning, J, 2014) |
| " One example of such initiatives is the Fixed-Dose Artesunate Combination Therapy (FACT) project consortium, which brought together institutions with different natures from both the North and the South, for the development of two antimalarial fixed-dose combinations recommended by the WHO - artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ)." | 3.80 | Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil. ( Kameda, K, 2014) |
| " The anti-malarial activity of standard doses of amodiaquine (AQ) with or without artemether (ART) and combined with varying doses of rifampicin (RIF 15 mg/kg or RIF 30 mg/kg body weight) was evaluated in 40 mice sub-divided into eight groups and inoculated intraperitoneally with 1 × 10(7) red blood cells infected with chloroquine-resistant P." | 3.80 | Interaction between rifampicin, amodiaquine and artemether in mice infected with chloroquine resistant Plasmodium berghei. ( Abiodun, OO; Akinola, O; Badejo, JA; Gbotosho, GO; Happi, CT; Sowunmi, A, 2014) |
| "A pilot programme of Cohort Event Monitoring (CEM) was conducted across the six geopolitical zones of Nigeria on patients treated for uncomplicated malaria with artemisinin-based combination therapy (ACT)." | 3.79 | Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study. ( Adesina, O; Bassi, PU; Coulter, D; Isah, A; Jalo, I; Kalat, M; Nwoasu, SC; Nyong, EE; Osakwe, AI; Osungwu, F; Pal, S; Suku, C; Ugochukwu, C; Wallberg, M; Wammanda, RD, 2013) |
| "A case of an acute reversible visual loss in a 10-year-old child who was on mefloquine prophylaxis, and was treated with artesunate-amodiaquine for an acute febrile illness diagnosed clinically as uncomplicated malaria, is reported." | 3.78 | Reversible binocular visual loss in temporal association with artesunate-amodiaquine treatment in a child on mefloquine chemoprophylaxis. ( Adabayeri, VM; Adjei, GO; Annobil, SH, 2012) |
| "In 2002, DNDi created the FACT project to develop two fixed-dose combinations, artesunate-amodiaquine and artesunate-mefloquine, to meet the WHO anti-malarial treatment recommendations and international regulatory agencies approval standards." | 3.77 | Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience. ( Bompart, F; Kiechel, JR; Pecoul, B; Sebbag, R, 2011) |
| " First line anti-malarial was Amodiaquine plus sulphadoxine-pyrimethamine (AQ+SP) bi-therapy." | 3.77 | Management of uncomplicated malaria in children under 13 years of age at a district hospital in Senegal: from official guidelines to usual practices. ( Cissé, M; Lalou, R; Le Hesran, JY; Sarrassat, S, 2011) |
| "A study to measure adherence to artesunate and amodiaquine (AS+AQ) therapy in patients treated for uncomplicated malaria in community health centres (CHC) was conducted in Sierra Leone." | 3.76 | Successful introduction of artesunate combination therapy is not enough to fight malaria: results from an adherence study in Sierra Leone. ( Baker, S; Dunkley, S; Gerstl, S; Maikere, J; Mukhtar, A, 2010) |
| "One year after the adoption of artesunate-amodiaquine (AS/AQ) as first-line therapy for the treatment of uncomplicated malaria, this study was designed to assess the treatment practices regarding anti-malarial drugs at health facilities in four rural areas in southern Cameroon." | 3.75 | Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in rural health facilities in southern Cameroon. ( Bley, D; Gausseres, M; Malvy, D; Millet, P; Sayang, C; Vernazza-Licht, N, 2009) |
| "After adoption of artesunate-amodiaquine (AS/AQ) as first-line therapy for the treatment of uncomplicated malaria by the malaria control programme, this study was designed to assess the availability of anti-malarial drugs, treatment practices and acceptability of the new protocol by health professionals, in the urban health facilities and drugstores of Yaoundé city, Cameroon." | 3.75 | Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in urban health facilities in Yaoundé, central province, Cameroon. ( Bley, D; Gausseres, M; Malvy, D; Millet, P; Sayang, C; Vernazza-Licht, N, 2009) |
| " Different techniques used to measure compliance were compared among children treated by the anti-malarial amodiaquine/sulphadoxine-pyrimethamine (AQ/SP) combination therapy, in use in Senegal between 2004 and 2006." | 3.75 | Self-reported data: a major tool to assess compliance with anti-malarial combination therapy among children in Senegal. ( Carlotti, MP; Lalou, R; Le Hesran, JY; Moulin, P; Sarrassat, S; Souares, A, 2009) |
| "In 2003, artesunate-amodiaquine (AS+AQ) was introduced as the new first-line treatment for uncomplicated malaria in Burundi." | 3.74 | Community coverage of an antimalarial combination of artesunate and amodiaquine in Makamba Province, Burundi, nine months after its introduction. ( Brasher, C; Checchi, F; Cohuet, S; Edoh, K; Gerstl, S; Guthmann, JP; Lesage, A, 2007) |
| "In November 2001, the National Health Ministry of Rwanda advocated a new therapeutic protocol replacing chloroquine by an amodiaquine+sulfadoxine-pyrimethamine combination for the treatment of uncomplicated malaria." | 3.74 | [Assessing the application of Rwanda's national protocol for uncomplicated malaria treatment in healthcare institutions in Kigali City, Rwanda]. ( Freund, RJ; Lombrail, P; Malvy, D; Millet, P; Nzayirambaho, M; Potel, G, 2008) |
| "Between 1998 and 2001, Kenya, Uganda, Tanzania, Zanzibar, Rwanda and Burundi changed antimalarial drug policy, in the face of widespread chloroquine resistance." | 3.72 | The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. ( , 2003) |
| "Amodiaquine (AQ) (2) is a 4-aminoquinoline antimalarial that can cause adverse side effects including agranulocytosis and liver damage." | 3.72 | Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. ( Bickley, JF; Bray, PG; Hindley, S; Hughes, RH; Maggs, JL; Mukhtar, A; O'Neil, IA; O'Neill, PM; Park, BK; Randle, LE; Stocks, PA; Storr, RC; Ward, SA; Winstanley, PA, 2003) |
| "Amodiaquine (AQ) is an antimalarial which is effective against chloroquino-resistant strains of Plasmodium falciparum but whose clinical use is severely restricted because of associated hepatotoxicity and agranulocytosis." | 3.71 | "One-pot" synthesis and antimalarial activity of formamidine derivatives of 4-anilinoquinoline. ( Dali Ali, F; Delarue, S; Girault, S; Grellier, P; Maes, L; Sergheraert, C, 2001) |
| "The adverse reactions associated with the antimalarial amodiaquine (AQ), agranulocytosis and hepatotoxicity, have been attributed to the bioactivation of the drug to a quinone imine metabolite." | 3.69 | The effect of chemical substitution on the metabolic activation, metabolic detoxication, and pharmacological activity of amodiaquine in the mouse. ( Jewell, H; Maggs, JL; O'Neill, PM; Park, BK; Ruscoe, JE; Storr, RC; Ward, SA, 1995) |
| "The activities of Mannich base antimalarials, including pyronaridine, have been explored against drug-sensitive (Plasmodium berghei N) and chloroquine-resistant (Plasmodium yoelii NS) rodent malaria parasites in vivo." | 3.68 | The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials. ( Peters, W; Robinson, BL, 1992) |
| "In view of the emergence of chloroquine resistant Plasmodium falciparum from more and more geographical areas profiling of the responses to other available antimalarials by in vitro methods have become essential." | 3.68 | An in-vitro profile of the action of four antimalarials on indigenous cases of Plasmodium falciparum malaria in Karnataka. ( Chakrabarti, NK; Nagaraj, C; Narasimham, MV, 1990) |
| "The authors evaluate the comparative efficiency of chloroquine and amodiaquine (35 mg/kg during 3 days) for uncomplicated malaria treatment in an area with high chemoresistance level." | 3.68 | [Uncomplicated malaria attack in an area with high chloroquine resistance. 2. Evaluation of first-choice therapeutic scheme]. ( Arrive, A; Eberlé, F; Gazin, P; Hengy, C; Jambou, R; Kouka-Bemba, D, 1990) |
| " falciparum to amodiaquine, quinine and quinidine was assessed in Tanga region where chloroquine resistance is established, to determine baseline susceptibility levels which could guide health care deliverers on the suitability of these drugs for the treatment of falciparum malaria in the areas studied." | 3.68 | The in vitro response of Plasmodium falciparum to amodiaquine, quinine and quinidine in Tanga region, Tanzania. ( Kilimali, VA, 1990) |
| " Oral amodiaquine (AQ) has been used to treat patients with symptomatic malaria in Zambia (n = 14) and Nigeria (n = 5)." | 3.68 | The disposition of amodiaquine in Zambians and Nigerians with malaria. ( Breckenridge, AM; Edwards, G; Kofi-Ekue, JM; Orme, ML; Salako, LA; Simooya, O; Walker, O; Winstanley, PA, 1990) |
| "An extended in vivo test of the sensitivity of Plasmodium falciparum to antimalarial drugs in Nigerian children showed no evidence of resistance to chloroquine and amodiaquine." | 3.67 | The sensitivity of Plasmodium falciparum to chloroquine and amodiaquine in Ibadan, Nigeria. ( Bademosi, K; Obih, PO; Salako, LA; Sodeinde, O; Walker, O, 1984) |
| "In the town of Edea, where falciparum malaria is hyperendemic, an in vivo study of amodiaquine sensitivity of the local strain of the parasite is performed in school children 6 to 12 years of age: 184 children with parasites in their blood and no chloroquine in their urine are given amodiaquine orally." | 3.67 | [In vivo sensitivity of Plasmodium falciparum to amodiaquine in the town of Edea (Cameroon)]. ( Combe, A; Eboumbou, J; Garnier, T; Macaigne, F; Michel, R; Ripert, C; Vincendeau, P, 1989) |
| "In eastern Thailand, 14 adults with moderately severe falciparum malaria were treated with intravenous amodiaquine dihydrochloride, loading dose 10 mg base/kg infused over 4 h followed by three further intravenous infusions of 5 mg base/kg at 24, 48, and 72 h." | 3.67 | Intravenous amodiaquine and oral amodiaquine/erythromycin in the treatment of chloroquine-resistant falciparum malaria. ( Attanath, P; Benjasurat, Y; Karbwang, J; Looareesuwan, S; Phillips, RE; Warrell, DA; White, NJ, 1985) |
| "6 out of 7 patients with severe neutropenia associated with the use of amodiaquine for malaria prophylaxis amodiaquine (400 mg weekly) plus proguanil (200 mg daily); 1 of these patients had also taken cotrimoxazole and another had taken sulphaguanidine." | 3.67 | Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. ( Bunch, C; Edwards, G; Hatton, CS; Pasvol, G; Peto, TE; Russell, SJ; Singer, CR; Winstanley, P, 1986) |
| "Seven patients developed hepatitis after receiving amodiaquine for malaria prophylaxis for 4 to 15 weeks." | 3.67 | Amodiaquine-induced hepatitis. A report of seven cases. ( Benhamou, JP; Castot, A; Feldmann, G; Larrey, D; Lenoir, A; Machayekhy, JP; Merigot, P; Pëssayre, D; Rueff, B, 1986) |
| "This report describes two patients who developed agranulocytosis while receiving prophylactic amodiaquine treatment." | 3.67 | Amodiaquine-induced immune agranulocytosis. ( Abel, L; Aymard, JP; Chau, F; Coulombel, L; Rouveix, B, 1989) |
| "Seven cases of agranulocytosis and two of liver damage that were probably due to amodiaquine treatment were studied." | 3.67 | Amodiaquine induced agranulocytosis and liver damage. ( Fehr, J; Frick, PG; Neftel, KA; Schmid, M; Woodtly, W, 1986) |
| "Since August 1983, several cases of chloroquine resistant malaria have been observed in caucasian adults living in the Central African Republic (CAR) despite an antimalarial prophylaxis." | 3.67 | [Status of drug resistance of Plasmodium falciparum in the Central African Republic. Results of studies carried out between 1984 and 1986]. ( Delmont, J; Faugère, B; Georges, AJ; Limbassa, J; Monges, P; Testa, J, 1987) |
| "We present two cases of Plasmodium falciparum malaria contracted in Douala despite adequate prophylaxis by Fansidar for one and by chloroquine for the other." | 3.67 | [2 cases of multiresistant Plasmodium falciparum malaria contracted in Douala with atypical clinical presentation]. ( Charmot, G; Le Bras, J; Simon, F, 1987) |
| "24 cases of Plasmodium falciparum malaria in a group of 73 non-immune subjects coming mostly from central Africa have been tested in vitro for chloroquine sensitivity: 5 are sensitive, 19 are resistant among whom one is also quinine-resistant." | 3.67 | [Current aspects of imported drug-resistant Plasmodium falciparum]. ( Buisson, Y; Chabiersky, M; Daly, JP; Le Bras, J; Roué, R; Saliou, P; Simon, F; Talarmin, F, 1987) |
| "We evaluated amodiaquine as a replacement drug for treating falciparum malaria in an area of Pakistani Punjab where chloroquine-resistant Plasmodium falciparum has recently emerged." | 3.67 | Amodiaquine fails to cure chloroquine resistant Plasmodium falciparum in the Punjab. ( Fox, E; Khaliq, AA; Sarwar, M; Strickland, GT, 1987) |
| "Three patients suffered from fulminant hepatitis within 23, 59 and 22 weeks after having ingested a total dose of 16, 26 and 15 g, respectively, of amodiaquine for the prophylaxis of malaria." | 3.67 | Amodiaquine-induced fulminant hepatitis. ( Benhamou, JP; Bernuau, J; Campillo, B; Degott, C; Larrey, D; Pessayre, D; Rueff, B; Verdier, F, 1988) |
| "A death from chloroquinoresistant falciparum malaria contracted by a traveller under chloroquine chemoprophylaxis during a stay in the Cameroon provides the authors with an opportunity to analyze the extension of chloroquinoresistance in Africa." | 3.67 | [A fatal case of chloroquine-resistant neuromalaria in a traveller to Cameroon]. ( Beylot, J; Combe, A; Le Bras, J; Le Bras, M; Raccurt, CP; Ripert, C, 1986) |
| "Bone-marrow culture in soft agar was used to determine the cause of neutropenia in a visitor to Tanzania who had been taking both amodiaquine and proguanil for antimalarial prophylaxis." | 3.67 | Neutropenia associated with dual antimalarial chemoprophylaxis--use of bone-marrow culture as an aid in further drug management. ( Addison, GM; Ellis, ME; Steed, AJ, 1987) |
| "Two patients are presented who during malaria prophylaxis with amodiaquine developed a hepatitis associated with granulocytopenia of short duration." | 3.67 | [Amodiaquine-induced hepatitis with leukopenia]. ( Siegrist, P; Vonmoos, P; Woodtli, W; Zollikofer, H, 1986) |
| "Amodiaquine hydrochloride (3 mg base kg-1) was given by constant rate intravenous injection over 10 min to seven healthy adult male volunteers, and by constant rate infusion (10 mg base kg-1) over 4 h to 10 adult patients admitted to hospital with falciparum malaria." | 3.67 | Pharmacokinetics of intravenous amodiaquine. ( Bunch, C; Edwards, G; Karbwang, J; Looareesuwan, S; Nicholl, DD; Phillips, RE; Warrell, DA; White, NJ, 1987) |
| "A village-based programme of presumptive treatment of fever, using voluntary village aides to dispense oral chloroquine or amodiaquine, was established in 1982 by the Papua New Guinea Institute of Medical Research (PNG IMR) in 35 rural villages or hamlets near Madang, on the north coast of PNG." | 3.67 | The role of voluntary village aides in the control of malaria by presumptive treatment of fever. 2. Impact on village health. ( Alpers, MP; Heywood, PF; Jolley, DJ; Moir, JS; Tulloch, JL; Vrbova, H, 1985) |
| "One hundred cases of slide-confirmed Plasmodium falciparum malaria admitted to the San Lazaro Hospital, Manila, Philippines were screened for in vitro resistance to chloroquine, quinine, amodiaquine and mefloquine using the microtechnique." | 3.67 | Studies of resistance to chloroquine, quinine, amodiaquine and mefloquine among Philippine strains of Plasmodium falciparum. ( Alcantara, AK; Buck, RL; Rodriguez, CS; Smrkovski, LL; Uylangco, CV, 1985) |
| "The sensitivity level of Plasmodium falciparum isolates to chloroquine and the activity of six other antimalarials were studied in the different climatic zones of Madagascar in 1983." | 3.67 | Plasmodium falciparum in Madagascar: in vivo and in vitro sensitivity to seven drugs. ( Coulanges, P; Deloron, P; Le Bras, J; Ramanamirija, JA, 1985) |
| "The authors have devised a specific HPLC method for amodiaquine assay which demonstrated that the drug disappeared rapidly from the blood of subjects under prophylaxis for malaria (10 mg/kg/week in a single oral dose)." | 3.67 | [Biotransformation of amiodaquine and prophylaxis of Plasmodium falciparum malaria]. ( Blayo, MC; Pocidalo, JJ; Pussard, E; Verdier, F, 1985) |
| "We report a patient who developed agranulocytosis following exposure to three drugs: amodiaquine, pyrimethamine and dipyrone." | 3.67 | Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serum. ( Douer, D; Ramot, B; Schwartz, E; Shaked, N, 1985) |
| "A combination of the drugs amodiaquine and tetracycline was used in a clinical trial at Phrabuddhabat Hospital in Central Thailand for treating Plasmodium falciparum malaria." | 3.66 | Treatment of Plasmodium falciparum malaria with a combination of amodiaquine and tetracycline in Central Thailand. ( Benjapong, W; Duriyananda, D; Malikul, S; Noeypatimanond, S; Ungkasrithongkul, M, 1983) |
| "A patient is presented who developed agranulocytosis while taking amodiaquine for suppressive therapy of malaria." | 3.66 | [Amodiaquine-induced agranulocytosis in malaria prevention: demonstration of an amodiaquine-induced cytotoxic antibody against granulocytes]. ( Gmür, J; Neftel, K; Schulthess, HK; von Felten, A, 1983) |
| "Evidence of resistance ot chloroquine was found in 13 out of 14 children from the East New Britain Province of Papua New Guinea, with Plasmodium falciparum malaria." | 3.66 | Chloroquine resistant Plasmodium falciparum malaria in East New Britain, Papua New Guinea. ( Tulloch, A, 1980) |
| "Chloroquine and amodiaquine are demonstrably still the most reliable drugs for the treatment of malaria, except in the south east Asia area, and in parts of south and central America where an altered sensitivity of falciparum plasmodia has been confirmed." | 3.65 | [Chemotherapy and chemoprophylaxis of malaria (author's transl)]. ( Bruce-Chwatt, LJ, 1976) |
| " Eleven volunteers received chloroquine in usually curative doses on a three-day schedule during acute clinical malaria attacks." | 3.64 | STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND. ( ALVING, AS; BREWER, GJ; MILLAR, JW; POWELL, RD, 1964) |
| "Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia." | 3.11 | Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial. ( Bamadio, A; Chico, RM; Cohee, LM; Coumare, S; Dara, A; Diarra, M; Djimde, AA; Doumbo, OK; Kodio, A; Maiga, H; Opondo, C; Sagara, I; Sidibe, B; Tekete, M; Traore, OB; Traore, ZI, 2022) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 3.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| " Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing." | 2.82 | Pharmacokinetic considerations in seasonal malaria chemoprevention. ( Chotsiri, P; Tarning, J; White, NJ, 2022) |
| " CF fortified with highly bioavailable iron improved iron status but not Hb concentration, despite three-monthly IPT of malaria." | 2.80 | The effect of iron-fortified complementary food and intermittent preventive treatment of malaria on anaemia in 12- to 36-month-old children: a cluster-randomised controlled trial. ( Adiossan, LG; Brittenham, GM; Diakité, VG; Glinz, D; Hurrell, RF; N'Goran, EK; Ouattara, M; Righetti, AA; Seifert, B; Utzinger, J; Wegmüller, R; Zimmermann, MB, 2015) |
| "Malaria and pneumonia are leading causes of childhood mortality." | 2.77 | Impact of community management of fever (using antimalarials with or without antibiotics) on childhood mortality: a cluster-randomized controlled trial in Ghana. ( Abbey, M; Adjuik, M; Aikins, M; Awini, E; Chinbuah, MA; Gyapong, JO; Gyapong, M; Kager, PA; Nonvignon, J; Pagnoni, F, 2012) |
| "Intermittent preventive treatment for malaria in children (IPTc) involves the administration of a full course of an anti-malarial treatment to children under 5 years old at specified time points regardless of whether or not they are known to be infected, in areas where malaria transmission is seasonal." | 2.75 | Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children. ( Chandramohan, D; Conteh, L; Greenwood, B; Kweku, M; Legood, R; Patouillard, E, 2010) |
| "1) of program and control retailers, respectively, reported correct knowledge on dosing with amodiaquine (OR = 29." | 2.74 | Impact of ministry of health interventions on private medicine retailer knowledge and practices on anti-malarial treatment in Kenya. ( Abuya, T; Fegan, G; Karisa, B; Marsh, V; Mutemi, W; Ochola, S; Rowa, Y, 2009) |
| " Secondary end-points were incidence of adverse events, mean haemoglobin concentration and prevalence of parasites carrying markers of resistance to SP." | 2.73 | A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. ( Bâ, el H; Boulanger, D; Cissé, B; Gaye, O; Greenwood, B; Hallett, R; Lines, J; Milligan, P; Simondon, F; Simondon, K; Sokhna, C; Sutherland, C; Targett, G; Trape, JF, 2008) |
| " Additionally, these models are able to identify patient characteristics that cause alterations in the expected PK/PD profiles and through simulations can recommend changes to dosing which compensate for the differences." | 2.72 | Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations. ( Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021) |
| "Acute malaria has been associated with a decreased antibody response to tetanus and diphtheria toxoids, meningococcal, salmonella, and Hib vaccines." | 2.71 | Malaria chemoprophylaxis and the serologic response to measles and diphtheria-tetanus-whole-cell pertussis vaccines. ( Breman, JG; Campaoré, P; Collins, WE; Lobel, HO; Manclark, CR; Meade, BD; Miller, MA; Roberts, JM; Rosen, JB; Saliou, P, 2005) |
| "The present monograph reviews data relevant to applying the biowaiver procedure for the approval of immediate release (IR) multisource solid dosage forms containing amodiaquine hydrochloride (ADQ) as the single active pharmaceutical ingredient (API)." | 2.48 | Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride. ( Abrahamsson, B; Barends, DM; Dressman, JB; Groot, DW; Kopp, S; Nair, A; Polli, JE; Shah, VP, 2012) |
| " Safe and effective drugs, capable of being administered as a single-dose or short-course treatment, are urgently needed to control the adaptable malaria parasite." | 2.36 | Falciparum malaria: the urgent need for safe and effective drugs. ( Rieckmann, KH, 1983) |
| "Malaria is not a disease of the past." | 2.36 | [Current information on treatment and prophylaxis of malaria (author's transl)]. ( Cambournac, FJ, 1979) |
| "Malaria is the leading cause of morbidity and mortality among infants and children under-five in sub-Saharan Africa." | 1.91 | Predictors of caregiver adherence to administration of amodiaquine during delivery of seasonal malaria chemoprevention in Nigeria, Burkina Faso, Chad, and Togo. ( Aidenagbon, A; Ibinaiye, T; Ogunmola, O; Oguoma, C; Oresanya, O; Rassi, C; Richardson, S, 2023) |
| "Malaria is the one of the deadliest infectious diseases worldwide." | 1.91 | Antimalarial Agents Derived from Metal-Amodiaquine Complexes with Activity in Multiple Stages of the Plasmodium Life Cycle. ( Araújo Nobrega, J; Azevedo Batista, A; Basilico, N; Colina-Vegas, L; D'Alessandro, S; da Cruz B Silva, M; de Souza Pereira, C; Isis Barros, A; Moreira, DRM; Navarro, M; Rottmann, M, 2023) |
| "Under-five malaria data for confirmed episodes, deaths, and number of children dosed per cycle of SMC campaign were extracted from the District Health Information Management System (DHIMS-2) for 2018-2019." | 1.72 | Effectiveness of seasonal malaria chemoprevention in reducing under-five malaria morbidity and mortality in the Savannah Region, Ghana. ( Abubakari, II; Adjei, MR; Baafi, JV; Buamah, M; Ibrahim, S; Kubio, C; Sadiq, A; Sarfo, A; Suuri, T, 2022) |
| " The present study hence evaluated the effect of MD on the disposition of AQ in mice with a view to investigating a possible pharmacokinetic interaction." | 1.56 | Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice. ( Adeagbo, BA; Adehin, A; Adepiti, AO; Bolaji, OO; Elujoba, AA, 2020) |
| " Here, we evaluated the population pharmacokinetic properties of amodiaquine and its active metabolite, desethylamodiaquine, in children receiving SMC under directly observed ideal conditions (n = 136), and the adherence of SMC at an implementation phase in children participating in a case-control study to evaluate SMC effectiveness (n = 869)." | 1.56 | Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children. ( Assao, B; Blessborn, D; Coldiron, ME; Ding, J; Grais, RF; Guindo, O; Koscalova, A; Langendorf, C; Tarning, J; Winterberg, M, 2020) |
| " Thus, the efficacy of ASAQ is maintained and appears to be increased after long-term use in contrast to what is observed for other ACTs used in Africa." | 1.56 | Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar. ( Abbas, FB; Ali, AS; Ali, AW; Barnes, R; Björkman, A; Frumento, P; Mårtensson, A; Morris, U; Msellem, M; Soe, A, 2020) |
| "There was no evidence of proarrhythmia with any treatment during the study although dihydroartemisinin-piperaquine, artesunate-amodiaquine and artemether-lumefantrine significantly prolonged QTc." | 1.51 | Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. ( Beavogui, AH; Borghini-Fuhrer, I; Djimdé, AA; Duparc, S; Felices, M; Funck-Brentano, C; Khan, Y; Ouedraogo, JB; Ouologuem, N; Sagara, I; Sirima, SB; Soulama, I; Voiriot, P, 2019) |
| "Different approaches are adopted when treating malaria." | 1.43 | Seeking treatment for uncomplicated malaria: experiences from the Kintampo districts of Ghana. ( Abokyi, LN; Afari-Asiedu, S; Asante, KP; Febir, LG; Gyapong, M; Kwarteng, A; Ogutu, B; Owusu-Agyei, S, 2016) |
| " The occurrence and severity of events was collected before, during and after treatment up to 28 days in order to generate information on all adverse events (AEs) as well as treatment-emerging signs/symptoms (TESS)." | 1.38 | Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western Senegal. ( Brasseur, P; Olliaro, PL; Vaillant, MT, 2012) |
| " The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity." | 1.37 | Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. ( Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011) |
| " Intermittent preventive treatment for children (IPTc) combined with timely treatment of malaria related febrile illness at home to reduce parasite prevalence and malaria morbidity in children aged between six and 60 months in a coastal community in Ghana." | 1.37 | Two-year evaluation of Intermittent Preventive Treatment for Children (IPTc) combined with timely home treatment for malaria control in Ghana. ( Ahorlu, CK; Koram, KA; Seake-Kwawu, A; Weiss, MG, 2011) |
| "Malaria is reportedly receding in different epidemiological settings, but local long-term surveys are limited." | 1.37 | Changing patterns of malaria during 1996-2010 in an area of moderate transmission in southern Senegal. ( Agnamey, P; Badiane, M; Brasseur, P; Cisse, M; Olliaro, PL; Vaillant, MT, 2011) |
| "malariae is correlated with increased P." | 1.35 | Increased Plasmodium falciparum gametocyte production in mixed infections with P. malariae. ( Arens, T; Bousema, JT; Drakeley, CJ; Gouagna, LC; Houben, R; Mens, PF; Omar, SA; Sauerwein, RW; Schallig, H, 2008) |
| "Amodiaquine is an amino-4-quinoline with the basic spectrum of activity of chloroquine." | 1.34 | Emergency liver transplantation in amodiaquine-induced fulminant hepatitis. ( Desmeules, J; Giostra, E; Hadengue, A; Markham, LN; Rebsamen, M; Rossier, M, 2007) |
| " The assay of amodiaquine hydrochloride in pharmaceutical dosage forms using one of the proposed sensors gave average recoveries of 104." | 1.33 | Amodiaquine polymeric membrane electrode. ( Amighi, K; Blankert, B; Kambu, O; Kauffmann, JM; Malongo, TK; Nsangu, J, 2006) |
| " The results indicate the suitability of this technique in antimalarial drug quality and bioavailability studies." | 1.33 | A simple technique for the detection of anti-malarial drug formulations and their presence in human urine. ( Akida, JA; Lemnge, MM; Lugimbana, L; Malebo, HM; Malle, LN; Segeja, MD, 2006) |
| " A 25-mg base/kg dosage of amodiaquine produced parasite clearance in 34 of 38 (89%) children in a mean of 2." | 1.27 | Evaluation of amodiaquine treatment of chloroquine-resistant Plasmodium falciparum malaria on Zanzibar, 1982. ( Campbell, CC; Khatib, OJ; Payne, D; Schwartz, IK, 1983) |
| " Reappraisal of quinine therapy has led to important modifications in dosage recommendations and recognition of a major complication of severe malaria associated with its use--hypoglycaemia." | 1.27 | Management of Plasmodium falciparum malaria. ( Phillips, RE, 1984) |
| "Chloroquine resistance was confirmed by testing in vitro and in vivo." | 1.27 | Multiple drug resistant Plasmodium falciparum malaria in a pregnant indigenous Zambian woman. ( Rolfe, M, 1988) |
| "Amodiaquine was not found in any sample, but the major metabolite monodesethylamodiaquine was detected and was assumed to be the sole derivative that contributed significantly to antimalarial activity in the blood." | 1.27 | Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. ( Blayo, MC; Faurisson, F; Le Bras, J; Pussard, E; Scherrmann, JM; Verdier, F, 1987) |
| "Amodiaquine was associated with a 3." | 1.27 | Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis. ( Gyr, N; Schär, M; Stürchler, D, 1987) |
| "Malaria is the only significant cause of ahaptoglobinaemia in subjects both with and without detectable parasitaemia." | 1.27 | Malaria, cause of ahaptoglobinaemia in Africans. ( Bosseno, MF; Engler, R; Fribourg-Blanc, A; Lallemant, M; Mouchet, J; Trape, JF, 1985) |
| " In an attempt to explain the discrepancy between its in vivo-in vitro activity, a pharmacokinetic study was conducted in healthy subjects with HPLC assays." | 1.27 | [Pharmacokinetics of amodiaquine and prevention of Plasmodium falciparum malaria]. ( Blayo, MC; Faurisson, F; Pussard, E; Verdier, F, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 201 (47.74) | 18.7374 |
| 1990's | 22 (5.23) | 18.2507 |
| 2000's | 71 (16.86) | 29.6817 |
| 2010's | 81 (19.24) | 24.3611 |
| 2020's | 46 (10.93) | 2.80 |
| Authors | Studies |
|---|---|
| Meister, S | 1 |
| Plouffe, DM | 1 |
| Kuhen, KL | 1 |
| Bonamy, GM | 1 |
| Wu, T | 1 |
| Barnes, SW | 1 |
| Bopp, SE | 1 |
| Borboa, R | 1 |
| Bright, AT | 1 |
| Che, J | 1 |
| Cohen, S | 1 |
| Dharia, NV | 1 |
| Gagaring, K | 1 |
| Gettayacamin, M | 1 |
| Gordon, P | 1 |
| Groessl, T | 1 |
| Kato, N | 1 |
| Lee, MC | 2 |
| McNamara, CW | 1 |
| Fidock, DA | 2 |
| Nagle, A | 1 |
| Nam, TG | 1 |
| Richmond, W | 1 |
| Roland, J | 1 |
| Rottmann, M | 3 |
| Zhou, B | 1 |
| Froissard, P | 1 |
| Glynne, RJ | 1 |
| Mazier, D | 2 |
| Sattabongkot, J | 1 |
| Schultz, PG | 1 |
| Tuntland, T | 1 |
| Walker, JR | 1 |
| Zhou, Y | 1 |
| Chatterjee, A | 1 |
| Diagana, TT | 1 |
| Winzeler, EA | 1 |
| Cross, RM | 1 |
| Flanigan, DL | 1 |
| Monastyrskyi, A | 2 |
| LaCrue, AN | 2 |
| Sáenz, FE | 1 |
| Maignan, JR | 2 |
| Mutka, TS | 1 |
| White, KL | 1 |
| Shackleford, DM | 1 |
| Bathurst, I | 1 |
| Fronczek, FR | 1 |
| Wojtas, L | 1 |
| Guida, WC | 1 |
| Charman, SA | 1 |
| Burrows, JN | 1 |
| Kyle, DE | 2 |
| Manetsch, R | 2 |
| Ongarora, DS | 1 |
| Strydom, N | 1 |
| Wicht, K | 1 |
| Njoroge, M | 1 |
| Wiesner, L | 1 |
| Egan, TJ | 1 |
| Wittlin, S | 3 |
| Jurva, U | 1 |
| Masimirembwa, CM | 1 |
| Chibale, K | 1 |
| Santos, SA | 1 |
| Lukens, AK | 1 |
| Coelho, L | 1 |
| Nogueira, F | 1 |
| Wirth, DF | 1 |
| Mazitschek, R | 1 |
| Moreira, R | 1 |
| Paulo, A | 1 |
| da Silva, RMRJ | 1 |
| Gandi, MO | 1 |
| Mendonça, JS | 1 |
| Carvalho, AS | 1 |
| Coutinho, JP | 1 |
| Aguiar, ACC | 1 |
| Krettli, AU | 1 |
| Boechat, N | 1 |
| Tibon, NS | 1 |
| Ng, CH | 1 |
| Cheong, SL | 1 |
| Brockmeyer, F | 1 |
| Zhao, Y | 1 |
| Maher, SP | 1 |
| Padin-Irizarry, V | 1 |
| Sakhno, YI | 1 |
| Parvatkar, PT | 1 |
| Asakawa, AH | 1 |
| Huang, L | 2 |
| Casandra, D | 1 |
| Mashkouri, S | 1 |
| Abuaku, B | 3 |
| Duah-Quashie, NO | 2 |
| Quashie, N | 2 |
| Gyasi, A | 1 |
| Afriyie, PO | 1 |
| Owusu-Antwi, F | 1 |
| Ghansah, A | 3 |
| Malm, KL | 1 |
| Bart-Plange, C | 2 |
| Koram, KA | 6 |
| Mahamar, A | 2 |
| Sumner, KM | 1 |
| Levitt, B | 1 |
| Freedman, B | 2 |
| Traore, A | 3 |
| Barry, A | 2 |
| Issiaka, D | 1 |
| Dembele, AB | 1 |
| Kanoute, MB | 1 |
| Attaher, O | 1 |
| Diarra, BN | 1 |
| Sagara, I | 9 |
| Djimde, A | 2 |
| Duffy, PE | 1 |
| Fried, M | 1 |
| Taylor, SM | 2 |
| Dicko, A | 7 |
| Marwa, K | 1 |
| Kapesa, A | 1 |
| Baraka, V | 2 |
| Konje, E | 1 |
| Kidenya, B | 1 |
| Mukonzo, J | 1 |
| Kamugisha, E | 1 |
| Swedberg, G | 1 |
| Peto, TJ | 1 |
| Tripura, R | 1 |
| Callery, JJ | 1 |
| Lek, D | 1 |
| Nghia, HDT | 1 |
| Nguon, C | 1 |
| Thuong, NTH | 1 |
| van der Pluijm, RW | 1 |
| Dung, NTP | 1 |
| Sokha, M | 1 |
| Van Luong, V | 1 |
| Long, LT | 1 |
| Sovann, Y | 1 |
| Duanguppama, J | 1 |
| Waithira, N | 1 |
| Hoglund, RM | 1 |
| Chotsiri, P | 3 |
| Chau, NH | 1 |
| Ruecker, A | 1 |
| Amaratunga, C | 1 |
| Dhorda, M | 1 |
| Miotto, O | 1 |
| Maude, RJ | 1 |
| Rekol, H | 1 |
| Chotivanich, K | 1 |
| Tarning, J | 7 |
| von Seidlein, L | 2 |
| Imwong, M | 1 |
| Mukaka, M | 1 |
| Day, NPJ | 1 |
| Hien, TT | 2 |
| White, NJ | 9 |
| Dondorp, AM | 2 |
| Koko, VS | 1 |
| Warsame, M | 2 |
| Vonhm, B | 1 |
| Jeuronlon, MK | 1 |
| Menard, D | 2 |
| Ma, L | 1 |
| Taweh, F | 1 |
| Tehmeh, L | 1 |
| Nyansaiye, P | 1 |
| Pratt, OJ | 1 |
| Parwon, S | 1 |
| Kamara, P | 1 |
| Asinya, M | 1 |
| Kollie, A | 1 |
| Ringwald, P | 3 |
| Pembet Singana, B | 1 |
| Casimiro, PN | 1 |
| Matondo Diassivi, B | 1 |
| Kobawila, SC | 1 |
| Youndouka, JM | 1 |
| Basco, LK | 1 |
| Briolant, S | 1 |
| Ndounga, M | 4 |
| Hien, D | 2 |
| Kaboré, JMT | 2 |
| Siribié, M | 2 |
| Soulama, I | 4 |
| Barry, N | 3 |
| Baguiya, A | 2 |
| Tiono, AB | 3 |
| Tchouatieu, AM | 2 |
| Sirima, SB | 6 |
| Maiga, H | 3 |
| Opondo, C | 1 |
| Chico, RM | 1 |
| Cohee, LM | 1 |
| Traore, OB | 1 |
| Tekete, M | 1 |
| Dara, A | 1 |
| Traore, ZI | 2 |
| Diarra, M | 2 |
| Coumare, S | 2 |
| Kodio, A | 1 |
| Bamadio, A | 1 |
| Sidibe, B | 2 |
| Doumbo, OK | 3 |
| Djimde, AA | 5 |
| Korwa, S | 1 |
| Wu, A | 1 |
| Green, CL | 1 |
| Clapp, S | 1 |
| Kirui, JK | 1 |
| O'Meara, WP | 1 |
| Njuguna, FM | 1 |
| Doumbia, S | 1 |
| Sogoba, N | 1 |
| Diakite, M | 1 |
| Toure, M | 1 |
| Keita, M | 1 |
| Konaté, D | 1 |
| Diawara, SI | 1 |
| Diarra, A | 2 |
| Sanogo, D | 1 |
| Kane, F | 1 |
| Diakite, SAS | 1 |
| Traore, K | 1 |
| Thiam, SM | 1 |
| Traoré, SF | 1 |
| Cisse, I | 1 |
| Mihigo, J | 3 |
| Coulibaly, MB | 1 |
| Dabitao, D | 1 |
| Alifrangis, M | 2 |
| Barry, AE | 1 |
| Müller, GC | 1 |
| Beier, JC | 1 |
| Shaffer, JG | 1 |
| Chan, XHS | 1 |
| Capel, RA | 1 |
| Pike, J | 1 |
| Hanboonkunupakarn, B | 1 |
| Lee, SJ | 1 |
| Hanafiah, M | 1 |
| Win, YN | 1 |
| Cremer, MA | 1 |
| Kiechel, JR | 7 |
| Ogutu, B | 2 |
| Taylor, WRJ | 1 |
| Burton, RB | 1 |
| Zoleko-Manego, R | 1 |
| Okwu, DG | 1 |
| Handrich, C | 1 |
| Dimessa-Mbadinga, LB | 1 |
| Akinosho, MA | 1 |
| Ndzebe-Ndoumba, WF | 1 |
| Davi, SD | 1 |
| Stelzl, D | 1 |
| Veletzky, L | 1 |
| Kreidenweiss, A | 1 |
| Nordmann, T | 1 |
| Adegnika, AA | 1 |
| Lell, B | 2 |
| Kremsner, PG | 4 |
| Ramharter, M | 1 |
| Mombo-Ngoma, G | 1 |
| Beshir, KB | 1 |
| Muwanguzi, J | 1 |
| Nader, J | 1 |
| Mansukhani, R | 1 |
| Gamougam, K | 1 |
| Ceesay, S | 2 |
| Bazie, T | 1 |
| Kolie, F | 1 |
| Lamine, MM | 1 |
| Cairns, M | 8 |
| Snell, P | 1 |
| Scott, S | 1 |
| Diallo, A | 1 |
| Merle, CS | 1 |
| NDiaye, JL | 4 |
| Razafindralambo, L | 1 |
| Moroso, D | 1 |
| Ouedraogo, JB | 8 |
| Zongo, I | 6 |
| Kessely, H | 1 |
| Doumagoum, D | 1 |
| Bojang, K | 1 |
| Loua, K | 1 |
| Laminou, IM | 1 |
| Ogboi, SJ | 1 |
| Eloike, T | 1 |
| Milligan, P | 6 |
| Sutherland, CJ | 1 |
| Nuwa, A | 1 |
| Baker, K | 1 |
| Bonnington, C | 1 |
| Odongo, M | 1 |
| Kyagulanyi, T | 1 |
| Bwanika, JB | 1 |
| Richardson, S | 2 |
| Nabakooza, J | 1 |
| Achan, J | 2 |
| Kajubi, R | 1 |
| Odong, DS | 1 |
| Nakirunda, M | 1 |
| Magumba, G | 1 |
| Beinomugisha, G | 1 |
| Marasciulo-Rice, M | 1 |
| Abio, H | 1 |
| Rassi, C | 2 |
| Rutazaana, D | 1 |
| Rubahika, D | 1 |
| Tibenderana, J | 1 |
| Opigo, J | 1 |
| Olukosi, AY | 1 |
| Musa, AZ | 1 |
| Ogbulafor, N | 1 |
| Aina, O | 1 |
| Mokuolu, O | 1 |
| Oguche, S | 1 |
| Wammanda, R | 1 |
| Okafor, H | 1 |
| Ekama, SO | 1 |
| David, AN | 1 |
| Happi, CT | 4 |
| Ozor, L | 1 |
| Babatunde, S | 1 |
| Ijezie, SN | 1 |
| Uhomoibhi, PE | 1 |
| Awolola, ST | 1 |
| Mohammed, AB | 1 |
| Salako, BL | 1 |
| Ibinaiye, T | 1 |
| Oresanya, O | 1 |
| Oguoma, C | 1 |
| Aidenagbon, A | 1 |
| Ogunmola, O | 1 |
| Roh, ME | 1 |
| Haro, A | 1 |
| Somé, AF | 2 |
| Yerbanga, RS | 2 |
| Conrad, MD | 1 |
| Wallender, E | 2 |
| Legac, J | 1 |
| Aweeka, F | 2 |
| Rosenthal, PJ | 6 |
| Colina-Vegas, L | 1 |
| da Cruz B Silva, M | 1 |
| de Souza Pereira, C | 1 |
| Isis Barros, A | 1 |
| Araújo Nobrega, J | 1 |
| Navarro, M | 1 |
| D'Alessandro, S | 1 |
| Basilico, N | 1 |
| Azevedo Batista, A | 1 |
| Moreira, DRM | 1 |
| Adjei, MR | 1 |
| Kubio, C | 1 |
| Buamah, M | 1 |
| Sarfo, A | 1 |
| Suuri, T | 1 |
| Ibrahim, S | 1 |
| Sadiq, A | 1 |
| Abubakari, II | 1 |
| Baafi, JV | 1 |
| Makenga, G | 1 |
| Francis, F | 1 |
| Nakato, S | 1 |
| Gesase, S | 2 |
| Mtove, G | 1 |
| Madebe, R | 1 |
| Kyaruzi, E | 1 |
| Minja, DTR | 1 |
| Lusingu, JPA | 1 |
| Geertruyden, JV | 1 |
| Afolabi, MO | 1 |
| Diaw, A | 1 |
| Fall, EHB | 1 |
| Sall, FB | 1 |
| Diédhiou, A | 1 |
| Seck, A | 1 |
| Camara, B | 1 |
| Niang, D | 1 |
| Manga, IA | 1 |
| Mbaye, I | 1 |
| Sougou, NM | 1 |
| Sow, D | 2 |
| Greenwood, B | 13 |
| Ndiaye, JLA | 1 |
| Djimde, M | 1 |
| Kayentao, K | 1 |
| Tshiongo, JK | 1 |
| Fofana, B | 2 |
| Arama, C | 1 |
| Beavogui, AH | 3 |
| Mens, PF | 3 |
| Schallig, HD | 1 |
| Falade, CO | 4 |
| Orimadegun, AE | 1 |
| Michael, OS | 1 |
| Dada-Adegbola, HO | 2 |
| Ogunkunle, OO | 2 |
| Badejo, JA | 2 |
| Funwei, RI | 1 |
| Ajayi, IO | 3 |
| Jegede, AS | 1 |
| Ojurongbe, OD | 1 |
| Ssekitooleko, J | 1 |
| Baba, E | 1 |
| Hamade, P | 1 |
| Webster, J | 1 |
| Chandramohan, D | 10 |
| Adepiti, AO | 3 |
| Adeagbo, BA | 1 |
| Adehin, A | 1 |
| Bolaji, OO | 3 |
| Elujoba, AA | 2 |
| Ding, J | 1 |
| Coldiron, ME | 2 |
| Assao, B | 1 |
| Guindo, O | 1 |
| Blessborn, D | 1 |
| Winterberg, M | 1 |
| Grais, RF | 2 |
| Koscalova, A | 1 |
| Langendorf, C | 1 |
| Rouamba, T | 1 |
| Sondo, P | 1 |
| Derra, K | 1 |
| Nakanabo-Diallo, S | 1 |
| Bihoun, B | 1 |
| Rouamba, E | 1 |
| Tarnagda, Z | 1 |
| Kazienga, A | 1 |
| Valea, I | 2 |
| Sorgho, H | 1 |
| Pagnoni, F | 4 |
| Samadoulougou-Kirakoya, F | 1 |
| Tinto, H | 4 |
| Petersen, E | 1 |
| Picot, S | 1 |
| Mairet-Khedim, M | 1 |
| Leang, R | 1 |
| Marmai, C | 1 |
| Khim, N | 1 |
| Kim, S | 1 |
| Ke, S | 1 |
| Kauy, C | 1 |
| Kloeung, N | 1 |
| Eam, R | 1 |
| Chy, S | 1 |
| Izac, B | 1 |
| Mey Bouth, D | 1 |
| Dorina Bustos, M | 1 |
| Ariey, F | 1 |
| Witkowski, B | 1 |
| Hema-Ouangraoua, S | 1 |
| Kabore, NF | 1 |
| Frédéric, N | 1 |
| Compaore, YD | 3 |
| Kuepfer, I | 2 |
| Nikiéma, F | 2 |
| Zongo, M | 1 |
| Somé, FA | 1 |
| Kaboré, N | 1 |
| Msellem, M | 1 |
| Morris, U | 1 |
| Soe, A | 1 |
| Abbas, FB | 1 |
| Ali, AW | 1 |
| Barnes, R | 1 |
| Frumento, P | 1 |
| Ali, AS | 2 |
| Mårtensson, A | 1 |
| Björkman, A | 2 |
| Gendrot, M | 1 |
| Duflot, I | 1 |
| Boxberger, M | 1 |
| Delandre, O | 1 |
| Jardot, P | 1 |
| Le Bideau, M | 1 |
| Andreani, J | 1 |
| Fonta, I | 1 |
| Mosnier, J | 1 |
| Rolland, C | 1 |
| Hutter, S | 1 |
| La Scola, B | 1 |
| Pradines, B | 1 |
| Aschenbrenner, DS | 1 |
| Shittu, O | 1 |
| Opeyemi, OA | 1 |
| Omotesho, OB | 1 |
| Fakayode, O | 1 |
| Asogwa, N | 1 |
| Adeniyi, OM | 1 |
| Fatoba, IM | 1 |
| Salawu, KM | 1 |
| Ajibaye, O | 1 |
| Babamale, OA | 1 |
| Iyiola, OA | 1 |
| Aremu, OI | 1 |
| Myers-Hansen, JL | 1 |
| Oyebola, MK | 1 |
| Mensah, BA | 2 |
| Ahorlu, C | 1 |
| Wilson, MD | 1 |
| Awandare, G | 1 |
| Ngwa, AA | 1 |
| Quashie, NB | 2 |
| Nombré, Y | 1 |
| Kiba Koumaré, A | 1 |
| Héma, A | 1 |
| Dianda, F | 1 |
| Savadogo, Y | 1 |
| Kouanda, S | 1 |
| Diawara, H | 2 |
| Walker, P | 1 |
| Steinhardt, LC | 2 |
| Diawara, F | 2 |
| Kamate, B | 2 |
| Duval, L | 1 |
| Sicuri, E | 1 |
| Sadou, A | 2 |
| Eckert, E | 2 |
| Conteh, L | 4 |
| Hughes, E | 1 |
| Mohamed Ali, A | 1 |
| Jagannathan, P | 1 |
| Savic, RM | 1 |
| Toure, OA | 1 |
| Assi, SB | 1 |
| Kiki-Barro, PMC | 1 |
| Yavo, W | 1 |
| Abba, T | 1 |
| Tiacoh, LN | 1 |
| Konate, AA | 1 |
| Angora, EK | 1 |
| Bedia, VA | 1 |
| Menan, H | 1 |
| Daho, AK | 1 |
| Emmanuel, B | 1 |
| Sudhakar, R | 1 |
| Das, D | 1 |
| Thanumalayan, S | 1 |
| Gorde, S | 1 |
| Sijwali, PS | 1 |
| Esu, EB | 1 |
| Oringanje, C | 1 |
| Meremikwu, MM | 1 |
| Chalon, S | 1 |
| Chughlay, MF | 1 |
| Abla, N | 1 |
| Marie Tchouatieu, A | 1 |
| Haouala, A | 1 |
| Hutter, B | 1 |
| Lorch, U | 1 |
| Macintyre, F | 1 |
| York, A | 1 |
| Mbaye, A | 1 |
| Gaye, A | 1 |
| Dieye, B | 1 |
| Ndiaye, YD | 1 |
| Bei, AK | 1 |
| Affara, M | 1 |
| Deme, AB | 1 |
| Yade, MS | 1 |
| Diongue, K | 1 |
| Ndiaye, IM | 1 |
| Ndiaye, T | 2 |
| Sy, M | 1 |
| Sy, N | 2 |
| Koita, O | 1 |
| Krogstad, DJ | 1 |
| Volkman, S | 1 |
| Nwakanma, D | 1 |
| Ndiaye, D | 1 |
| Clark, RL | 1 |
| Vallières, C | 1 |
| Avery, SV | 1 |
| Abuaku, BK | 1 |
| Ofori, MF | 1 |
| Myers-Hansen, J | 1 |
| Derkyi-Kwarteng, AN | 1 |
| Essilfie, F | 1 |
| Dokurugu, M | 1 |
| Amoakoh, E | 1 |
| Aprioku, JS | 1 |
| Mankwe, AC | 1 |
| Traore, T | 1 |
| Kone, DT | 1 |
| Kone, D | 1 |
| Diallo, M | 1 |
| Pitt, C | 2 |
| Ndiaye, M | 3 |
| Sy, O | 2 |
| Hadj Ba, E | 1 |
| Cissé, B | 6 |
| Gomis, JF | 3 |
| Gaye, O | 5 |
| Milligan, PJ | 5 |
| Banek, K | 2 |
| Webb, EL | 2 |
| Smith, SJ | 2 |
| Staedke, SG | 5 |
| Ali, AM | 1 |
| Penny, MA | 1 |
| Smith, TA | 1 |
| Workman, L | 1 |
| Sasi, P | 2 |
| Adjei, GO | 3 |
| Jullien, V | 1 |
| Rijken, MJ | 1 |
| McGready, R | 1 |
| Mwesigwa, J | 1 |
| Kristensen, K | 1 |
| Stepniewska, K | 3 |
| Barnes, KI | 2 |
| Denti, P | 1 |
| Camara, A | 1 |
| Moriarty, LF | 1 |
| Guilavogui, T | 1 |
| Diakité, PS | 1 |
| Zoumanigui, JS | 1 |
| Sidibé, S | 1 |
| Bah, I | 1 |
| Kaba, I | 1 |
| Kourouma, D | 1 |
| Zoumanigui, K | 1 |
| Plucinski, M | 1 |
| Funck-Brentano, C | 1 |
| Ouologuem, N | 1 |
| Duparc, S | 1 |
| Felices, M | 1 |
| Borghini-Fuhrer, I | 1 |
| Khan, Y | 1 |
| Voiriot, P | 1 |
| Tapily, A | 1 |
| Yerbanga, S | 1 |
| Thera, I | 1 |
| Doumbo, O | 1 |
| Suárez-Sánchez, P | 1 |
| García, B | 1 |
| Nzang, J | 1 |
| Ncogo, P | 1 |
| Riloha, M | 1 |
| Berzosa, P | 1 |
| Benito, A | 1 |
| Romay-Barja, M | 1 |
| Bisoffi, Z | 1 |
| Sirima, BS | 1 |
| Gobbi, F | 1 |
| Angheben, A | 1 |
| Buonfrate, D | 1 |
| Van den Ende, J | 1 |
| Bassi, PU | 1 |
| Osakwe, AI | 1 |
| Isah, A | 1 |
| Suku, C | 1 |
| Kalat, M | 1 |
| Jalo, I | 1 |
| Wammanda, RD | 1 |
| Ugochukwu, C | 1 |
| Adesina, O | 1 |
| Nyong, EE | 1 |
| Osungwu, F | 1 |
| Pal, S | 1 |
| Nwoasu, SC | 1 |
| Wallberg, M | 1 |
| Coulter, D | 1 |
| Adabayeri, VM | 1 |
| Annobil, SH | 1 |
| Pukrittayakamee, S | 1 |
| Faiz, MA | 1 |
| Mokuolu, OA | 1 |
| Chinbuah, MA | 2 |
| Adjuik, M | 4 |
| Cobelens, F | 1 |
| Abbey, M | 2 |
| Gyapong, M | 3 |
| Kager, PA | 2 |
| Gyapong, JO | 2 |
| Scarsi, KK | 1 |
| Fehintola, FA | 1 |
| Ma, Q | 1 |
| Aweeka, FT | 1 |
| Darin, KM | 1 |
| Morse, GD | 1 |
| Akinola, IT | 1 |
| Adedeji, WA | 1 |
| Lindegardh, N | 1 |
| Ojengbede, O | 1 |
| Adewole, IF | 1 |
| Taiwo, B | 1 |
| Murphy, RL | 1 |
| Akinyinka, OO | 1 |
| Parikh, S | 1 |
| RAY, AP | 4 |
| NAIR, CP | 1 |
| CHAUDHURI, RN | 1 |
| RAI CHAUDHURI, MN | 1 |
| GOSH, S | 1 |
| DUTTA, BN | 1 |
| HAMILTON, CS | 1 |
| Oguike, MC | 1 |
| Nash, O | 1 |
| Ademowo, OG | 2 |
| Kameda, K | 1 |
| Abiodun, OO | 3 |
| Akinola, O | 2 |
| Sowunmi, A | 3 |
| Gbotosho, GO | 5 |
| Nambozi, M | 1 |
| Mulenga, M | 1 |
| Halidou, T | 1 |
| Tagbor, H | 2 |
| Mwapasa, V | 1 |
| Phiri, LK | 1 |
| Kalanda, G | 1 |
| Traore, M | 1 |
| Mwakazanga, D | 1 |
| Claeys, Y | 1 |
| Schurmans, C | 1 |
| De Crop, M | 1 |
| Menten, J | 1 |
| Ravinetto, R | 1 |
| Thriemer, K | 1 |
| Van Geertruyden, JP | 1 |
| Mutabingwa, T | 1 |
| D'Alessandro, U | 4 |
| Falajiki, YF | 1 |
| Adedeji, ON | 1 |
| Osonuga, OA | 1 |
| Sutherland, C | 3 |
| Nosten, F | 1 |
| Wotodjo, AN | 1 |
| Richard, V | 1 |
| Boyer, S | 1 |
| Doucoure, S | 1 |
| Diagne, N | 1 |
| Touré-Baldé, A | 1 |
| Tall, A | 1 |
| Faye, N | 1 |
| Gaudart, J | 2 |
| Trape, JF | 7 |
| Sokhna, C | 6 |
| Glinz, D | 1 |
| Hurrell, RF | 1 |
| Ouattara, M | 1 |
| Zimmermann, MB | 1 |
| Brittenham, GM | 1 |
| Adiossan, LG | 1 |
| Righetti, AA | 1 |
| Seifert, B | 1 |
| Diakité, VG | 1 |
| Utzinger, J | 1 |
| N'Goran, EK | 1 |
| Wegmüller, R | 1 |
| Gerstl, S | 3 |
| Namagana, A | 1 |
| Palacios, L | 1 |
| Mweshi, F | 1 |
| Aprile, S | 1 |
| Lima, A | 1 |
| Antwi, GD | 1 |
| Acheampong, PR | 1 |
| Bart Plange, C | 1 |
| Duah, N | 1 |
| Quaye, L | 1 |
| Malm, K | 1 |
| Koram, K | 1 |
| Gignoux, E | 1 |
| Azman, AS | 1 |
| de Smet, M | 1 |
| Azuma, P | 1 |
| Massaquoi, M | 1 |
| Job, D | 1 |
| Tiffany, A | 1 |
| Petrucci, R | 1 |
| Sterk, E | 1 |
| Potet, J | 1 |
| Suzuki, M | 1 |
| Kurth, A | 1 |
| Cannas, A | 1 |
| Bocquin, A | 1 |
| Strecker, T | 1 |
| Logue, C | 1 |
| Pottage, T | 1 |
| Yue, C | 1 |
| Cabrol, JC | 1 |
| Serafini, M | 1 |
| Ciglenecki, I | 1 |
| Febir, LG | 1 |
| Asante, KP | 2 |
| Afari-Asiedu, S | 1 |
| Abokyi, LN | 1 |
| Kwarteng, A | 1 |
| Owusu-Agyei, S | 2 |
| Gbimadee, N | 1 |
| Iwalewa, EO | 1 |
| Bamiselu, OF | 1 |
| Ajayi, I | 1 |
| Fawole, O | 1 |
| Dairo, D | 1 |
| Ajumobi, O | 1 |
| Oladimeji, A | 1 |
| Steven, Y | 1 |
| Maxmen, A | 1 |
| Aregawi, M | 1 |
| Sillah-Kanu, M | 1 |
| Seppeh, J | 1 |
| Kamara, AR | 1 |
| Williams, RO | 1 |
| Aponte, JJ | 2 |
| Bosman, A | 1 |
| Alonso, P | 1 |
| Kateera, F | 1 |
| Nsobya, SL | 2 |
| Tukwasibwe, S | 1 |
| Hakizimana, E | 1 |
| Mutesa, L | 1 |
| Grobusch, MP | 2 |
| van Vugt, M | 1 |
| Kumar, N | 1 |
| Ba, EH | 3 |
| Ndour, CT | 1 |
| Molez, JF | 1 |
| Fall, FB | 2 |
| Faye, B | 2 |
| Kouevijdin, E | 2 |
| Niane, FK | 1 |
| Rogier, C | 1 |
| Greenwood, BM | 4 |
| Dial, Y | 1 |
| Faye, E | 1 |
| Lo, A | 1 |
| Tine, R | 1 |
| Faye, S | 1 |
| Konate, L | 1 |
| Flach, C | 1 |
| Faye, O | 1 |
| Thior, PM | 1 |
| Faye, OK | 1 |
| Walker, LA | 1 |
| Sullivan, DJ | 1 |
| Owusu, R | 1 |
| Amenga-Etego, S | 1 |
| Dosoo, DK | 1 |
| Gyapong, J | 1 |
| Pérez, MA | 1 |
| Cortés, LJ | 1 |
| Guerra, AP | 1 |
| Knudson, A | 1 |
| Usta, C | 1 |
| Nicholls, RS | 1 |
| Buffet, PA | 1 |
| Briand, V | 1 |
| Rénia, L | 1 |
| Thellier, M | 1 |
| Danis, M | 2 |
| Browne, EN | 2 |
| Bateganya, F | 2 |
| Yar, D | 1 |
| Happi, C | 1 |
| Yusuf, B | 2 |
| Boateng, S | 1 |
| Mugittu, K | 1 |
| Cousens, S | 4 |
| Nanyunja, M | 1 |
| Sarrassat, S | 4 |
| Senghor, P | 1 |
| Le Hesran, JY | 5 |
| Guévart, E | 1 |
| Aguémon, A | 1 |
| Atta, H | 1 |
| Klena, JD | 1 |
| Waqar, BA | 1 |
| Elmi, HH | 1 |
| Jibril, AM | 1 |
| Hassan, HM | 1 |
| Hassan, AM | 1 |
| Sakho, M | 1 |
| Kweku, M | 2 |
| Liu, D | 1 |
| Binka, F | 1 |
| Seidu, M | 1 |
| Billal, DS | 1 |
| Hotomi, M | 1 |
| Yamanaka, N | 1 |
| Dodoo, AN | 1 |
| Fogg, C | 1 |
| Asiimwe, A | 1 |
| Nartey, ET | 1 |
| Kodua, A | 1 |
| Tenkorang, O | 1 |
| Ofori-Adjei, D | 2 |
| Greenhouse, B | 2 |
| Slater, M | 2 |
| Njama-Meya, D | 2 |
| Nzarubara, B | 2 |
| Maiteki-Sebuguzi, C | 2 |
| Clark, TD | 2 |
| Kamya, MR | 4 |
| Hubbard, A | 1 |
| Dorsey, G | 4 |
| O'Neill, PM | 5 |
| Park, BK | 5 |
| Shone, AE | 2 |
| Maggs, JL | 4 |
| Roberts, P | 2 |
| Stocks, PA | 4 |
| Biagini, GA | 2 |
| Bray, PG | 3 |
| Gibbons, P | 1 |
| Berry, N | 2 |
| Winstanley, PA | 4 |
| Mukhtar, A | 3 |
| Bonar-Law, R | 1 |
| Hindley, S | 3 |
| Bambal, RB | 2 |
| Davis, CB | 2 |
| Bates, M | 2 |
| Hart, TK | 1 |
| Gresham, SL | 2 |
| Lawrence, RM | 1 |
| Brigandi, RA | 2 |
| Gomez-delas-Heras, FM | 1 |
| Gargallo, DV | 2 |
| Ward, SA | 6 |
| Stanford, D | 1 |
| Nixon, G | 1 |
| Asadollahy, E | 1 |
| Biagini, G | 1 |
| Davies, J | 1 |
| Hall, C | 1 |
| Rimmer, K | 1 |
| Gomez-de-Las-Heras, FM | 1 |
| Parapini, S | 2 |
| Vivas, L | 1 |
| Lander, H | 1 |
| Taramelli, D | 2 |
| Kiboi, DM | 1 |
| Irungu, BN | 1 |
| Langat, B | 1 |
| Brun, R | 2 |
| Chollet, J | 1 |
| Abiodun, O | 1 |
| Nganga, JK | 1 |
| Nyambati, VC | 1 |
| Rukunga, GM | 1 |
| Bell, A | 1 |
| Nzila, A | 2 |
| Mutabingwa, TK | 2 |
| Muze, K | 1 |
| Ord, R | 1 |
| Briceño, M | 1 |
| Drakeley, C | 1 |
| Whitty, CJ | 2 |
| Abdulrahaman, A | 1 |
| Mwai, L | 1 |
| Muriithi, S | 1 |
| Straimer, J | 1 |
| Schieck, E | 1 |
| Rippert, A | 1 |
| Bashraheil, M | 1 |
| Salim, A | 1 |
| Peshu, J | 1 |
| Awuondo, K | 1 |
| Lowe, B | 1 |
| Pirmohamed, M | 1 |
| Winstanley, P | 2 |
| Ward, S | 1 |
| Borrmann, S | 1 |
| Abuya, T | 1 |
| Fegan, G | 1 |
| Rowa, Y | 1 |
| Karisa, B | 1 |
| Ochola, S | 1 |
| Mutemi, W | 1 |
| Marsh, V | 1 |
| Souares, A | 2 |
| Lalou, R | 3 |
| Sene, I | 1 |
| Sayang, C | 2 |
| Gausseres, M | 2 |
| Vernazza-Licht, N | 2 |
| Malvy, D | 3 |
| Bley, D | 2 |
| Millet, P | 4 |
| Taylor, W | 1 |
| Ouedraogo, EB | 1 |
| Ouedraogo, A | 2 |
| Gansané, A | 2 |
| Simpson, JA | 1 |
| Morgan, CC | 1 |
| Graz, B | 2 |
| Willcox, ML | 2 |
| Diakite, C | 2 |
| Falquet, J | 2 |
| Dackuo, F | 1 |
| Sidibe, O | 2 |
| Giani, S | 2 |
| Diallo, D | 2 |
| Gosling, R | 1 |
| Mosha, J | 1 |
| Moulin, P | 1 |
| Carlotti, MP | 1 |
| Ahorlu, CK | 2 |
| Seakey, AK | 1 |
| Weiss, MG | 2 |
| Cames, C | 1 |
| Simondon, K | 2 |
| Roederer, MW | 1 |
| Dunkley, S | 1 |
| Baker, S | 1 |
| Maikere, J | 1 |
| Folarin, O | 1 |
| Okuboyejo, T | 1 |
| Michael, O | 1 |
| Fatunmbi, B | 1 |
| Patouillard, E | 1 |
| Legood, R | 1 |
| Dackouo, F | 1 |
| Sesay, S | 1 |
| Touray, E | 1 |
| Sowe, M | 1 |
| Bojang, KA | 2 |
| Beeson, JG | 2 |
| Rogerson, SJ | 2 |
| Mueller, I | 2 |
| Richards, JS | 1 |
| Fowkes, FJ | 1 |
| Akor, F | 1 |
| Webb, E | 1 |
| Bittaye, O | 1 |
| Conway, DJ | 1 |
| Jasseh, M | 1 |
| Wiseman, V | 2 |
| Konaté, AT | 1 |
| Yaro, JB | 1 |
| Ouédraogo, AZ | 1 |
| Kangoyé, DT | 1 |
| Kaboré, Y | 1 |
| Ouédraogo, E | 1 |
| Ouédraogo, IN | 1 |
| Diallo, DA | 1 |
| Seake-Kwawu, A | 1 |
| Lacaze, C | 1 |
| Kauss, T | 1 |
| Caminiti, A | 1 |
| Fawaz, F | 1 |
| Terrassin, L | 1 |
| Cuart, S | 1 |
| Grislain, L | 1 |
| Navaratnam, V | 1 |
| Ghezzoul, B | 1 |
| Gaudin, K | 1 |
| Olliaro, PL | 3 |
| Bompart, F | 1 |
| Sebbag, R | 1 |
| Pecoul, B | 2 |
| Chadwick, J | 1 |
| Amewu, RK | 1 |
| Marti, F | 1 |
| Garah, FB | 1 |
| Sharma, R | 1 |
| Berry, NG | 1 |
| Burrell-Saward, H | 1 |
| Brasseur, P | 3 |
| Badiane, M | 1 |
| Cisse, M | 2 |
| Agnamey, P | 1 |
| Vaillant, MT | 2 |
| Tekete, MM | 1 |
| Toure, S | 2 |
| Fredericks, A | 1 |
| Sangare, CP | 1 |
| Evans, A | 1 |
| Smith, P | 1 |
| Frank, M | 1 |
| Lehners, N | 1 |
| Mayengue, PI | 1 |
| Gabor, J | 1 |
| Dal-Bianco, M | 1 |
| Kombila, DU | 1 |
| Ngoma, GM | 1 |
| Supan, C | 1 |
| Ntoumi, F | 1 |
| Dietz, K | 1 |
| Adjalley, SH | 1 |
| Johnston, GL | 1 |
| Li, T | 1 |
| Eastman, RT | 1 |
| Ekland, EH | 1 |
| Eappen, AG | 1 |
| Richman, A | 1 |
| Sim, BK | 1 |
| Hoffman, SL | 1 |
| Senn, N | 1 |
| Rarau, P | 1 |
| Stanisic, DI | 1 |
| Robinson, L | 1 |
| Barnadas, C | 1 |
| Manong, D | 1 |
| Salib, M | 1 |
| Iga, J | 1 |
| Tarongka, N | 1 |
| Ley, S | 1 |
| Rosanas-Urgell, A | 1 |
| Zimmerman, PA | 1 |
| Schofield, L | 1 |
| Siba, P | 1 |
| Reeder, JC | 1 |
| Thanh, NX | 1 |
| Trung, TN | 1 |
| Phong, NC | 1 |
| Quang, HH | 1 |
| Dai, B | 1 |
| Shanks, GD | 1 |
| Chavchich, M | 1 |
| Edstein, MD | 1 |
| Togo, A | 1 |
| Sanogo, K | 1 |
| Dembele, D | 1 |
| Giorgi, R | 1 |
| Donegan, S | 1 |
| Williamson, P | 1 |
| Tudur Smith, C | 1 |
| Nair, A | 1 |
| Abrahamsson, B | 1 |
| Barends, DM | 1 |
| Groot, DW | 1 |
| Kopp, S | 1 |
| Polli, JE | 1 |
| Shah, VP | 1 |
| Dressman, JB | 1 |
| Amuasi, JH | 1 |
| Diap, G | 1 |
| Nguah, SB | 1 |
| Karikari, P | 1 |
| Boakye, I | 1 |
| Jambai, A | 1 |
| Lahai, WK | 1 |
| Louie, KS | 1 |
| Awini, E | 1 |
| Nonvignon, J | 1 |
| Aikins, M | 1 |
| Oduro-Boatey, C | 1 |
| Rodrigues, OP | 1 |
| Hoegberg, LC | 1 |
| Kurtzhals, JA | 2 |
| Goka, BQ | 2 |
| Hirschel, B | 2 |
| González, IJ | 1 |
| Padilla, JO | 1 |
| Giraldo, LE | 1 |
| Saravia, NG | 1 |
| Tavrow, P | 1 |
| Shabahang, J | 1 |
| Makama, S | 1 |
| LOVE, J | 1 |
| FOULK, R | 1 |
| WILLIAMS, RG | 1 |
| MITCHELL, RB | 1 |
| KALBIAN, VH | 1 |
| KALVIAN, VV | 1 |
| DE SMET, R | 1 |
| COPIN, R | 1 |
| JAME, P | 2 |
| MARTIN, JR | 1 |
| DE MELLO, JP | 2 |
| DE MELLO, RN | 2 |
| BASU, PC | 1 |
| LAUFER, WE | 1 |
| FREEDMAN, ML | 1 |
| CAMBOURNAC, FJ | 2 |
| QUEIROS, JS | 1 |
| DA FONSECA, AE | 1 |
| SINGH, J | 1 |
| MISRA, BG | 1 |
| MILLER, MJ | 1 |
| PETER, G | 1 |
| HOUEL, G | 1 |
| VAN GOOR, WT | 1 |
| KHATRI, LD | 1 |
| SAMUELS, RD | 1 |
| SRIVASTAVA, JR | 1 |
| HOEKENGA, MT | 4 |
| PATEL, JC | 1 |
| DALAL, SD | 1 |
| WALKER, AJ | 1 |
| EDESON, JF | 2 |
| WILSON, T | 1 |
| TURNER, LH | 2 |
| LAING, AB | 3 |
| BORODA, C | 1 |
| CHARLES, LJ | 1 |
| LOZANO MORALES, A | 1 |
| VELAZQUES GAZTELU, F | 1 |
| GROUNDS, JG | 1 |
| YOUNG, MD | 3 |
| CAMPBELL, CH | 1 |
| CLYDE, DF | 6 |
| COLLINS, WE | 4 |
| JEFFERY, GM | 2 |
| SKINNER, JC | 2 |
| POWELL, RD | 3 |
| BREWER, GJ | 2 |
| ALVING, AS | 2 |
| MILLAR, JW | 1 |
| ZUIDEMA, PJ | 1 |
| DEGOWIN, RL | 1 |
| COLLIS, WR | 1 |
| AUDU, IS | 1 |
| DAVID, HL | 1 |
| DUTTA, CP | 1 |
| PRADHAN, J | 1 |
| BHATTACHARJEE, SK | 1 |
| LE HUNSEC, J | 1 |
| Randle, LE | 1 |
| Storr, RC | 2 |
| Bickley, JF | 1 |
| O'Neil, IA | 1 |
| Hughes, RH | 1 |
| HERRERO, MT | 1 |
| de LUCENA, DT | 1 |
| MEIN, RM | 1 |
| BERTAGNA, P | 1 |
| KHAN, N | 1 |
| SURI, RM | 1 |
| NAIR, PM | 1 |
| PAYNE, E | 1 |
| VILLAREJOS, VM | 1 |
| SHARP, EA | 2 |
| REINERTSON, JW | 1 |
| WILLE, WS | 1 |
| MANDOUL, R | 1 |
| PESTRE, A | 1 |
| Ginsburg, H | 1 |
| Golenser, J | 1 |
| Thomas, F | 1 |
| Erhart, A | 1 |
| Rosen, JB | 2 |
| Breman, JG | 2 |
| Majori, G | 1 |
| BURCKHALTER, JH | 1 |
| Bhattarai, A | 1 |
| Maini-Thapar, M | 1 |
| Traebert, M | 1 |
| Dumotier, B | 1 |
| Sibbald, B | 1 |
| Madji, N | 1 |
| Manirakiza, A | 1 |
| Djalle, D | 1 |
| Koula, MR | 1 |
| Talarmin, A | 1 |
| Yeka, A | 1 |
| Bakyaita, N | 1 |
| Talisuna, A | 1 |
| Kironde, F | 1 |
| Kilian, A | 1 |
| Reingold, A | 1 |
| Wabwire-Mangen, F | 1 |
| McIntosh, HM | 3 |
| Jones, KL | 1 |
| Manclark, CR | 1 |
| Meade, BD | 1 |
| Lobel, HO | 1 |
| Saliou, P | 2 |
| Roberts, JM | 1 |
| Campaoré, P | 1 |
| Miller, MA | 1 |
| Meshnick, SR | 1 |
| Alker, AP | 1 |
| Malongo, TK | 1 |
| Blankert, B | 1 |
| Kambu, O | 1 |
| Amighi, K | 1 |
| Nsangu, J | 1 |
| Kauffmann, JM | 1 |
| Akanmori, BD | 1 |
| Guzmán, V | 1 |
| Carmona-Fonseca, J | 1 |
| Edwards, G | 6 |
| Boulanger, D | 2 |
| Dieng, Y | 1 |
| Remoue, F | 1 |
| Capuano, F | 1 |
| Dieme, JL | 1 |
| Simondon, F | 2 |
| Guthmann, JP | 2 |
| Pinoges, L | 1 |
| Checchi, F | 2 |
| Balkan, S | 1 |
| van Herp, M | 1 |
| Legros, D | 1 |
| Olliaro, P | 3 |
| Swarthout, TD | 1 |
| van den Broek, IV | 1 |
| Kayembe, G | 1 |
| Montgomery, J | 1 |
| Pota, H | 1 |
| Roper, C | 1 |
| Kim, M | 1 |
| ter Kuile, FO | 1 |
| Nau, JY | 1 |
| Hampton, T | 1 |
| Markham, LN | 1 |
| Giostra, E | 1 |
| Hadengue, A | 1 |
| Rossier, M | 1 |
| Rebsamen, M | 1 |
| Desmeules, J | 1 |
| Cohuet, S | 1 |
| Edoh, K | 1 |
| Brasher, C | 1 |
| Lesage, A | 1 |
| Nyunt, MM | 1 |
| Plowe, CV | 1 |
| Benca, J | 1 |
| Dubai, A | 1 |
| Sladeckova, V | 1 |
| Nzayirambaho, M | 1 |
| Freund, RJ | 1 |
| Lombrail, P | 1 |
| Potel, G | 1 |
| PAYNE, EH | 1 |
| NICKER, KC | 1 |
| Garshong, B | 1 |
| Agyei-Baffour, P | 1 |
| Doamekpor, L | 1 |
| Balyeku, A | 1 |
| Munguti, K | 1 |
| Bâ, el H | 1 |
| Hallett, R | 1 |
| Targett, G | 1 |
| Lines, J | 1 |
| Lugimbana, L | 1 |
| Malebo, HM | 1 |
| Segeja, MD | 1 |
| Akida, JA | 1 |
| Malle, LN | 1 |
| Lemnge, MM | 2 |
| Bousema, JT | 1 |
| Drakeley, CJ | 1 |
| Arens, T | 1 |
| Houben, R | 1 |
| Omar, SA | 1 |
| Gouagna, LC | 1 |
| Schallig, H | 1 |
| Sauerwein, RW | 1 |
| Gasasira, AF | 1 |
| Mebrahtu, T | 1 |
| Kalyango, JN | 1 |
| Ruel, T | 1 |
| Charlebois, E | 1 |
| Kekitiinwa, A | 1 |
| Havlir, D | 1 |
| Nurse, GT | 1 |
| Watkins, WM | 1 |
| Sixsmith, DG | 2 |
| Spencer, HC | 4 |
| Boriga, DA | 1 |
| Kariuki, DM | 1 |
| Kipingor, T | 2 |
| Koech, DK | 3 |
| Oloo, AJ | 1 |
| Watkins, WW | 1 |
| Churchill, FC | 1 |
| Deloron, P | 9 |
| Le Bras, J | 17 |
| Ramanamirija, JA | 10 |
| Stürchler, D | 2 |
| Rieckmann, KH | 5 |
| Noeypatimanond, S | 1 |
| Malikul, S | 1 |
| Benjapong, W | 1 |
| Duriyananda, D | 1 |
| Ungkasrithongkul, M | 1 |
| Agure, R | 1 |
| Chulay, JD | 1 |
| Campbell, CC | 3 |
| Payne, D | 1 |
| Schwartz, IK | 1 |
| Khatib, OJ | 1 |
| Nieuwoudt, NJ | 1 |
| Walker, O | 2 |
| Salako, LA | 3 |
| Obih, PO | 2 |
| Bademosi, K | 1 |
| Sodeinde, O | 1 |
| Verdier, P | 1 |
| Coulanges, P | 8 |
| Verdíer, F | 8 |
| Phillips, RE | 3 |
| Loban, KM | 1 |
| Polozok, ES | 1 |
| Schulthess, HK | 1 |
| von Felten, A | 1 |
| Gmür, J | 1 |
| Neftel, K | 2 |
| Stace, JD | 1 |
| Pariwa, S | 1 |
| Tulloch, A | 1 |
| Sharp, PT | 1 |
| Harvey, P | 1 |
| Barkakaty, BN | 1 |
| Das, S | 1 |
| Deka, RP | 1 |
| Sen, T | 1 |
| Roy, RG | 1 |
| Pattanayak, S | 1 |
| Wery, M | 1 |
| Coosemans, M | 1 |
| Go, ML | 1 |
| Ngiam, TL | 1 |
| Wan, AS | 1 |
| Darlow, B | 1 |
| Vrbova, H | 3 |
| Stace, J | 1 |
| Sweeney, TR | 1 |
| Olatunde, A | 1 |
| Lepeu, G | 1 |
| Codine, P | 1 |
| Janbon, F | 1 |
| Bertrand, A | 1 |
| Ruscoe, JE | 1 |
| Jewell, H | 1 |
| Nicolas, P | 1 |
| Hovette, P | 1 |
| Merouze, F | 1 |
| Touze, JE | 1 |
| Martet, G | 1 |
| Bloland, PB | 1 |
| Ruebush, TK | 1 |
| Mengesha, T | 2 |
| Makonnen, E | 1 |
| Mussano, P | 1 |
| Delarue, S | 1 |
| Girault, S | 1 |
| Dali Ali, F | 1 |
| Maes, L | 1 |
| Grellier, P | 1 |
| Sergheraert, C | 1 |
| Seboxa, T | 1 |
| Fitch, CD | 1 |
| Gonzalez, Y | 1 |
| Chevli, R | 1 |
| Bruce-Chwatt, LJ | 3 |
| Cedillos, RA | 1 |
| Warren, M | 1 |
| Schmidt, LH | 1 |
| Vaughan, D | 1 |
| Mueller, D | 1 |
| Crosby, R | 1 |
| Hamilton, R | 1 |
| Hedman, P | 1 |
| Brohult, J | 1 |
| Forslund, J | 1 |
| Sirleaf, V | 1 |
| Bengtsson, E | 1 |
| McCarthy, VC | 4 |
| Miller, RM | 3 |
| Hornick, RB | 2 |
| Dennis, DT | 1 |
| Boberstyn, EB | 1 |
| Sissay, A | 1 |
| Davidson, DE | 1 |
| Johnsen, DO | 1 |
| Tanticharoenyos, P | 1 |
| Hickman, RL | 1 |
| Kinnamon, KE | 1 |
| Trenholme, GM | 2 |
| Williams, RL | 2 |
| Frischer, H | 2 |
| Carson, PE | 2 |
| Hall, AP | 1 |
| Segal, HE | 1 |
| Pearlman, EJ | 1 |
| Phintuyothin, P | 1 |
| Kosakal, S | 1 |
| Peters, W | 4 |
| Robinson, BL | 1 |
| Ye, XY | 2 |
| Shao, BR | 2 |
| Chu, YH | 2 |
| Fadat, G | 1 |
| Hengy, C | 3 |
| Louis, JP | 1 |
| Gimou, MM | 1 |
| Trigg, PI | 1 |
| Carme, B | 5 |
| Moudzeo, H | 3 |
| Mbitsi, A | 4 |
| Samba, G | 2 |
| Baird, JK | 1 |
| Basri, H | 1 |
| Jones, TR | 1 |
| Bangs, MJ | 1 |
| Ritonga, A | 1 |
| Broderson, JR | 1 |
| Richardson, BB | 1 |
| Ma, NS | 1 |
| Stanfill, PS | 1 |
| Clarke, JB | 1 |
| Kitteringham, NR | 1 |
| Sathounkasi, C | 1 |
| Gay, F | 3 |
| Chandenier, J | 1 |
| Schmitt, JL | 1 |
| Nagaraj, C | 1 |
| Chakrabarti, NK | 1 |
| Narasimham, MV | 1 |
| Eberlé, F | 1 |
| Arrive, A | 1 |
| Kouka-Bemba, D | 2 |
| Gazin, P | 2 |
| Jambou, R | 2 |
| Kilimali, VA | 2 |
| Sathounkazi, C | 1 |
| Brandicourt, O | 2 |
| Gentilini, M | 2 |
| Dinis, DV | 1 |
| Schapira, A | 2 |
| Simooya, O | 1 |
| Kofi-Ekue, JM | 1 |
| Orme, ML | 2 |
| Breckenridge, AM | 2 |
| Arias, AE | 2 |
| Corredor, A | 1 |
| Macaigne, F | 1 |
| Combe, A | 2 |
| Vincendeau, P | 1 |
| Eboumbou, J | 1 |
| Garnier, T | 1 |
| Michel, R | 1 |
| Ripert, C | 2 |
| Garrigue, G | 1 |
| Abissègue, B | 1 |
| Ghogomu, NA | 1 |
| Gelas, H | 1 |
| Lepelletier, L | 1 |
| Nadire-Galliot, M | 1 |
| Poman, JP | 1 |
| Bellony, S | 1 |
| Claustre, J | 1 |
| Traore, BM | 1 |
| Mouchet, J | 2 |
| Ndumbe, PM | 1 |
| Raymond, JM | 1 |
| Dumas, F | 1 |
| Baldit, C | 1 |
| Couzigou, P | 1 |
| Beraud, C | 1 |
| Amouretti, M | 1 |
| Pyakalyia, T | 1 |
| Simooya, OO | 1 |
| Aderounmu, AF | 1 |
| Looareesuwan, S | 2 |
| Karbwang, J | 2 |
| Benjasurat, Y | 1 |
| Attanath, P | 1 |
| Warrell, DA | 3 |
| Gascón, J | 1 |
| Soldevila, M | 1 |
| Merlos, A | 1 |
| Bada, JL | 1 |
| Hatton, CS | 1 |
| Peto, TE | 1 |
| Bunch, C | 2 |
| Pasvol, G | 1 |
| Russell, SJ | 1 |
| Singer, CR | 1 |
| Carr, R | 1 |
| Larrey, D | 2 |
| Castot, A | 1 |
| Pëssayre, D | 2 |
| Merigot, P | 1 |
| Machayekhy, JP | 1 |
| Feldmann, G | 1 |
| Lenoir, A | 1 |
| Rueff, B | 2 |
| Benhamou, JP | 2 |
| Zotter, GM | 2 |
| Grainger, W | 1 |
| Feldmeier, H | 2 |
| Rougemont, A | 1 |
| Dumbo, O | 1 |
| Bouvier, M | 1 |
| Soula, G | 1 |
| Perrin, L | 1 |
| Tamoura, B | 1 |
| Yerly, S | 1 |
| Dolo, A | 1 |
| Brenner, E | 1 |
| Kodio, B | 1 |
| Rouveix, B | 1 |
| Coulombel, L | 1 |
| Aymard, JP | 1 |
| Chau, F | 1 |
| Abel, L | 1 |
| Huang, OL | 1 |
| Ouyang, WC | 1 |
| Zhou, JX | 2 |
| Wu, Z | 2 |
| Zhang, KY | 2 |
| Huang, JK | 2 |
| Cai, XZ | 2 |
| Pang, XJ | 1 |
| Fu, SG | 2 |
| Wang, XF | 1 |
| Draper, CC | 1 |
| Hills, M | 1 |
| Brubaker, G | 1 |
| Inambao, AW | 1 |
| Graninger, W | 1 |
| Rocha, RM | 1 |
| Wiedermann, G | 1 |
| Huang, QL | 1 |
| Quyang, WC | 1 |
| Pan, XJ | 1 |
| Huang, XF | 1 |
| McDermott, JM | 1 |
| Heymann, DL | 2 |
| Wirima, JJ | 2 |
| Macheso, AP | 1 |
| Wahl, RD | 1 |
| Steketee, RW | 1 |
| Rolfe, M | 1 |
| Reyes, S | 1 |
| Osanai, CH | 1 |
| Passos, AD | 1 |
| Neftel, KA | 1 |
| Woodtly, W | 1 |
| Schmid, M | 1 |
| Frick, PG | 1 |
| Fehr, J | 1 |
| Sexton, JD | 1 |
| Bugilimfura, L | 1 |
| Sezibera, C | 1 |
| Schwalbach, JF | 1 |
| Biddulph, J | 1 |
| Long, GW | 2 |
| Watt, G | 2 |
| Buck, RL | 2 |
| Sangalang, RP | 1 |
| Ranoa, CP | 2 |
| Chiodini, PL | 1 |
| Ndinga, M | 1 |
| Eozenou, P | 1 |
| Delmont, J | 1 |
| Testa, J | 1 |
| Monges, P | 1 |
| Limbassa, J | 1 |
| Georges, AJ | 1 |
| Faugère, B | 1 |
| Simon, F | 4 |
| Porte, J | 2 |
| Guigon, D | 1 |
| Drouville, C | 1 |
| Charmot, G | 1 |
| Calmel, MB | 1 |
| Hatin, I | 1 |
| Marchais, H | 3 |
| Clausse, JL | 1 |
| Biaud, JM | 4 |
| Rosenheim, M | 1 |
| Druilhe, P | 1 |
| Datry, A | 1 |
| Brucker, G | 1 |
| Duflo, B | 1 |
| Roué, R | 1 |
| Talarmin, F | 1 |
| Buisson, Y | 1 |
| Daly, JP | 1 |
| Chabiersky, M | 1 |
| Pussard, E | 3 |
| Faurisson, F | 2 |
| Scherrmann, JM | 1 |
| Blayo, MC | 3 |
| Khaliq, AA | 2 |
| Fox, E | 2 |
| Sarwar, M | 2 |
| Strickland, GT | 2 |
| Khoromana, CO | 1 |
| Hu, H | 1 |
| Liu, XM | 1 |
| Lin, BY | 1 |
| Zhang, JX | 1 |
| Huang, LS | 1 |
| Bernuau, J | 1 |
| Campillo, B | 1 |
| Degott, C | 1 |
| Breckenridge, A | 1 |
| Orme, M | 1 |
| Macdonald, M | 1 |
| Raccurt, CP | 1 |
| Le Bras, M | 1 |
| Beylot, J | 1 |
| Ramiliarisoa, O | 1 |
| Padre, L | 1 |
| Alban, P | 1 |
| Sangalang, R | 2 |
| Laughlin, LW | 1 |
| Wittes, R | 1 |
| Ellis, ME | 1 |
| Steed, AJ | 1 |
| Addison, GM | 1 |
| Schär, M | 1 |
| Gyr, N | 1 |
| Markus, MB | 1 |
| Woodtli, W | 1 |
| Vonmoos, P | 1 |
| Siegrist, P | 1 |
| Zollikofer, H | 1 |
| Dedet, JP | 1 |
| Esterre, P | 1 |
| Nicholl, DD | 2 |
| Moir, JS | 2 |
| Tulloch, JL | 2 |
| Jolley, DJ | 2 |
| Heywood, PF | 2 |
| Alpers, MP | 2 |
| Smrkovski, LL | 1 |
| Alcantara, AK | 1 |
| Rodriguez, CS | 1 |
| Uylangco, CV | 1 |
| Espinal, CA | 1 |
| Cortes, GT | 1 |
| Guerra, P | 1 |
| Fribourg-Blanc, A | 1 |
| Bosseno, MF | 1 |
| Lallemant, M | 1 |
| Engler, R | 1 |
| Pocidalo, JJ | 1 |
| Mihaly, GW | 1 |
| Douer, D | 1 |
| Schwartz, E | 1 |
| Shaked, N | 1 |
| Ramot, B | 1 |
| Glew, RH | 1 |
| Miller, LH | 1 |
| Howard, WA | 1 |
| Wyler, DJ | 1 |
| Chaves-Carballo, E | 1 |
| Neva, FA | 1 |
| DuPont, HL | 2 |
| Dola, SK | 1 |
| Fasan, PO | 1 |
| Kofie, BA | 1 |
| Adeleye, I | 1 |
| Cooke, A | 1 |
| Patterson, EC | 1 |
| Johnson, CM | 2 |
| Shute, GT | 1 |
| Molina, JJ | 1 |
| Osnes, M | 1 |
| Gilman, RH | 1 |
| Imperato, PJ | 1 |
| Shookhoff, HB | 1 |
| Harvey, RP | 1 |
| Saint-Yves, IF | 1 |
| Weise, HJ | 1 |
| Botelho, A | 1 |
| Temple, C | 1 |
| Rose, JD | 1 |
| Montgomery, JA | 1 |
| Benazet, F | 1 |
| Godard, C | 1 |
| Elslager, EF | 2 |
| Rachmilewitz, D | 1 |
| Hunsicker, LG | 1 |
| Gusmão, HH | 1 |
| Juarez, E | 1 |
| Myint, UH | 1 |
| Win, UK | 1 |
| Natarajan, PN | 1 |
| Lan, NT | 1 |
| Harrison, SL | 1 |
| Elko, EE | 2 |
| Cantrell, W | 2 |
| Hopff, BM | 1 |
| Motabar, M | 1 |
| Mofidi, C | 1 |
| Saebi, A | 1 |
| Ghiassedin, M | 1 |
| Rouhani, F | 1 |
| Knüttgen, HJ | 1 |
| Schneider, MD | 1 |
| Tendick, FH | 1 |
| Werbel, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and [NCT03355664] | Phase 3 | 310 participants (Actual) | Interventional | 2018-03-19 | Completed | ||
| Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)[NCT03178643] | Phase 4 | 246 participants (Actual) | Interventional | 2018-01-23 | Completed | ||
| Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection[NCT04264130] | Phase 2 | 54 participants (Actual) | Interventional | 2018-07-31 | Completed | ||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon[NCT06173206] | Phase 3 | 900 participants (Anticipated) | Interventional | 2024-03-15 | Not yet recruiting | ||
| Associations Between Drug Levels and the Risk of Malaria and Drug Resistance in the Setting of Seasonal Malaria Chemoprevention in Bobo-Dioulasso, Burkina Faso[NCT04969185] | 310 participants (Actual) | Observational | 2021-08-16 | Completed | |||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Zambia[NCT06166498] | Phase 3 | 600 participants (Anticipated) | Interventional | 2024-02-15 | Not yet recruiting | ||
| Feasibility, Acceptability and Costs of a Strategy Deploying Multiple First-lines Artemisinin-based Combination Therapies for Uncomplicated Malaria: a Pilot Programme in the Health District of Kaya, Burkina Faso[NCT04265573] | 150,000 participants (Actual) | Observational | 2018-11-10 | Completed | |||
| An Open-label Individually Randomised Controlled Trial to Assess the Efficacy of Artemether-lumefantrine Prophylaxis for Malaria Among Forest Goers in Cambodia[NCT04041973] | 1,480 participants (Actual) | Interventional | 2020-03-11 | Completed | |||
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| Measuring the Impact of Seasonal Malaria Chemoprevention as Part of Routine Malaria Control in Kita, Mali[NCT02894294] | 1,162 participants (Actual) | Observational [Patient Registry] | 2014-07-31 | Completed | |||
| Comparison of IST Using Ultra-sensitive Malaria Rapid Diagnostic Test and Pyronaridine - Artesunate - PYRAMAX®) to Standard IPT Sulfadoxine-pyrimethamine to Prevent Malaria in Pregnant Women Living in Endemic Areas[NCT04783051] | Phase 3 | 250 participants (Actual) | Interventional | 2021-05-06 | Completed | ||
| Adherence to Artemisinin-Based Combination Therapy (ACT) for the Treatment of Malaria in Sierra Leone[NCT01967472] | 1,145 participants (Actual) | Interventional | 2013-09-16 | Completed | |||
| A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children[NCT02211729] | Phase 3 | 22,090 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care[NCT01976325] | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Infections in Migrants in Sweden - the Importance of Malaria and Other Parasitic Infections[NCT05086887] | 715 participants (Anticipated) | Observational [Patient Registry] | 2019-04-15 | Recruiting | |||
| Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes[NCT02325180] | Phase 4 | 338 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria[NCT00852423] | Phase 3 | 3,428 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Effectiveness of Seasonal Malaria Chemoprevention in Koulikoro, Mali[NCT04149106] | Phase 3 | 4,556 participants (Anticipated) | Interventional | 2019-07-01 | Active, not recruiting | ||
| Randomized Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of Dihydroartemisinin-piperaquine for Seasonal IPT to Prevent Malaria in Children Under 5 Years[NCT00941785] | Phase 2/Phase 3 | 1,500 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Aetiology, Prevention and Control of Anaemia in Sub-Saharan Africa - Work Package 2: Efficacy Study: Efficacy of 2 Iron Fortified Porridges and IPT for the Prevention of Anemia in Young Children in Côte d'Ivoire.[NCT01634945] | 629 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal[NCT00712374] | Phase 4 | 100,000 participants (Anticipated) | Interventional | 2008-09-30 | Enrolling by invitation | ||
| A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218] | Phase 3 | 5,920 participants (Actual) | Interventional | 2017-04-17 | Completed | ||
| A Non-Inferiority, Open-Labelled, Randomised Trial Of The Efficacy And Safety Of Artesunate-Amodiaquine, Artemether-Lumefantrine, And Artesunate-Lapdap For Treatment Of Uncomplicated P. Falciparum Malaria Among Children In Ghana[NCT00119145] | Phase 4 | 510 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana[NCT00119132] | Phase 2/Phase 3 | 2,602 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy[NCT00123552] | Phase 3 | 601 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania[NCT00146731] | Phase 3 | 310 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Exploring the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04167566] | 5,000 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia[NCT00944840] | Phase 3 | 1,312 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission[NCT00376155] | Phase 4 | 14,000 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children[NCT00738946] | 6,000 participants (Anticipated) | Interventional | 2008-08-31 | Completed | |||
| Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04301531] | 5,861 participants (Actual) | Interventional | 2020-03-01 | Completed | |||
| Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants[NCT00285662] | 1,100 participants (Anticipated) | Interventional | 2006-06-30 | Completed | |||
| A Randomised Trial of the Efficacy and Safety of Four Drug Regimens When Used for Intermittent Preventive Treatment of Malaria in Senegalese Children[NCT00132548] | Phase 3 | 2,200 participants | Interventional | 2004-06-30 | Completed | ||
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910] | Phase 2/Phase 3 | 204 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The time taken for the tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours (NCT03355664)
Timeframe: 42 day
| Intervention | Hours to fever clearance (Mean) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 18.3 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 14.9 |
Total bilirubin, Alanine transaminase, Aspartate transaminase, Alkaline phosphatase and creatinine will be measured (NCT03355664)
Timeframe: 42 day
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 53 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 63 |
We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. (NCT03355664)
Timeframe: 28 day
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 |
"All numerators in AE tables mean that the AE was reported as present according to the definitions defined in the US government DAIDS 2017 grading tables for reporting of adverse events. The AEs are reported without grading in this table, but are graded in the paper reporting this clinical trial.~All Primary analyses are reported (also in the accepted manuscript) along with the secondary outcomes needed to support the primary analysis. Secondary outcomes not involving the randomised comparison will be updated when the analyses are available. Please note that analyses of these Secondary outcomes will take time." (NCT03355664)
Timeframe: 42 days
| Intervention | Participants (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 2 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5 |
Parasite clearance half-life assessed by microscopy as primary parameter to determine parasite clearance (NCT03355664)
Timeframe: 42 day
| Intervention | Hours (Mean) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 5 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5.5 |
Efficacy is defined as participants, following initial parasite and fever clearance, not having a recrudescence of the original plasmodium infection and fever, up to 42 days of follow up. (NCT03355664)
Timeframe: 42 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 146 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 151 |
We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. There were zero events of this at any time point in either study arm. So no further analyses are possible. (NCT03355664)
Timeframe: Hour 4, Hour 24, Hour 28, Hour 48, Hour 52, Hour 60, Hour 64, Day 7 and Day 28 and between these time points
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 |
42-day polymerase chain reaction corrected efficacy defined as adequate clinical and parasitological response (ACPR) according to site/geographic region. (NCT03355664)
Timeframe: 42 day
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| West Cambodia | East Cambodia | Vietnam | |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 35 | 90 | 26 |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 32 | 91 | 23 |
Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.
| Intervention | No. of events/1000 person years at risk (Number) |
|---|---|
| SMC With SP+AQ | 304.8 |
| RTS,S/AS01 | 278.2 |
| RTS,S/AS01 PLUS SMC With SP+AQ | 113.3 |
35 reviews available for amodiaquine and Malaria
| Article | Year |
|---|---|
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
Topics: Animals; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance; Humans; Malaria; Molecular St | 2020 |
Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Co | 2022 |
Pharmacokinetic considerations in seasonal malaria chemoprevention.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2022 |
Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
Topics: Amodiaquine; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins | 2021 |
Intermittent preventive treatment for malaria in infants.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemisinins; Bias; Confidence Intervals; Di | 2021 |
Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Malaria; Malar | 2017 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Cytochrome P450 enzymes and genotype-guided drug therapy.
Topics: Amodiaquine; Anticoagulants; Antimalarials; Breast Neoplasms; Cytochrome P-450 Enzyme System; Estrog | 2009 |
Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride.
Topics: Administration, Oral; Amodiaquine; Animals; Antimalarials; Excipients; Humans; Malaria; Tablets; The | 2012 |
Glutathione is involved in the antimalarial action of chloroquine and its modulation affects drug sensitivity of human and murine species of Plasmodium.
Topics: Acetylcysteine; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Glutathione; Hemi | 2003 |
Can amodiaquine be used safely during pregnancy?
Topics: Africa; Amodiaquine; Antimalarials; Contraindications; Female; Humans; Malaria; Pregnancy; Pregnancy | 2004 |
Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations.
Topics: Amodiaquine; Antibody Formation; Antimalarials; Humans; Immunity, Cellular; Infant; Malaria; Vaccine | 2004 |
[Combined antimalarial therapy using artemisinin].
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Doxycycline; | 2004 |
Antimalarial drugs: QT prolongation and cardiac arrhythmias.
Topics: Amodiaquine; Drug Approval; Electrophysiology; Humans; Long QT Syndrome; Malaria; Phenanthrenes; Ris | 2005 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2005 |
[Cytochrome P-450 and the response to antimalarial drugs].
Topics: Administration, Oral; Adult; Amodiaquine; Animals; Antimalarials; Biotransformation; Child; Chloroqu | 2006 |
Resisting resistance: dealing with the irrepressible problem of malaria.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Dapsone; Drug Combinations; Drug Resistance; H | 2006 |
Malaria prophylaxis in travellers: the current position.
Topics: Africa; Amodiaquine; Antimalarials; Asia; Chloroquine; Culicidae; Drug Resistance; Female; Humans; I | 1984 |
Falciparum malaria: the urgent need for safe and effective drugs.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Dapsone; Drug Combinations; Humans; Malaria; Plas | 1983 |
[Drug resistance in malaria].
Topics: Africa; Amodiaquine; Animals; Asia; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Plasmo | 1980 |
The present status of malaria chemotherapy: mefloquine, a novel antimalarial.
Topics: Amodiaquine; Animals; Antimalarials; Aotus trivirgatus; Chemical Phenomena; Chemistry; Chloroquine; | 1981 |
Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.
Topics: Africa, Eastern; Africa, Western; Amodiaquine; Antimalarials; Chloroquine; Drug Combinations; Drug C | 1999 |
Amodiaquine for treating malaria.
Topics: Amodiaquine; Antimalarials; Humans; Malaria | 2000 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2000 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2001 |
[Current information on treatment and prophylaxis of malaria (author's transl)].
Topics: Adolescent; Adult; Amodiaquine; Child; Child, Preschool; Chloroquine; Dose-Response Relationship, Dr | 1979 |
Malaria chemoprophylaxis: an update.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child, Preschool; Dapsone; Drug Combinations; Female; | 1987 |
The chemoprophylaxis of malaria.
Topics: Amodiaquine; Animals; Chloroquine; Dapsone; Drug Combinations; Drug Resistance; Malaria; Plasmodium | 1987 |
Recent advances in antimalarial chemotherapy and drug resistance.
Topics: Agglutination; Amodiaquine; Animals; Anti-Bacterial Agents; Antimalarials; Chloroquine; Cross Reacti | 1974 |
The problem of drug-resistant malaria.
Topics: Amodiaquine; Anopheles; Antimalarials; Asia; Chloroquine; Drug Resistance, Microbial; Humans; Insect | 1972 |
Development of new antimalarial drugs.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Resistance, Microbial; Folic Acid Antagonists; Humans; | 1972 |
[Importation of malaria into the Federal Republic of Germany including Berlin (West) in the last ten years (1963-1972)].
Topics: Africa; Age Factors; Aircraft; Amodiaquine; Antimalarials; Asia; Berlin; Chloroquine; Disease Outbre | 1974 |
New perspectives on the chemotherapy of malaria, filariasis, and leprosy.
Topics: Amodiaquine; Aniline Compounds; Antimalarials; Chloroquine; Cresols; Dapsone; Drug Resistance; Filar | 1974 |
The pharmacology of the antimalarials. A rational approach to the therapy of resistant falciparum malaria.
Topics: Amodiaquine; Antimalarials; Chemical Phenomena; Chemistry; Chloroquine; Dapsone; Drug Resistance, Mi | 1969 |
Malaria. Chemoprophylaxis and chemotherapy.
Topics: Amodiaquine; Antimalarials; Chloroquine; Dapsone; Drug Resistance, Microbial; Drug Synergism; Humans | 1971 |
74 trials available for amodiaquine and Malaria
| Article | Year |
|---|---|
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Dru | 2022 |
Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial.
Topics: Amodiaquine; Anemia; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy | 2022 |
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemisinins; Chemoprevention; Child; Child, Presch | 2022 |
Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Drug | 2022 |
A non-randomized controlled trial to assess the protective effect of SMC in the context of high parasite resistance in Uganda.
Topics: Amodiaquine; Animals; Antimalarials; Chemoprevention; Child; Drug Combinations; Humans; Infant; Mala | 2023 |
Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial.
Topics: Amodiaquine; Antimalarials; Artesunate; Child; COVID-19; Drug Combinations; Hemoglobins; Humans; Inc | 2023 |
Provider and User Acceptability of Integrated Treatment for the Control of Malaria and Helminths in Saraya, South-Eastern Senegal.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Child; Female; Helminthiasis; Helminths; Humans; Mala | 2023 |
Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Bur | 2020 |
Efficacy and safety of artesuante-amodiaquine and artemether lumefantrine, the first line malaria treatment in six sentinel's sites of Côte d'Ivoire, West Africa.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Cot | 2020 |
Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine.
Topics: Amodiaquine; Antimalarials; Atovaquone; Drug Combinations; Drug Therapy, Combination; Female; Humans | 2022 |
Efficacy of Artesunate/Amodiaquine in the Treatment of Uncomplicated Malaria among Children in Ghana.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinations; Gh | 2017 |
Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2018 |
Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2018 |
Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2018 |
Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2018 |
Adherence to treatment with artemether-lumefantrine or amodiaquine-artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, P | 2018 |
Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Drug Administration Schedule | 2018 |
Impact of treating young children with antimalarials with or without antibiotics on morbidity: a cluster-randomized controlled trial in Ghana.
Topics: Amodiaquine; Amoxicillin; Anemia; Anti-Bacterial Agents; Antimalarials; Artemisinins; Caregivers; Ch | 2013 |
Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo™) for the treatment of acute uncomplicated malaria in Nigerian children.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chlorphen | 2014 |
Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial.
Topics: Adult; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesuna | 2015 |
Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in
Topics: Administration, Oral; Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Chromatography, H | 2015 |
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Case-Control Studies; Chemoprevention; Child | 2015 |
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Case-Control Studies; Chemoprevention; Child | 2015 |
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Case-Control Studies; Chemoprevention; Child | 2015 |
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Case-Control Studies; Chemoprevention; Child | 2015 |
The effect of iron-fortified complementary food and intermittent preventive treatment of malaria on anaemia in 12- to 36-month-old children: a cluster-randomised controlled trial.
Topics: Amodiaquine; Anemia; Antimalarials; Child, Preschool; Cote d'Ivoire; Diphosphates; Drug Combinations | 2015 |
Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Chemoprevention; Child, Preschool; Drug Combin | 2016 |
Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2016 |
Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2016 |
Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2016 |
Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2016 |
Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Humans; Inf | 2016 |
An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; | 2008 |
[Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Colombia; Drug Combinati | 2008 |
Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial.
Topics: Amodiaquine; Anemia; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; G | 2008 |
Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Resistance; Dr | 2009 |
Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania.
Topics: Adult; Amodiaquine; Artemisinins; Artesunate; Dapsone; Drug Combinations; Drug Therapy, Combination; | 2009 |
Impact of ministry of health interventions on private medicine retailer knowledge and practices on anti-malarial treatment in Kenya.
Topics: Amodiaquine; Antimalarials; Commerce; Community Health Services; Health Knowledge, Attitudes, Practi | 2009 |
Population pharmacokinetics of artesunate and amodiaquine in African children.
Topics: Africa; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Biological Availability; Biotransforma | 2009 |
Argemone mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications.
Topics: Adolescent; Amodiaquine; Antimalarials; Argemone; Artemisinins; Child; Child, Preschool; Drug Combin | 2010 |
Effectiveness of combined intermittent preventive treatment for children and timely home treatment for malaria control.
Topics: Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Caregivers; Child, Preschool; | 2009 |
Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children.
Topics: Age Factors; Amodiaquine; Antimalarials; Body Weight; Child; Child, Preschool; Dose-Response Relatio | 2010 |
Use of area under the curve to evaluate the effects of antimalarial drugs on malaria-associated anemia after treatment.
Topics: Amodiaquine; Anemia; Antimalarials; Area Under Curve; Artemether, Lumefantrine Drug Combination; Art | 2011 |
Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Drug Comb | 2010 |
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children.
Topics: Amodiaquine; Anemia; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Cost-Benefit Analysi | 2010 |
Is parasite clearance clinically important after malaria treatment in a high transmission area? A 3-month follow-up of home-based management with herbal medicine or ACT.
Topics: Adolescent; Amodiaquine; Antimalarials; Argemone; Artemisinins; Child; Child, Preschool; Drug Combin | 2011 |
A trial of intermittent preventive treatment and home-based management of malaria in a rural area of The Gambia.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Double-Blind Method; Drug Combinations; Female; Gambia | 2011 |
Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomised controlled trial.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Infant; Inse | 2011 |
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Double-Blind Method; Drug Combinations; | 2011 |
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Double-Blind Method; Drug Combinations; | 2011 |
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Double-Blind Method; Drug Combinations; | 2011 |
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Double-Blind Method; Drug Combinations; | 2011 |
Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Blood Chemical Analysis; Child, Preschool; Dru | 2011 |
Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial.
Topics: Amodiaquine; Antimalarials; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Malaria; Mal | 2012 |
The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.
Topics: Adolescent; Adult; Amodiaquine; Animals; Artemisinins; Blood; Child; Child, Preschool; Drug Combinat | 2012 |
Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2012 |
Impact of community management of fever (using antimalarials with or without antibiotics) on childhood mortality: a cluster-randomized controlled trial in Ghana.
Topics: Amodiaquine; Amoxicillin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antimalarials; Artemis | 2012 |
Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Bra | 2012 |
[Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Nariño, Colombia, 1999-2002].
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Colombia; Drug Combinations; | 2003 |
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Chloroquine; Drug Combinations; Drug The | 2005 |
Malaria chemoprophylaxis and the serologic response to measles and diphtheria-tetanus-whole-cell pertussis vaccines.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Diphtheria-Tetanus-Pertussis Vaccine; Female; H | 2005 |
Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks.
Topics: Amodiaquine; Animals; Anthelmintics; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschoo | 2007 |
Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Democratic Republic | 2006 |
Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2008 |
A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Topics: Amodiaquine; Antimalarials; Arsenites; Child; Drug Combinations; Drug Resistance; Drug Therapy, Comb | 2008 |
A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Topics: Amodiaquine; Antimalarials; Arsenites; Child; Drug Combinations; Drug Resistance; Drug Therapy, Comb | 2008 |
A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Topics: Amodiaquine; Antimalarials; Arsenites; Child; Drug Combinations; Drug Resistance; Drug Therapy, Comb | 2008 |
A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Topics: Amodiaquine; Antimalarials; Arsenites; Child; Drug Combinations; Drug Resistance; Drug Therapy, Comb | 2008 |
High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda.
Topics: Amodiaquine; Anti-HIV Agents; Antimalarials; Artemisinins; Artesunate; Chemoprevention; Child; Child | 2008 |
Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya.
Topics: Adolescent; Amodiaquine; Blood; Child; Chloroquine; Drug Combinations; Drug Resistance, Microbial; F | 1984 |
Amodiaquine more effective than chloroquine against Plasmodium falciparum malaria on Kenya coast.
Topics: Amodiaquine; Child; Chloroquine; Humans; Kenya; Malaria; Plasmodium falciparum | 1984 |
The present status of malaria chemotherapy: mefloquine, a novel antimalarial.
Topics: Amodiaquine; Animals; Antimalarials; Aotus trivirgatus; Chemical Phenomena; Chemistry; Chloroquine; | 1981 |
Amodiaquine resistant falciparum malaria in Thailand.
Topics: Administration, Oral; Adolescent; Adult; Aminoquinolines; Amodiaquine; Chloroquine; Chromatography; | 1975 |
[Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique].
Topics: Adult; Amodiaquine; Animals; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combinat | 1990 |
Sensitivity of Plasmodium falciparum to chloroquine, amodiaquine and mefloquine in Ibadan, Nigeria.
Topics: Amodiaquine; Animals; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Humans; In Vitr | 1988 |
Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, | 1988 |
A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Brazil; Clindamycin; Clinical Trials as Topi | 1988 |
Falciparum malaria and pregnancy: relationship and treatment response.
Topics: Adolescent; Adult; Amodiaquine; Animals; Female; Humans; Malaria; Plasmodium falciparum; Pregnancy; | 1988 |
[Efficacy of amodiaquine, Fansidar and their combination in the treatment of chloroquine-resistant falciparum malaria].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Chloroquine; Double-Blind Method; Drug Combi | 1988 |
Efficacy of chemoprophylaxis in preventing Plasmodium falciparum parasitaemia and placental infection in pregnant women in Malawi.
Topics: Amodiaquine; Animals; Chloroquine; Female; Humans; Malaria; Malawi; Placenta Diseases; Plasmodium fa | 1988 |
[In vivo resistance of Plasmodium falciparum to 4-aminoquinolines and to a sulfadoxine-pyrimethamine combination. II. Study of Manaus, Amazonas 1983-1984].
Topics: Adolescent; Adult; Amodiaquine; Animals; Brazil; Chloroquine; Clinical Trials as Topic; Drug Resista | 1986 |
Amodiaquine and sulfadoxine-pyrimethamine as treatment for chloroquine-resistant Plasmodium falciparum in Rwanda.
Topics: Amodiaquine; Animals; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Hum | 1988 |
Evaluation of four therapeutic regimens for falciparum malaria in Mozambique, 1986.
Topics: Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Drug Therapy, Combination; | 1988 |
Effects of chloroquine, amodiaquine and pyrimethamine-sulfadoxine on Plasmodium falciparum gametocytemia.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinatio | 1986 |
Amodiaquine less effective than chloroquine in the treatment of falciparum malaria in the Philippines.
Topics: Adolescent; Adult; Amodiaquine; Biological Availability; Chloroquine; Clinical Trials as Topic; Drug | 1987 |
Orally administered amodiaquine base suspensions in the treatment of acute malaria infections of young children in Nigeria.
Topics: Administration, Oral; Amodiaquine; Blood; Child; Child, Preschool; Chloroquine; Dose-Response Relati | 1974 |
A trial of CI-564 (dapolar), a repository antimalarial for prophylaxis in Amapá, Brazil.
Topics: Acetanilides; Amodiaquine; Antimalarials; Brazil; Child; Child, Preschool; Clinical Trials as Topic; | 1970 |
Prophylactic and sporontocidal treatment of chloroquine resistant Plasmodium falciparum from Malaya.
Topics: Adult; Amodiaquine; Anopheles; Antimalarials; Blood; Chloroquine; Clinical Trials as Topic; Dapsone; | 1970 |
The suppression of malaria with dapolar: a trial of 4-monthly doses in a village community in the Gambia, West Africa.
Topics: Acetanilides; Adolescent; Adult; Age Factors; Amodiaquine; Antimalarials; Child; Child, Preschool; F | 1971 |
313 other studies available for amodiaquine and Malaria
| Article | Year |
|---|---|
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resista | 2011 |
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
Topics: Animals; Antimalarials; Humans; Inhibitory Concentration 50; Malaria; Mice; Microsomes, Liver; Paras | 2014 |
Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies.
Topics: Aminoquinolines; Animals; Antimalarials; Benzene Derivatives; Humans; Malaria; Malaria, Falciparum; | 2015 |
Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
Topics: Antimalarials; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Indoles; Malar | 2015 |
New hybrid trifluoromethylquinolines as antiplasmodium agents.
Topics: Animals; Antimalarials; Cell Line; Drug Discovery; Erythrocytes; Halogenation; Haplorhini; Humans; M | 2019 |
Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1
Topics: Administration, Oral; Animals; Antimalarials; Cyclization; Disease Models, Animal; Ethers; Female; H | 2021 |
Trends and predictive factors for treatment failure following artemisinin-based combination therapy among children with uncomplicated malaria in Ghana: 2005-2018.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2021 |
Effect of three years' seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Cross-Sectional Studies; Drug | 2022 |
Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Child | 2022 |
Prevalence of malaria among febrile patients and assessment of efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated malaria in Dolisie, Republic of the Congo.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Child | 2022 |
Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2022 |
A Decade of Progress Accelerating Malaria Control in Mali: Evidence from the West Africa International Center of Excellence for Malaria Research.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinations; Humans; Malari | 2022 |
Cardiovascular concentration-effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies.
Topics: Amodiaquine; Animals; Antimalarials; Kenya; Malaria; Mice | 2023 |
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Drug Combinations; Drug Resistance; Genomics; Ha | 2023 |
Design, Implementation, and Coordination of Malaria Therapeutic Efficacy Studies in Nigeria in 2018.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Drug Combi | 2023 |
Predictors of caregiver adherence to administration of amodiaquine during delivery of seasonal malaria chemoprevention in Nigeria, Burkina Faso, Chad, and Togo.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Caregivers; Chad; Chemoprevention; Child; Drug Combination | 2023 |
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Case-Control Studies; Chemoprevention; Child; Child, Presc | 2023 |
Antimalarial Agents Derived from Metal-Amodiaquine Complexes with Activity in Multiple Stages of the Plasmodium Life Cycle.
Topics: Amodiaquine; Antimalarials; Coordination Complexes; Humans; Malaria; Plasmodium; Plasmodium falcipar | 2023 |
Effectiveness of seasonal malaria chemoprevention in reducing under-five malaria morbidity and mortality in the Savannah Region, Ghana.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Ghana; Humans; Infant; Malaria | 2022 |
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Topics: Africa; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesun | 2023 |
Consequences of restricting antimalarial drugs to rapid diagnostic test-positive febrile children in south-west Nigeria.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Cross-Sectional Studies; Drug Combinatio | 2019 |
Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice.
Topics: Amodiaquine; Animals; Antimalarials; Drug Combinations; Drug Interactions; Female; Herb-Drug Interac | 2020 |
Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children.
Topics: Africa; Amodiaquine; Antimalarials; Case-Control Studies; Chemoprevention; Child, Preschool; Female; | 2020 |
Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Child; Child, Preschool; Cohort | 2020 |
The End of the Artemisinin Era-We Should Aim at Malaria Eradication in Asia Using Free, Effective Treatment.
Topics: Amodiaquine; Artemisinins; Artesunate; Asia; Cambodia; Humans; Malaria; Plasmodium falciparum | 2021 |
Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Asia; Cambodia; Child; Humans; Malaria; | 2021 |
Serotype Profile of Nasopharyngeal Isolates of
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Azithromycin; Burkina Faso; Carrier State; Chemop | 2020 |
Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar.
Topics: Amodiaquine; Antimalarials; Artesunate; Asia; Drug Combinations; Drug Resistance; Humans; Malaria; M | 2020 |
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Betaco | 2020 |
Treatment Approved for Severe Malaria.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Monitori | 2020 |
Clinical Probe of Cyp2C8*2 Mutants in a Malaria Hyperendemic Zone: Evidence from North-Central, Nigeria.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Cytochrome P-450 CYP2C8; Drug Resistan | 2020 |
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Amodiaquine; Antimalarials; Case-Control Studie | 2020 |
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Amodiaquine; Antimalarials; Case-Control Studie | 2020 |
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Amodiaquine; Antimalarials; Case-Control Studie | 2020 |
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Amodiaquine; Antimalarials; Case-Control Studie | 2020 |
Assessment of antimalarial drug resistant markers in asymptomatic Plasmodium falciparum infections after 4 years of indoor residual spraying in Northern Ghana.
Topics: Amodiaquine; Antimalarials; Biomarkers, Pharmacological; Carrier State; Child, Preschool; Chloroquin | 2020 |
Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries.
Topics: Amodiaquine; Chloroquine; COVID-19 Drug Treatment; Drug Resistance; Humans; Malaria; Plasmodium | 2021 |
Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Bur | 2021 |
Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child, Preschool; Communicable Disease Control; Cost-Be | 2021 |
Plasmodium falciparum Atg18 localizes to the food vacuole via interaction with the multi-drug resistance protein 1 and phosphatidylinositol 3-phosphate.
Topics: Amodiaquine; Animals; Antimalarials; Autophagy; Autophagy-Related Proteins; Biological Transport; Ch | 2021 |
Seasonal malaria chemoprevention in the Sahel.
Topics: Africa; Amodiaquine; Antimalarials; Chemoprevention; Child, Preschool; Drug Combinations; Female; Hu | 2017 |
Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; DNA, Pro | 2017 |
The Candidate Antimalarial Drug MMV665909 Causes Oxygen-Dependent mRNA Mistranslation and Synergizes with Quinoline-Derived Antimalarials.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Malaria; Oxygen; Primaquine; Protein Biosynth | 2017 |
Study on testicular response to prolong artemisinin-based combination therapy treatments in guinea pigs.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug C | 2018 |
Measuring the impact of seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali.
Topics: Amodiaquine; Anemia; Antimalarials; Chemoprevention; Child; Child, Preschool; Cross-Sectional Studie | 2017 |
Large-scale delivery of seasonal malaria chemoprevention to children under 10 in Senegal: an economic analysis.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Community Health Workers; Cost | 2017 |
Seasonal malaria chemoprevention: successes and missed opportunities.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Chemoprevention; Child, Preschool; Drug Comb | 2017 |
Prescriber practices and patient adherence to artemisinin-based combination therapy for the treatment of uncomplicated malaria in Guinea, 2016.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Arte | 2019 |
Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method.
Topics: Adolescent; Amodiaquine; Antimalarials; Arrhythmias, Cardiac; Artemether; Artemether, Lumefantrine D | 2019 |
Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Azithromycin; Burkina Faso; Child Mortality; Chil | 2019 |
Failures in the case management of children with uncomplicated malaria in Bata district of Equatorial Guinea and associated factors.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Case Management; Child; Child, Preschool; Cros | 2019 |
Should malaria treatment be guided by a point of care rapid test? A threshold approach to malaria management in rural Burkina Faso.
Topics: Adult; Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Decision Making; Drug Combination | 2013 |
Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.
Topics: Adolescent; Adult; Amodiaquine; Anti-Infective Agents; Antimalarials; Artemisinins; Child; Child, Pr | 2013 |
Reversible binocular visual loss in temporal association with artesunate-amodiaquine treatment in a child on mefloquine chemoprophylaxis.
Topics: Amodiaquine; Anti-Inflammatory Agents; Antimalarials; Artemisinins; Chemoprevention; Child; Dexameth | 2012 |
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
Topics: Adolescent; Adult; Amodiaquine; Anti-Retroviral Agents; Antimalarials; Antiretroviral Therapy, Highl | 2014 |
Suppressive action of mepacrine, aphacrine, chloroquin, camoquin and proguanil against P. knowlesi in S. rhesus monkeys.
Topics: Amodiaquine; Animals; Chloroquine; Humans; Macaca mulatta; Malaria; Proguanil; Quinacrine | 1950 |
Comparison of the action of paludrine (proguanil), chloroquine and camoquin in single doses.
Topics: Amodiaquine; Chloroquine; Humans; Malaria; Proguanil | 1950 |
Camoquin and chloroquine in the treatment of malaria.
Topics: Amodiaquine; Chloroquine; Humans; Malaria | 1950 |
Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Brazil; Drug Combinations; Drug Discovery; Dru | 2014 |
Interaction between rifampicin, amodiaquine and artemether in mice infected with chloroquine resistant Plasmodium berghei.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Drug Interactions; Drug Resistance; D | 2014 |
Amodiaquine-Ciprofloxacin: a potential combination therapy against drug resistant malaria.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Ciprofloxacin; Dose-Response Relationship, Drug; D | 2015 |
The implication of long-lasting insecticide-treated net use in the resurgence of malaria morbidity in a Senegal malaria endemic village in 2010-2011.
Topics: Adolescent; Adult; Amodiaquine; Animals; Artemisinins; Child; Child, Preschool; Cross-Sectional Stud | 2015 |
High adherence to malaria treatment: promising results of an adherence study in South Kivu, Democratic Republic of the Congo.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Animals; Antimalarials; Artemisinins; Child | 2015 |
Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine combinations in the treatment of uncomplicated malaria in two ecological zones in Ghana.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Ec | 2016 |
Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease.
Topics: Adolescent; Adult; Amodiaquine; Anti-Bacterial Agents; Antimalarials; Artemether, Lumefantrine Drug | 2016 |
Seeking treatment for uncomplicated malaria: experiences from the Kintampo districts of Ghana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Antimalarials; Artemether, Lumefantrine Dru | 2016 |
Lopinavir/ritonavir enhanced the antimalarial activity of amodiaquine and artesunate in a mouse model of Plasmodium berghei.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Disease Models, Animal; Drug Synergis | 2016 |
Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug Ther | 2016 |
Evaluation of the combination of Uvaria chamae (P. Beauv.) and amodiaquine in murine malaria.
Topics: Amodiaquine; Animals; Antimalarials; Herb-Drug Interactions; Malaria; Mice; Plant Preparations; Plas | 2016 |
Adherence to malaria diagnosis and treatment guidelines among healthcare workers in Ogun State, Nigeria.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Case Management; Cross-Sectional Studie | 2016 |
Busting the billion-dollar myth: how to slash the cost of drug development.
Topics: Africa; Amodiaquine; Anti-Bacterial Agents; Artemisinins; Benzamides; Boron Compounds; Child; Clinic | 2016 |
Impact of the Mass Drug Administration for malaria in response to the Ebola outbreak in Sierra Leone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Antimalarials; Artemisinins; Child; Child, | 2016 |
Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Dru | 2016 |
Impact of Extended Duration of Artesunate Treatment on Parasitological Outcome in a Cytocidal Murine Malaria Model.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Disease Models, Animal; F | 2017 |
Intermittent preventive antimalarial treatment to children (IPTc): firebreak or fire trap?
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Decision Making; Drug Administration Sch | 2008 |
Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; A | 2008 |
Trends in malaria morbidity following the introduction of artesunate plus amodiaquine combination in M'lomp village dispensary, south-western Senegal.
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combina | 2008 |
[Two cases of fulminant hepatitis during a curative treatment with an artesunate-amodiaquine combination].
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Chemical and Drug Induced Liver Injury; | 2009 |
Efficacy of monotherapies and artesunate-based combination therapies in children with uncomplicated malaria in Somalia.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Com | 2009 |
Biological measure of compliance to Artesunate plus Amodiaquine association: interest in a Mono-Desethyl-Amodiaquine blood assay?
Topics: Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Chromatography, High Pressure Liquid; Drug | 2009 |
Intermittent preventive treatment with antimalarial drugs.
Topics: Amodiaquine; Anemia; Antimalarials; Drug Administration Schedule; Drug Combinations; Humans; Infant; | 2009 |
Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; | 2009 |
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Benzylamines; Cytochrome P-450 Enzyme Inhibito | 2009 |
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Cell Survival; Chloroquine; Dogs; Drug Resista | 2009 |
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Disease Models, Animal; Drug Resista | 2009 |
In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Cohort Studies; Female; Humans; Infant; Kenya | 2009 |
Factors related to compliance to anti-malarial drug combination: example of amodiaquine/sulphadoxine-pyrimethamine among children in rural Senegal.
Topics: Amodiaquine; Animals; Antimalarials; Caregivers; Child; Child, Preschool; Drug Administration Schedu | 2009 |
Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in rural health facilities in southern Cameroon.
Topics: Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Cameroon; Child, Preschool; Drug Combinations | 2009 |
Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in urban health facilities in Yaoundé, central province, Cameroon.
Topics: Adult; Aged; Aged, 80 and over; Amodiaquine; Antimalarials; Artemisinins; Cameroon; Child, Preschool | 2009 |
Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants.
Topics: Amodiaquine; Antimalarials; Clinical Trials as Topic; Drug Combinations; Drug Resistance; Female; Hu | 2009 |
Self-reported data: a major tool to assess compliance with anti-malarial combination therapy among children in Senegal.
Topics: Amodiaquine; Antimalarials; Caregivers; Child; Child, Preschool; Drug Administration Schedule; Drug | 2009 |
Successful introduction of artesunate combination therapy is not enough to fight malaria: results from an adherence study in Sierra Leone.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Caregivers; Child; Ch | 2010 |
Intermittent preventive treatment to reduce the burden of malaria in children: new evidence on integration and delivery.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Drug Combinations; Female; Humans; Infant; Infant, New | 2011 |
Two-year evaluation of Intermittent Preventive Treatment for Children (IPTc) combined with timely home treatment for malaria control in Ghana.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chemoprevention; Child, Preschool; Drug Combinati | 2011 |
Two-year evaluation of Intermittent Preventive Treatment for Children (IPTc) combined with timely home treatment for malaria control in Ghana.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chemoprevention; Child, Preschool; Drug Combinati | 2011 |
Two-year evaluation of Intermittent Preventive Treatment for Children (IPTc) combined with timely home treatment for malaria control in Ghana.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chemoprevention; Child, Preschool; Drug Combinati | 2011 |
Two-year evaluation of Intermittent Preventive Treatment for Children (IPTc) combined with timely home treatment for malaria control in Ghana.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chemoprevention; Child, Preschool; Drug Combinati | 2011 |
The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chemistry, Pharmaceutical; Drug Combinations; Humans; Mala | 2011 |
Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Antimalarials; Artemisinins; Case-Control S | 2011 |
Antimalarial mannoxanes: hybrid antimalarial drugs with outstanding oral activity profiles and a potential dual mechanism of action.
Topics: Administration, Oral; Amodiaquine; Animals; Antimalarials; Hemeproteins; Hemin; Humans; Malaria; Man | 2011 |
Changing patterns of malaria during 1996-2010 in an area of moderate transmission in southern Senegal.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Com | 2011 |
Management of uncomplicated malaria in children under 13 years of age at a district hospital in Senegal: from official guidelines to usual practices.
Topics: Adolescent; Amodiaquine; Antimalarials; Blood; Child; Child, Preschool; Drug Combinations; Drug Ther | 2011 |
A thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in Gabon.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; DNA, Protozoan; Drug Combinations; Drug Resis | 2011 |
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.
Topics: Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Blotting, Southern; Dose-Response Rela | 2011 |
Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Dap | 2012 |
Access to artemisinin-combination therapy (ACT) and other anti-malarials: national policy and markets in Sierra Leone.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Drug Costs; Geography; Health Policy; Health S | 2012 |
Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western Senegal.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Amodiaquine; Antimalarials; Artemisinins | 2012 |
Questions about the antimalarial amodiaquine.
Topics: Amodiaquine; Antimalarials; Humans; Malaria; Neutropenia | 2003 |
Vendor-to-vendor education to improve malaria treatment by private drug outlets in Bungoma District, Kenya.
Topics: Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Commerce; Drug Combinations | 2003 |
Evaluation of amodiaquin (camoquin) in the treatment of relapsing vivax malaria.
Topics: Amodiaquine; Malaria; Malaria, Vivax; Recurrence | 1953 |
Clinical trials with Camoquin in malaria.
Topics: Amodiaquine; Humans; Malaria | 1952 |
[Malaria prevention by amodiaquine].
Topics: Amodiaquine; Humans; Malaria | 1952 |
[Use of camoquine in treatment of malaria].
Topics: Amodiaquine; Humans; Malaria | 1952 |
Treatment of sub-tertian malaria with camoquin.
Topics: Amodiaquine; Humans; Malaria | 1952 |
Screening of antimalarials against P. gallinaceum in chicks.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Chickens; Chloroquine; Malaria; Proguanil; Qui | 1952 |
Camoquin in malaria.
Topics: Amodiaquine; Humans; Malaria | 1953 |
[Results of experiences with chloroquine, proguanil and amodiaquine in the prophylaxis of malaria].
Topics: Amodiaquine; Chloroquine; Humans; Malaria; Proguanil | 1952 |
Suppressive treatment with amodiaquin.
Topics: Amodiaquine; Antimalarials; Humans; Malaria | 1953 |
A comparison of the antimalarial effects of suppressive doses of chloroquine, amodiaquin, and pyrimethamine.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria; Pyrimethamine | 1954 |
Nivaquine and camoquin in malaria.
Topics: Amodiaquine; Antimalarials; Chloroquine; Malaria; Quinolines | 1954 |
[Treatment of some forms of malaria with flavoquine; 201 observations].
Topics: Amodiaquine; Antimalarials; Humans; Malaria | 1954 |
[Medicinal prophylaxis of malaria by monthly doses of chloroquine and amodiaquine].
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria | 1954 |
A note on clinical trial of pyrimethamine (daraprim) and amodiaquin (camaquin) at the malaria field station, Thirmalapur, Nizamabad district.
Topics: Amodiaquine; Antimalarials; Malaria; Pyrimethamine | 1953 |
Therapeutic trials with pyrimethamine (daraprim), resochin, amodiaquin (camoquin) and quinine.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria; Pyrimethamine; Quinine | 1953 |
The treatment of acute malaria with single oral doses of amodiaquin, chloroquine, hydroxychloroquine and pyrimethamine.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Pyrimethamine | 1954 |
Treatment of malaria with a single dose of amodiaquin (Camoquin).
Topics: Amodiaquine; Antimalarials; Malaria | 1954 |
Camoquin as a malaria suppressant.
Topics: Amodiaquine; Antimalarials; Malaria | 1955 |
Potentialities of monthly doses of camoquin and a gametocidal drug in malaria control.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria | 1955 |
Studies on the chemotherapy of malaria. IV. The treatment of acute malaria with amodiaquin (camoquin).
Topics: Amodiaquine; Antimalarials; Malaria | 1955 |
Studies on the chemotherapy of malaria. V. The suppression of malaria by amodiaquin (camoquin).
Topics: Amodiaquine; Antimalarials; Malaria | 1955 |
Treatment on malaria with single doses of mepacrine, chloroquine and amodiaquin.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria; Quinacrine | 1955 |
Comparative assessment of chloroquine and amodiaquine as malaria suppressives in Nigeria.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria; Nigeria | 1958 |
[4-Aminoquinolines in eradication of malaria; epidemiologic evaluation of a single or double dose of 600 milligrams of camoquin].
Topics: Aminoquinolines; Amodiaquine; Antimalarials; Humans; Malaria | 1958 |
Single dose treatment of malaria with amodiaquin chloroquine and mepacrine in a semi-immune poplation.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria; Quinacrine | 1960 |
Amodiaquine and hydroxychloroquine resistance in Plasmodium falciparum.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Plasmodium falciparum | 1961 |
Pigmentation of the nail-beds, palate and skin occurring during malarial suppressive therapy with "camoquin".
Topics: Amodiaquine; Antimalarials; Humans; Malaria; Nails; Palate; Pigmentation; Pigmentation Disorders; Sk | 1960 |
Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika.
Topics: Africa; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Culicidae; Humans; Malaria; Primaquine | 1962 |
FLUORESCENT ANTIBODY STUDIES IN HUMAN MALARIA. II. DEVELOPMENT AND PERSISTENCE OF ANTIBODIES TO PLASMODIUM FALCIPARUM.
Topics: Amodiaquine; Antibodies; Antigen-Antibody Reactions; Chloroquine; Fluorescent Antibody Technique; Hu | 1964 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND.
Topics: Amodiaquine; Antimalarials; Asia, Southeastern; Biomedical Research; Chloroquine; Drug Resistance; D | 1964 |
[A PATIENT WITH TROPICAL MALARIA].
Topics: Amodiaquine; Antimalarials; Chloroquine; Dosage Forms; Drug Resistance; Drug Resistance, Microbial; | 1964 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM VIET-NAM.
Topics: Amodiaquine; Antimalarials; Biomedical Research; Chloroquine; Drug Therapy; Humans; Malaria; Malaria | 1964 |
MALARIA IN CHILDHOOD MODERN CONCEPTS OF IMMUNITY, TREATMENT, PROPHYLAXIS.
Topics: Amodiaquine; Child; Chloroquine; Diagnosis; Drug Therapy; Epidemiology; Humans; Infant; Infant, Newb | 1965 |
SOME FEATURES OF MALARIA IN DILI, PORTUGUESE TIMOR, DURING 1963-64.
Topics: Amodiaquine; Anemia; Chloroquine; Clinical Laboratory Techniques; Drug Therapy; Epidemiology; Humans | 1965 |
Field trials of nivaquine, camoquin and resochin against human malaria.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria; Quinolines; Uricosuric Agents | 1954 |
[Malaria prevention trial with amodiaquine on the Thuan-Loi plantation].
Topics: Amodiaquine; Antimalarials; Biomedical Research; Humans; Malaria | 1955 |
The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy.
Topics: Africa, Eastern; Amodiaquine; Antimalarials; Chloroquine; Disease Susceptibility; Drug Combinations; | 2003 |
Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Crystallography, X-Ray; Malaria; Male; Plasmod | 2003 |
[Synthetic antimalarials; camoquin].
Topics: Amodiaquine; Antimalarials; Malaria; Quinolines | 1950 |
[Treatment of malaria with camoquin].
Topics: Amodiaquine; Humans; Malaria; Quinolines | 1950 |
The treatment of malaria with a single dose of camoquin.
Topics: Amodiaquine; Malaria | 1951 |
Camoquin in the treatment of human malaria.
Topics: Amodiaquine; Malaria | 1951 |
[General sketch on documentation relative to amodiaquine].
Topics: Amodiaquine; Documentation; Humans; Malaria; Quinolines | 1951 |
Camoquin in malaria.
Topics: Amodiaquine; Malaria | 1951 |
Intravenous amodiaquin (camoquin) in naturally acquired and induced malaria.
Topics: Amodiaquine; Malaria | 1951 |
[Flavoquine in the treatment of malaria].
Topics: Amodiaquine; Humans; Malaria | 1951 |
Treatment of malaria with a single dose of amodiaquine or chloroquine.
Topics: Amodiaquine; Chloroquine; Humans; Malaria | 1952 |
The anomalous antimalarial activity of O-methyl camoquin.
Topics: Amodiaquine; Antimalarials; Humans; Malaria | 1949 |
Camoquin treatment of malaria a preliminary report.
Topics: Amodiaquine; Humans; Malaria; Quinolines | 1950 |
Amodiaquine during pregnancy.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Malaria; | 2004 |
New malaria combination cheaper and easier to take.
Topics: Administration, Oral; Amodiaquine; Artemisinins; Artesunate; Drug Costs; Drug Therapy, Combination; | 2005 |
Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Central African Republic; Child, Preschool; Chloroquine; Drug Combinatio | 2005 |
Amodiaquine and combination chemotherapy for malaria.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Hum | 2005 |
Amodiaquine polymeric membrane electrode.
Topics: Adipates; Amodiaquine; Antimalarials; Chemistry, Pharmaceutical; Diethylhexyl Phthalate; Electrodes; | 2006 |
Factors contributing to the development of anaemia in Plasmodium falciparum malaria: what about drug-resistant parasites?
Topics: Amodiaquine; Anemia; Animals; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug R | 2006 |
Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004.
Topics: Africa; Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Clinical Trials as Topic; Drug Co | 2006 |
Cost-effectiveness study of three antimalarial drug combinations in Tanzania.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2006 |
Amodiaquine, malaria, pregnancy: the old new drug.
Topics: Amodiaquine; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; Ghana; Humans; Mal | 2006 |
[Against malaria: ASAQ, one dollar per box].
Topics: Amodiaquine; Artemisinins; Costs and Cost Analysis; Drug Combinations; Humans; Malaria | 2007 |
Antimalarial drugs--here and on the horizon.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Aspartic Acid Endopeptidases; Drug Combinations; | 2007 |
Emergency liver transplantation in amodiaquine-induced fulminant hepatitis.
Topics: Adult; Amodiaquine; Antimalarials; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; | 2007 |
Community coverage of an antimalarial combination of artesunate and amodiaquine in Makamba Province, Burundi, nine months after its introduction.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Burundi; Child, Preschool; Community Health Se | 2007 |
[ASAQ, a breakthrough in the fight against malaria].
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Industry; Humans; Inte | 2007 |
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Design; | 2007 |
Clinical symptoms, treatment and outcome of highlands malaria in Eldoret (2420 m a.s.l.) and comparison to malaria in hyper-immune population in endemic region of Southern Sudan.
Topics: Altitude; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Drug Therapy, Combination; Endemic D | 2007 |
[Assessing the application of Rwanda's national protocol for uncomplicated malaria treatment in healthcare institutions in Kigali City, Rwanda].
Topics: Adult; Amodiaquine; Antimalarials; Drug Prescriptions; Drug Therapy, Combination; Female; Guideline | 2008 |
Parenteral use of camoquin hydrochloride as an antimalarial.
Topics: Amodiaquine; Antimalarials; Malaria | 1949 |
A simple technique for the detection of anti-malarial drug formulations and their presence in human urine.
Topics: Amodiaquine; Antimalarials; Biological Assay; Biological Availability; Chloroquine; Chromatography, | 2006 |
Pharmacokinetic determinants of the window of selection for antimalarial drug resistance.
Topics: Algorithms; Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Computer Simulation; Dru | 2008 |
Increased Plasmodium falciparum gametocyte production in mixed infections with P. malariae.
Topics: Amodiaquine; Animals; Antimalarials; Child; Drug Combinations; Gametogenesis; Humans; Malaria; Plasm | 2008 |
Disease and drug interactions: treating malaria with artesunate plus amodiaquine in patients also receiving treatment for concomitant HIV infection.
Topics: Amodiaquine; Anti-HIV Agents; Antimalarials; Artemisinins; Artesunate; Drug Interactions; Drug Thera | 2008 |
Malaria control and primary health care.
Topics: Amodiaquine; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Papua New Guinea; Plasmodium | 1983 |
Amodiaquine and chloroquine efficacy against Plasmodium falciparum in Madagascar.
Topics: Amodiaquine; Chloroquine; Humans; Madagascar; Malaria; Plasmodium falciparum | 1984 |
Treatment of Plasmodium falciparum malaria with a combination of amodiaquine and tetracycline in Central Thailand.
Topics: Adolescent; Adult; Aged; Amodiaquine; Drug Therapy, Combination; Female; Humans; Malaria; Male; Midd | 1983 |
Plasmodium falciparum in Kisumu, Kenya: differences in sensitivity to amodiaquine and chloroquine in vitro.
Topics: Amodiaquine; Child; Chloroquine; Drug Resistance, Microbial; Female; Humans; Kenya; Malaria; Male; M | 1983 |
Evaluation of amodiaquine treatment of chloroquine-resistant Plasmodium falciparum malaria on Zanzibar, 1982.
Topics: Amodiaquine; Child; Child, Preschool; Chloroquine; Drug Evaluation; Drug Resistance; Humans; Infant; | 1983 |
Treatment of chloroquine-resistant Plasmodium falciparum malaria.
Topics: Amodiaquine; Chloroquine; Drug Resistance; Drug Therapy, Combination; Humans; Malaria; Plasmodium fa | 1984 |
The sensitivity of Plasmodium falciparum to chloroquine and amodiaquine in Ibadan, Nigeria.
Topics: Amodiaquine; Child; Child, Preschool; Chloroquine; Female; Humans; Infant; Malaria; Male; Microbial | 1984 |
[4-Aminoquinoline-sensitivity of Plasmodium falciparum in Madagascar. I. Study in two regions of the west coast].
Topics: Adolescent; Aged; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Res | 1984 |
[4-Aminoquinoline-sensitivity of Plasmodium falciparum in Madagascar. II. Study in two regions of the east coast].
Topics: Aminoquinolines; Amodiaquine; Antimalarials; Child; Chloroquine; Drug Resistance, Microbial; Humans; | 1984 |
[4-Aminoquinoline-sensitivity of Plasmodium falciparum in Madagascar. III. Studies in three regions of the interior].
Topics: Aminoquinolines; Amodiaquine; Antimalarials; Chloroquine; Drug Resistance, Microbial; Humans; Madaga | 1984 |
Management of Plasmodium falciparum malaria.
Topics: Amodiaquine; Anemia; Antimalarials; Brain Diseases; Chloroquine; Drug Resistance; Female; Humans; Hy | 1984 |
[Drug prevention of malaria].
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Humans; Infant; Malari | 1983 |
[Amodiaquine-induced agranulocytosis in malaria prevention: demonstration of an amodiaquine-induced cytotoxic antibody against granulocytes].
Topics: Adolescent; Agglutinins; Agranulocytosis; Amodiaquine; Antibody-Dependent Cell Cytotoxicity; Blood T | 1983 |
Reduction in malaria parasite rate in young children by distribution of prophylactic amodiaquine through voluntary village workers.
Topics: Amodiaquine; Child, Preschool; Humans; Infant; Infant, Newborn; Malaria; Papua New Guinea; Pilot Pro | 1981 |
Chloroquine resistant Plasmodium falciparum malaria in East New Britain, Papua New Guinea.
Topics: Amodiaquine; Child, Preschool; Chloroquine; Drug Resistance; Humans; Infant; Malaria; Plasmodium fal | 1980 |
Malaria and growth stunting in young children of the highlands of Papua New Guinea.
Topics: Amodiaquine; Anthropometry; Child; Child, Preschool; Chloroquine; Female; Growth Disorders; Health S | 1980 |
Response to 600 mg amodiaquine base with 45 mg primaquine as presumptive treatment in chloroquine resistant Plasmodium falciparum infection in Assam.
Topics: Adolescent; Adult; Amodiaquine; Child; Chloroquine; Drug Resistance, Microbial; Humans; India; Infan | 1980 |
Synthesis of some novel amodiaquine analogues as potential antimalarial and antifilarial compounds.
Topics: Amodiaquine; Animals; Anthelmintics; Antimalarials; Chemical Phenomena; Chemistry; Filariasis; Filar | 1981 |
Acute malaria in children in Madang: endemicity, clinical presentation and treatment.
Topics: Amodiaquine; Child, Preschool; Chloroquine; Drug Resistance; Humans; Malaria; Papua New Guinea; Plas | 1981 |
Use and misuse of 4-aminoquinoline antimalarials in tropical Africa and re-examination of itch reaction to these drugs.
Topics: Amodiaquine; Chloroquine; Health Surveys; Humans; Malaria; Nigeria; Pruritus | 1981 |
[Amodiaquine-induced agranulocytosis].
Topics: Adult; Agranulocytosis; Amodiaquine; Humans; Malaria; Male | 1981 |
The effect of chemical substitution on the metabolic activation, metabolic detoxication, and pharmacological activity of amodiaquine in the mouse.
Topics: Amodiaquine; Animals; Bile; Biotransformation; Inactivation, Metabolic; Malaria; Male; Mice; Structu | 1995 |
[Cytokines and malaria. A study of TNF-alpha, IL1-beta, IL6 and IL2R in 28 patients].
Topics: Adolescent; Adult; Amodiaquine; C-Reactive Protein; Chloroquine; Humans; Interleukin-1; Interleukin- | 1994 |
Amodiaquine.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Chloroquine; Drug Resistance; Health Policy; | 1996 |
"One-pot" synthesis and antimalarial activity of formamidine derivatives of 4-anilinoquinoline.
Topics: Amidines; Amodiaquine; Animals; Antimalarials; Cell Line; Humans; Inhibitory Concentration 50; Macro | 2001 |
Amodiaquine: the exempted antimalarial drug in Ethiopia.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Ethiopia; Humans; Malaria; Plasmo | 1998 |
Amodiaquin accumulation by mouse erythrocytes infected with Plasmodium berghei.
Topics: Amodiaquine; Animals; Erythrocytes; Glucose; Hydrogen-Ion Concentration; Malaria; Male; Mice; Plasmo | 1975 |
Prevention and treatment of malaria.
Topics: Amodiaquine; Chloroquine; Drug Resistance; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Qu | 1977 |
Field evaluation of primaquine in the control of Plasmodium vivax.
Topics: Adolescent; Adult; Amodiaquine; Child; Child, Preschool; Humans; Infant; Malaria; Plasmodium vivax; | 1978 |
Activities of various 4-aminoquinolines against infections with chloroquine-resistant strains of Plasmodium falciparum.
Topics: Aminoquinolines; Amodiaquine; Animals; Chloroquine; Drug Resistance, Microbial; Female; Haplorhini; | 1977 |
A pocket of controlled malaria in a holoendemic region of West Africa.
Topics: Amodiaquine; Anopheles; Child; Child, Preschool; Chloroquine; Costs and Cost Analysis; Humans; Liber | 1979 |
Chloroquine-resistant falciparum malaria from Irian Jaya (Indonesian New Guinea).
Topics: Amodiaquine; Chloroquine; Drug Resistance; Humans; Malaria; Male; Piperidines; Plasmodium falciparum | 1976 |
Letter: Response of Ethiopian strains of Plasmodium falciparum to amodiaquine.
Topics: Amodiaquine; Ethiopia; Malaria; Plasmodium falciparum | 1975 |
Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys.
Topics: Amodiaquine; Animals; Antimalarials; Dapsone; Disease Models, Animal; Dose-Response Relationship, Dr | 1976 |
[Chemotherapy and chemoprophylaxis of malaria (author's transl)].
Topics: Adult; Amodiaquine; Antimalarials; Asia, Southeastern; Central America; Child; Chloroquine; Drug Res | 1976 |
Host failure in treatment of malaria with sulfalene and pyrimethamine.
Topics: Adult; Amodiaquine; Drug Resistance; Drug Therapy, Combination; Erythrocytes; Humans; Malaria; Male; | 1975 |
The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Drug Resistance; Malaria; Mannich Bases; Mice; | 1992 |
[The blood schizontocidal effects of pyronaridine, amodiaquine, mefloquine and qinghaosu on mice infected with Plasmodium berghei].
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Resistance; Female; Malaria; Male; Mefloquin | 1992 |
Comparison of effects of pyronaridine, amodiaquine, mefloquine and qinghaosu on rodent malaria.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Administration Schedule; Drug Evaluation, Pr | 1992 |
Efficacy of amodiaquine against chloroquine-resistant malaria in Cameroon.
Topics: Adolescent; Adult; Amodiaquine; Animals; Cameroon; Child; Child, Preschool; Chloroquine; Drug Resist | 1991 |
Drug use and design in the nineties.
Topics: Aminoquinolines; Amodiaquine; Antimalarials; Artemisinins; Calcium Channel Blockers; Chloroquine; Hu | 1991 |
[Prevention and treatment of malaria in expatriates living in Black Africa. Influence of chemoresistance. Investigations conducted in Brazzaville (Congo)].
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; | 1991 |
Stabilization of drug resistance (chloroquine and amodiaquine) of Plasmodium falciparum in semiimmune populations in the Congo.
Topics: Amodiaquine; Animals; Child; Chloroquine; Drug Resistance; Humans; Malaria; Plasmodium falciparum | 1991 |
Resistance to antimalarials by Plasmodium falciparum in Arso PIR, Irian Jaya, Indonesia.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans | 1991 |
Infection of Aotus vociferans monkeys with different strains of Plasmodium falciparum.
Topics: Amodiaquine; Animals; Anopheles; Cebidae; Chloroquine; Malaria; Mefloquine; Plasmodium falciparum; T | 1991 |
Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine.
Topics: Adult; Aged; Amodiaquine; Antibodies, Anti-Idiotypic; Chloroquine; Dose-Response Relationship, Immun | 1991 |
[Comparative efficacy of chloroquine and amodiaquine (25 and 35 mg/kg) in school children infected with P. falciparum (Brazzaville, March 1990)].
Topics: Amodiaquine; Animals; Child; Chloroquine; Congo; Humans; Malaria; Plasmodium falciparum | 1991 |
An in-vitro profile of the action of four antimalarials on indigenous cases of Plasmodium falciparum malaria in Karnataka.
Topics: Amodiaquine; Animals; Chloroquine; Drug Resistance, Microbial; Malaria; Mefloquine; Microbial Sensit | 1990 |
[Uncomplicated malaria attack in an area with high chloroquine resistance. 2. Evaluation of first-choice therapeutic scheme].
Topics: Amodiaquine; Animals; Cameroon; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Human | 1990 |
The in vitro response of Plasmodium falciparum to amodiaquine, quinine and quinidine in Tanga region, Tanzania.
Topics: Adolescent; Amodiaquine; Animals; Child; Drug Resistance; Humans; Malaria; Plasmodium falciparum; Qu | 1990 |
[Plasmodium falciparum drug resistance in the Congo. Evaluation of surveys carried out from 1985 to 1989].
Topics: Adolescent; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroqui | 1990 |
The disposition of amodiaquine in Zambians and Nigerians with malaria.
Topics: Administration, Oral; Adolescent; Adult; Amodiaquine; Erythrocytes; Female; Humans; Malaria; Male; M | 1990 |
Low response of Colombian strains of Plasmodium vivax to classical antimalarial therapy.
Topics: Adult; Aged; Amodiaquine; Animals; Chloroquine; Colombia; Drug Resistance; Drug Therapy, Combination | 1989 |
[In vivo sensitivity of Plasmodium falciparum to amodiaquine in the town of Edea (Cameroon)].
Topics: Amodiaquine; Animals; Child; Conjunctival Diseases; Humans; Hyperemia; Malaria; Microbial Sensitivit | 1989 |
[Surveillance of Plasmodium falciparum drug sensitivity in Yaounde and its surroundings (Cameroon). In vivo and in vitro study].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Cameroon; Child; Child, Preschool; Chloroqui | 1989 |
[Malaria in Guiana. I. General status of the endemic].
Topics: Adolescent; Adult; Amodiaquine; Animals; Child; Child, Preschool; Chloroquine; Drug Resistance; Fren | 1989 |
Curative and preventive treatment of uncomplicated malaria in public health institutions in Cameroon.
Topics: Amodiaquine; Antimalarials; Cameroon; Child; Chloroquine; Drug Combinations; Female; Humans; Malaria | 1989 |
Fatal acute hepatitis due to amodiaquine.
Topics: Adult; Amodiaquine; Chemical and Drug Induced Liver Injury; Female; Humans; Malaria | 1989 |
Progress and problems in the diagnosis and treatment of malaria and development of an effective referral system in Papua New Guinea.
Topics: Amodiaquine; Chloroquine; Humans; Laboratories; Malaria; Papua New Guinea; Referral and Consultation | 1989 |
Intravenous amodiaquine and oral amodiaquine/erythromycin in the treatment of chloroquine-resistant falciparum malaria.
Topics: Administration, Oral; Adolescent; Adult; Amodiaquine; Child; Chloroquine; Drug Combinations; Drug Re | 1985 |
Chloroquine and amodiaquine resistant falciparum malaria in Rwanda.
Topics: Amodiaquine; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Plasmodium falciparum; Rwanda | 1985 |
Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria.
Topics: Acute Disease; Adult; Agranulocytosis; Amodiaquine; Drug Combinations; Drug Therapy, Combination; Fe | 1986 |
Neutropenia and prophylactic amodiaquine.
Topics: Adolescent; Aged; Agranulocytosis; Amodiaquine; Humans; Malaria; Male; Middle Aged; Neutropenia | 1986 |
Amodiaquine-induced hepatitis. A report of seven cases.
Topics: Adult; Alanine Transaminase; Amodiaquine; Aspartate Aminotransferases; Asthenia; Chemical and Drug I | 1986 |
Amodiaquine-resistant malaria in Brazil.
Topics: Adolescent; Adult; Amodiaquine; Brazil; Drug Evaluation; Drug Resistance; Female; Humans; Malaria; M | 1987 |
Hypohaptoglobinaemia as an epidemiological and clinical indicator for malaria. Results of two studies in a hyperendemic region in West Africa.
Topics: Adolescent; Adult; Africa, Western; Amodiaquine; Animals; Carrier State; Child; Cross-Sectional Stud | 1988 |
Amodiaquine-induced immune agranulocytosis.
Topics: Agranulocytosis; Amodiaquine; Female; Humans; Immunoglobulin G; Malaria; Male; Middle Aged; Neutroph | 1989 |
Serial studies on the evolution of drug resistance in malaria in an area of east Africa: findings from 1979 up to 1986.
Topics: Age Factors; Amodiaquine; Animals; Antibodies, Protozoan; Antimalarials; Child; Child, Preschool; Ch | 1988 |
In vivo and in vitro sensitivity of Plasmodium falciparum to chloroquine at Lubwe and Kalene in Zambia: use of amodiaquine as an alternative antimalarial drug.
Topics: Adolescent; Amodiaquine; Animals; Child; Chloroquine; Drug Resistance; Humans; Malaria; Plasmodium f | 1988 |
Multiple drug resistant Plasmodium falciparum malaria in a pregnant indigenous Zambian woman.
Topics: Adult; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Erythro | 1988 |
Agranulocytosis associated with the use of amodiaquine for malaria prophylaxis.
Topics: Agranulocytosis; Amodiaquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Proguan | 1986 |
Amodiaquine induced agranulocytosis and liver damage.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amodiaquine; Chemical and Drug Induced Liver Injury; Femal | 1986 |
In vitro drug response of Plasmodium falciparum in the Philippines: increased resistance to amodiaquine.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Mefloquine; Phil | 1987 |
[Drug resistance of Plasmodium falciparum in the Congo. 2. Comparative study in vivo of chloroquine and amodiaquine in Brazzaville schoolchildren (November 1986)].
Topics: Amodiaquine; Animals; Child; Chloroquine; Congo; Drug Resistance; Female; Humans; Malaria; Male; Pla | 1987 |
[Status of drug resistance of Plasmodium falciparum in the Central African Republic. Results of studies carried out between 1984 and 1986].
Topics: Amodiaquine; Animals; Antimalarials; Central African Republic; Child; Child, Preschool; Chloroquine; | 1987 |
[Drug sensitivity of malaria in a population of children in Pointe-Noire, Congo, in the first half of 1986].
Topics: Adolescent; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Congo; Drug R | 1987 |
[2 cases of multiresistant Plasmodium falciparum malaria contracted in Douala with atypical clinical presentation].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Cameroon; Chloroquine; Drug Combinations; Dr | 1987 |
[Sensitivity of Plasmodium falciparum to quinolines and therapeutic strategies: comparison of the situation in Africa and Madagascar between 1983 and 1986].
Topics: Amodiaquine; Angola; Animals; Antimalarials; Burkina Faso; Cameroon; Chloroquine; Drug Resistance; H | 1987 |
[Development of drug resistance in cases of P. falciparum malaria of African origin in a Parisian hospital. Comparison with field data and therapeutic consequences].
Topics: Africa; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; France | 1987 |
[Current aspects of imported drug-resistant Plasmodium falciparum].
Topics: Adult; Africa, Central; Aged; Aged, 80 and over; Amodiaquine; Animals; Antimalarials; Chloroquine; D | 1987 |
Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria.
Topics: Adult; Amiodarone; Amodiaquine; Animals; Female; Half-Life; Humans; Malaria; Male; Middle Aged; Plas | 1987 |
Amodiaquine fails to cure chloroquine resistant Plasmodium falciparum in the Punjab.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Mefloquine; Paki | 1987 |
Comparative efficacy of alternative primary therapies for Plasmodium falciparum infections in Malawi.
Topics: Amodiaquine; Animals; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Humans; Mal | 1987 |
[Synthesis of trifluoromethyl amodiaquine analogs and antimalarial activity].
Topics: Amodiaquine; Animals; Antimalarials; Chemical Phenomena; Chemistry; Malaria; Mice; Plasmodium berghe | 1987 |
[In vivo and in vitro sensitivity to 4-aminoquinolines of Plasmodium falciparum in Madagascar: results of a study conducted on the east coast (July 1985-July 1986)].
Topics: Adolescent; Adult; Aminoquinolines; Amodiaquine; Animals; Child; Child, Preschool; Chloroquine; Drug | 1987 |
[In vivo and in vitro study of the chemosensitivity of Plasmodium falciparum in Madagascar--1982-1986].
Topics: Adolescent; Amodiaquine; Animals; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; Inf | 1987 |
Amodiaquine-induced fulminant hepatitis.
Topics: Adolescent; Adult; Amodiaquine; Chemical and Drug Induced Liver Injury; Female; Humans; Malaria; Mal | 1988 |
Clinical pharmacology looks at tropical medicine.
Topics: Amodiaquine; Anthelmintics; Antimalarials; Chloroquine; Diethylcarbamazine; Filariasis; Filaricides; | 1987 |
Amodiaquine in malaria treatment.
Topics: Amodiaquine; Humans; Malaria | 1987 |
[A fatal case of chloroquine-resistant neuromalaria in a traveller to Cameroon].
Topics: Africa; Amodiaquine; Cameroon; Cerebral Hemorrhage; Chloroquine; Coma; Drug Resistance; Humans; Mala | 1986 |
[Drug sensitivity of malaria in Madagascar. Comparison in vivo and in vitro of the effects of chloroquine and amodiaquine on P. falciparum in 1984].
Topics: Adolescent; Amodiaquine; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; Madagascar; | 1986 |
Neuromyopathy associated with amodiaquine hydrochloride.
Topics: Adult; Amodiaquine; Female; Humans; Malaria; Neuromuscular Diseases | 1987 |
Neutropenia associated with dual antimalarial chemoprophylaxis--use of bone-marrow culture as an aid in further drug management.
Topics: Adult; Agranulocytosis; Amodiaquine; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Drug Therapy, | 1987 |
Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Erythrocyte Cou | 1987 |
Complications of antimalarial prophylaxis.
Topics: Amodiaquine; Antimalarials; Drug Therapy, Combination; Humans; Malaria | 1986 |
Amodiaquine and hepatitis.
Topics: Adult; Amodiaquine; Drug Resistance; Female; Humans; Malaria; Male | 1986 |
[Amodiaquine-induced hepatitis with leukopenia].
Topics: Adult; Agranulocytosis; Amodiaquine; Chemical and Drug Induced Liver Injury; Diagnosis, Differential | 1986 |
Lack of effect of antimalarial prophylaxis with chloroquine or amodiaquine in cutaneous leishmaniasis in French Guiana.
Topics: Amodiaquine; Chloroquine; Humans; Leishmaniasis; Malaria | 1986 |
Pharmacokinetics of intravenous amodiaquine.
Topics: Adult; Amodiaquine; Humans; Infusions, Intravenous; Injections, Intravenous; Kinetics; Malaria; Male | 1987 |
The role of voluntary village aides in the control of malaria by presumptive treatment of fever. 1. Selection, training and practice.
Topics: Adult; Amodiaquine; Attitude to Health; Chloroquine; Community Health Workers; Female; Fever; Humans | 1985 |
The role of voluntary village aides in the control of malaria by presumptive treatment of fever. 2. Impact on village health.
Topics: Adolescent; Amodiaquine; Child; Child, Preschool; Chloroquine; Community Health Workers; Fever; Huma | 1985 |
Studies of resistance to chloroquine, quinine, amodiaquine and mefloquine among Philippine strains of Plasmodium falciparum.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Mefloquine; Ph | 1985 |
Sensitivity of Plasmodium falciparum to antimalarial drugs in Colombia.
Topics: Amodiaquine; Antimalarials; Chloroquine; Colombia; Drug Combinations; Drug Resistance, Microbial; Ge | 1985 |
Malaria prophylaxis for Canadian travellers.
Topics: Amodiaquine; Canada; Chloroquine; Dapsone; Doxycycline; Drug Combinations; Drug Resistance, Microbia | 1985 |
Plasmodium falciparum in Madagascar: in vivo and in vitro sensitivity to seven drugs.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Humans; I | 1985 |
Malaria, cause of ahaptoglobinaemia in Africans.
Topics: Amodiaquine; Antimalarials; Child; Congo; Haptoglobins; Humans; Malaria; Mefloquine; Plasmodium falc | 1985 |
[In vivo and in vitro sensitivity to 4-aminoquinolines of Plasmodium falciparum in Madagascar: results of 2 years' study].
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Human | 1985 |
Drug-resistant malaria--changing patterns mean difficult decisions.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance, Microbial; Humans | 1985 |
[Pharmacokinetics of amodiaquine and prevention of Plasmodium falciparum malaria].
Topics: Adult; Amodiaquine; Female; Half-Life; Humans; Malaria; Male; Middle Aged; Plasmodium falciparum | 1985 |
[Biotransformation of amiodaquine and prophylaxis of Plasmodium falciparum malaria].
Topics: Amodiaquine; Animals; Biotransformation; Chromatography, High Pressure Liquid; Erythrocytes; Female; | 1985 |
High-performance liquid chromatographic analysis of amodiaquine in human plasma.
Topics: Adult; Amodiaquine; Chromatography, High Pressure Liquid; Drug Stability; Half-Life; Humans; Malaria | 1985 |
Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serum.
Topics: Agranulocytosis; Amodiaquine; Bone Marrow Cells; Colony-Forming Units Assay; Dipyrone; Drug Interact | 1985 |
Response to treatment in man of multi-drug resistant Plasmodium falciparum from Panama.
Topics: Adult; Amodiaquine; Animals; Anopheles; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug | 1974 |
Characterization of a drug resistant strain of Plasmodium falciparum from Burma.
Topics: Adult; Amodiaquine; Anopheles; Chloroquine; Drug Resistance, Microbial; Human Experimentation; Human | 1973 |
Mass drug administration as a supplementary attack measure in malaria eradication programme.
Topics: Adolescent; Amodiaquine; Child; Child, Preschool; Chloroquine; Drug Combinations; Humans; Indian Oce | 1974 |
A method for the determination of amodiaquine.
Topics: Amodiaquine; Humans; Malaria; Spectrometry, Fluorescence | 1974 |
Plasmodium falciparum malaria in Panama resistant to 4-aminoquinoline drugs.
Topics: Amodiaquine; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Panama; Plasmodium falciparum | 1972 |
Preliminary studies on a Philippine strain of Plasmodium falciparum resistant to amodiaquine.
Topics: Adult; Amodiaquine; Body Weight; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Male; Phi | 1972 |
Response of drug-resistant Plasmodium falciparum to combined therapy in Panama.
Topics: Adult; Amodiaquine; Child; Chloroquine; Drug Resistance, Microbial; Humans; Infant; Malaria; Panama; | 1972 |
[Treatment of malaria].
Topics: Adolescent; Amodiaquine; Child; Child, Preschool; Humans; Infant; Malaria; Plasmodium; Plasmodium fa | 1972 |
Characterisation of a drug resistant strain of Plasmodium falciparum from Sabah.
Topics: Adult; Amodiaquine; Borneo; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Male; Plasmodi | 1973 |
Malaria in New York City. IV. 1960-1971.
Topics: Adolescent; Adult; Africa, Western; Age Factors; Amodiaquine; Child; Child, Preschool; Chloroquine; | 1974 |
The chemotherapy and prophylaxis of malaria.
Topics: Adolescent; Adult; Amodiaquine; Child; Child, Preschool; Chloroquine; Drug Resistance, Microbial; Fe | 1973 |
Considerations on the use of sulphones and sulphonamides with a pyrimidine derivative.
Topics: Adult; Amodiaquine; Child; Dapsone; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; | 1974 |
Amodiaquine analogs. Synthesis of 6-((3-(N,N-diethylamino)methyl-4-hydroxy)anilino)5,8-dimethoxy-2,4-dimethylquinoline and related compounds.
Topics: Amodiaquine; Aniline Compounds; Animals; Antimalarials; Diethylamines; Macaca; Malaria; Mice; Plasmo | 1974 |
[Treatment of drug-resistant malaria: animal experiments].
Topics: Amodiaquine; Animals; Chloroquine; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy, Comb | 1974 |
[Increased incidence of malaria in Sinai and its prevention].
Topics: Adult; Amodiaquine; Humans; Israel; Malaria; Male; Time Factors | 1973 |
Determination of the drug sensitivity of Plasmodium falciparum.
Topics: Acute Disease; Amodiaquine; Antimalarials; Chloroquine; Drug Resistance, Microbial; Folic Acid Antag | 1971 |
The routine treatment of malaria.
Topics: Acute Disease; Adolescent; Adult; Amodiaquine; Child; Child, Preschool; Chloroquine; Chronic Disease | 1971 |
Preparation of a camoquine derivative with quaternary carbon side chain.
Topics: Amodiaquine; Animals; Antimalarials; Malaria; Mice | 1972 |
The role of drugs in a malaria program.
Topics: Amodiaquine; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Malaria; Primaqui | 1972 |
Is malaria chemosuppression necessary in an infant?
Topics: Age Factors; Amodiaquine; Chloroquine; Disease Reservoirs; Humans; Infant, Newborn; Infant, Newborn, | 1970 |
Nonspecific phagocytic activity in rats infected with Plasmodium berghei and treated with amodiaquine or chloroquine.
Topics: Amodiaquine; Animals; Body Weight; Carbon; Chloroquine; Colloids; Injections, Intravenous; Liver; Lu | 1970 |
Plasmodium berghei: phagocytic hyperactivity of infected rats.
Topics: Amodiaquine; Animals; Carbon; Colloids; Disease Models, Animal; Malaria; Male; Organ Size; Phagocyto | 1970 |
A medicated salt project in the Kazeroun area, Iran--1962-1967.
Topics: Amodiaquine; Anopheles; Blood; Child; Child, Preschool; Chloroquine; Humans; Infant; Infant, Newborn | 1971 |
[Management of acute malaria].
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Injections, Intramuscular; Malaria; Primaquine; Tro | 1968 |
Characteristics and cross-resistance patterns of chloroquine-resistant Plasmodium berghei infections in mice.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Dapsone; Drug Resistance, Microbial; Female; Hemat | 1968 |
Repository drugs. 8. Ester and amide congeners of amodiaquine, hydroxychloroquine, oxychloroquine, primaquine, quinacrine, and related substances as potential long-acting antimalarial agents.
Topics: Amodiaquine; Animals; Antimalarials; Chemical Phenomena; Chemistry; Delayed-Action Preparations; Est | 1969 |
Drug resistance in Plasmodium berghei Vincke and Lips, 1948. I. Chloroquine resistance.
Topics: Amodiaquine; Animals; Chloroquine; Dapsone; Malaria; Mice; Plasmodium; Primaquine; Proguanil; Pyrime | 1965 |